PROSTATITIS A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R EFERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright ©2004 by ICON Group International, Inc. Copyright ©2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Prostatitis: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-84055-5 1. Prostatitis-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on prostatitis. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON PROSTATITIS .............................................................................................. 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Prostatitis.................................................................................... 14 E-Journals: PubMed Central ....................................................................................................... 33 The National Library of Medicine: PubMed ................................................................................ 34 CHAPTER 2. NUTRITION AND PROSTATITIS .................................................................................... 77 Overview...................................................................................................................................... 77 Finding Nutrition Studies on Prostatitis .................................................................................... 77 Federal Resources on Nutrition ................................................................................................... 80 Additional Web Resources ........................................................................................................... 81 CHAPTER 3. ALTERNATIVE MEDICINE AND PROSTATITIS .............................................................. 83 Overview...................................................................................................................................... 83 National Center for Complementary and Alternative Medicine.................................................. 83 Additional Web Resources ........................................................................................................... 93 General References ....................................................................................................................... 96 CHAPTER 4. PATENTS ON PROSTATITIS........................................................................................... 97 Overview...................................................................................................................................... 97 Patents on Prostatitis................................................................................................................... 97 Patent Applications on Prostatitis............................................................................................. 114 Keeping Current ........................................................................................................................ 118 CHAPTER 5. BOOKS ON PROSTATITIS ............................................................................................ 121 Overview.................................................................................................................................... 121 Book Summaries: Federal Agencies............................................................................................ 121 Book Summaries: Online Booksellers......................................................................................... 125 The National Library of Medicine Book Index ........................................................................... 126 Chapters on Prostatitis .............................................................................................................. 126 Directories.................................................................................................................................. 127 CHAPTER 6. MULTIMEDIA ON PROSTATITIS ................................................................................. 129 Overview.................................................................................................................................... 129 Video Recordings ....................................................................................................................... 129 CHAPTER 7. PERIODICALS AND NEWS ON PROSTATITIS .............................................................. 131 Overview.................................................................................................................................... 131 News Services and Press Releases.............................................................................................. 131 Newsletters on Prostatitis.......................................................................................................... 133 Newsletter Articles .................................................................................................................... 133 Academic Periodicals covering Prostatitis ................................................................................. 134 CHAPTER 8. RESEARCHING MEDICATIONS ................................................................................... 135 Overview.................................................................................................................................... 135 U.S. Pharmacopeia..................................................................................................................... 135 Commercial Databases ............................................................................................................... 136 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 141 Overview.................................................................................................................................... 141 NIH Guidelines.......................................................................................................................... 141 NIH Databases........................................................................................................................... 143 Other Commercial Databases..................................................................................................... 145 APPENDIX B. PATIENT RESOURCES ............................................................................................... 147 Overview.................................................................................................................................... 147 Patient Guideline Sources.......................................................................................................... 147 Finding Associations.................................................................................................................. 153
viii Contents
APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 155 Overview.................................................................................................................................... 155 Preparation................................................................................................................................. 155 Finding a Local Medical Library................................................................................................ 155 Medical Libraries in the U.S. and Canada ................................................................................. 155 ONLINE GLOSSARIES................................................................................................................ 161 Online Dictionary Directories ................................................................................................... 164 PROSTATITIS DICTIONARY.................................................................................................... 165 INDEX .............................................................................................................................................. 221
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with prostatitis is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about prostatitis, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to prostatitis, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on prostatitis. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to prostatitis, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on prostatitis. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON PROSTATITIS Overview In this chapter, we will show you how to locate peer-reviewed references and studies on prostatitis.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and prostatitis, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “prostatitis” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Predictors of Patient Response to Antibiotic Therapy for the Chronic Prostatitis. Chronic Pelvic Pain Syndrome: A Prospective Multicenter Clinical Trial Source: Journal of Urology. 165(5): 1539-1544. May 2001. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: Antibiotics are the most popular choice of therapy for all categories of the chronic prostatitis or chronic pelvic pain syndrome. This article reports on a study undertaken to determine if culture, leukocyte, or antibody status of prostate specific specimens predicts patient response to antibiotic therapy. Patients clinically diagnosed with the chronic prostatitis or chronic pelvic pain syndrome according to the National Institutes of Health (NIH) definition had a lower urinary tract evaluation that included
4
Prostatitis
standard microscopy and culture of prostate specific specimens, and determination of the ratios of antibody levels against identified prostate pathogens. Symptom evaluation consisted of the NIH chronic prostatitis symptom index pain scale 0 to 21, symptom severity index scale 0 to 100, symptom frequency questionnaire scale 0 to 50, and quality of life scale 0 to 6. Patients were stratified according to microscopy, culture, and immune statu; were treated with 12 weeks of ofloxacin, and were assessed at 4, 12, and 24 weeks with symptom scores as well as global assessments. Based on leukocyte and culture results, 102 evaluable patients were stratified into categories II (14 percent), IIIA (48 percent), and IIIB (38 percent) of the chronic prostatitis or chronic pelvic pain syndrome. Of the cases, 23 percent were categorized as antibody positive and 77 percent as antibody negative. Average age was 42 years (plus or minus 10 years) and 92 percent of patients were white. Of the patients, 57 percent believed that they had moderate to marked improvement. All categories of the chronic prostatitis or chronic pelvic pain syndrome and patients in whom antibody was positive or negative had significant improvement in the NIH chronic prostatitis symptom index, symptom severity index, symptom frequency questionnaire, and quality of life scores compared with baseline. There was no significant difference in patient response to the stratification based on culture, leukocyte, or antibody status. The authors conclude that culture, leukocyte, and antibody status of prostate specific specimens does not predict antibiotic response in patients with the chronic prostatitis or chronic pelvic pain syndrome. The perceived beneficial effect of antibiotics needs to be evaluated in a randomized placebo controlled trial. 3 figures. 3 tables. 34 references. •
Managing Prostatitis in the Elderly Source: Geriatrics. 46(1): 60-63. January 1, 1991. Summary: Bacterial prostatitis is primarily a disease of elderly men, and it is the most common urinary tract infection seen in this age group. Urosepsis from prostatitis or prostatic abscess occurs less frequently than with urological manipulation, but must always be considered in elderly men with prostatitis. This article focuses on the diagnosis and antibiotic treatment of bacterial prostatitis in the elderly. Sections cover the clinical presentation, the physical examination and laboratory evaluations used for diagnosis, and the treatment options, including drug therapy and the role of surgery. 3 tables. 7 references. (AA-M).
•
National Institutes of Health Chronic Prostatitis Symptom Index: Development and Validation of a New Outcome Measure Source: Journal of Urology. 162(2): 369-375. August 1999. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: Chronic abacterial prostatitis is a syndrome characterized by pelvic pain and voiding symptoms, which is poorly defined, poorly understood, poorly treated, and bothersome. Research and clinical efforts to help men with this syndrome have been hampered by the absence of a widely accepted, reliable, and valid instrument to measure symptoms and quality of life impact. This article reports work on the development and validation of a new outcome measure in which the researchers developed a psychometrically valid index of symptoms and quality of life impact for men with chronic prostatitis. The authors conducted a series of focus groups comprising chronic prostatitis patients at four centers in North America, in which they identified the most important symptoms and effects of the condition. The results were used to create
Studies
5
an initial draft of 55 questions that were used for formal cognitive testing on chronic prostatitis patients at the same centers. After expert panel review, formal validation testing of a revised 21 item draft was performed in a diverse group of chronic prostatitis patients and two control groups of benign prostatic hyperplasia (BPH) patients and healthy men. Based on this validation study, the index was finalized. Analysis yielded an index of nine items that address three different aspects of the chronic prostatitis experience. The primary component was pain, which was captured in four items focused on location, severity, and frequency. Urinary function, another important component of symptoms, was captured in two items (one irritative and one obstructive). Quality of life impact was captured with three items about the effect of symptoms on daily activities. The nine items had high test retest reliability and internal consistency. All but the urinary items discriminated well between men with and without chronic prostatitis. The authors conclude that this National Institutes of Health chronic prostatitis symptom index provides a valid outcome measure for men with chronic prostatitis. The index is psychometrically robust, easily self administered, and highly discriminative. It may be useful in clinical practice as well as in research protocols. 2 appendices. 5 tables. 27 references. •
Autoimmune Prostatitis: Evidence of T Cell Reactivity with Normal Prostatic Proteins Source: Urology. 50(6): 893-899. 1997. Summary: Chronic prostatitis is a common diagnosis, but the disease is poorly understood. Men present with pelvic pain, irritative voiding symptoms, and sexual dysfunction complaints, all of which are nonspecific. This article reports on a study undertaken to determine whether men with chronic prostatitis or chronic pelvic pain syndrome have evidence of an autoimmune response to prostatic proteins. The authors examined men with a history of this problem for evidence of T lymphocyte reactivity to seminal plasma. Patients underwent automated leukopheresis to obtain peripheral blood mononuclear cells. The authors performed a recall antigen proliferation assay to detect specific proliferation of peripheral helper T lymphocytes in men with chronic prostatitis or chronic pelvic pain syndrome and compared the results with those of normal men. The antigen for these studies consisted of seminal plasma from normal donors and men with seminal vesicle atresia. A specific recall proliferative response to seminal plasma was observed in 3 of 10 men with a history of chronic prostatitis or chronic pelvic pain syndrome compared with none of 15 normal men. The recall responses of both the syndrome group and the normal subjects to the recall antigens tetanus toxoid and Candida extract were equivalent. The authors conclude that the data represent the first direct evidence that some men with chronic prostatitis or chronic pelvic pain syndrome have an autoimmune component to their disease. Autoimmunity is a potential etiology for chronic nonbacterial prostatitis. 2 figures. 3 tables. 24 references.
•
Emerging Concepts in the Management of Prostatitis Chronic Pelvic Pain Syndrome. (editorial) Source: Journal of Urology. 169(2): 597-598. February 2003. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: Chronic prostatitis or chronic pelvic pain syndrome is a common problem that causes considerable morbidity and economic impact. The syndrome is characterized by chronic pain with varying degrees of urinary symptoms. This editorial considers the
6
Prostatitis
use of the NIH Chronic Prostatitis Symptom Index (CPSI) to measure symptoms. Other topics include the etiology of the chronic pelvic pain syndrome, diagnostic tests (tissue biopsies of the prostate), the role of bacteria in the development of the chronic pelvic pain syndrome, the role of the PSA (prostate specific antigen) test, and treatment strategies for chronic pelvic pain syndrome. •
Prostatitis: Sorting Out The Different Causes Source: Postgraduate Medicine. 94(5): 191-194. October 1993. Summary: In this article, the author summarizes the characteristics of each of the four types of prostatitis, focusing on the diagnosis and treatment by the primary care physician. The four types covered are: acute bacterial prostatitis; chronic bacterial prostatitis; nonbacterial prostatitis; and prostatodynia. The author stresses that successful management of prostatitis depends on accurately classifying the condition according to systemic signs and symptoms and the results obtained by examination of expressed prostatic secretions and urine cultures. 6 references.
•
Female Urethral Syndrome: A Female Prostatitis? Source: Western Journal of Medicine. 164(5): 435-438. May 1996. Summary: In this article, the authors present evidence that the female urethral syndrome may be analogous to prostatitis in the male. They note that there is now strong evidence that the microscopic paraurethral glands connected to the distal third of the urethra in the prevaginal space are homologous to the prostate. They stain histologically for prostate-specific antigen and, like the prostate, are subject to both infection and cancer. The most important aspect of recognizing this microscopic 'female prostate' as an anatomic feature is that its infections may completely explain many cases of the urethral syndrome. Further, the diagnosis is not elusive if trained clinicians palpate for localized and objective paraurethral tenderness through the anterior vagina wall to one or both sides of the urethra. Treatment parallel to that for male prostatitis is usually rewarded by the elimination of symptoms and the objective finding of the loss of tenderness of the paraurethral glands. The authors conclude by reiterating the importance of alerting primary care physicians to this disorder and to eliminate the widespread practice of treating affected women with either invasive urethral dilation or tranquilizers. 3 figures. 31 references. (AA-M).
•
Prevalence of Prostatitis-Like Symptoms in a Population Based Study Using the National Institutes of Health Chronic Prostatitis Symptom Index Source: Journal of Urology. 165(6): 842-845. March 2001. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: In this community based study, the National Institutes of Health (NIH) chronic prostatitis symptom index was used to determine the prevalence of prostatitis like symptoms among men (age 20 to 74 years) at risk. The questionnaire collected information on two domains of chronic prostatitis identified in the NIH chronic prostatitis symptom index, including pain (location, severity and frequency), voiding function (irritative, obstructive), demographics, quality of life, general health, and health seeking behavior. A total of 2,987 eligible men received the survey, and it was completed by 868 (29 percent). Of these men, 84 (9.7 percent) were identified as having chronic prostatitis like symptoms. The average age of the prostatitis population was 50
Studies
7
years compared with 52 years for men without the prostatitis like symptoms. Prevalence was 11.5 percent in men younger than 50 years and 8.5 percent in men 50 years or older. Of the sample population, 57 (6.6 percent) men had prostatitis like symptoms and an index pain score 8 or greater (moderate to severe). Of the prostatitis group, 60 percent sought medical help for their symptoms. The authors conclude that using this new prostatitis symptom index confirms that chronic prostatitis like symptoms are common. 1 figure. 1 table. 16 references. •
Prostatitis: Sorting the Myths from the Facts in Daily Practice Source: Urology Times. 25(9): 12. September 1997. Contact: Available from Advanstar Communications, Inc. Corporate and Editorial Offices, 7500 Old Oak Boulevard, Cleveland, OH 44130. (216) 243-8100. Summary: In this second part of a 2 part series, a urologist examines diagnostic and treatment issues surrounding prostatitis (inflammation of the prostate), with a focus on antibiotic therapy and prostatic massage. The article is written in a question and answer format and addresses common concerns that urologists and primary care practitioners may face in their everyday practice with male patients. Most patients with acute bacterial prostatitis will respond to antibiotic therapy and not develop chronic prostatitis. While there is a precedent for chronic inflammatory conditions being associated with an increased risk for cancers, this has not yet been demonstrated with epidemiological studies in the case of prostatitis. The author notes that some men who have prostatitis syndrome (chronic prostatitis) may indeed have interstitial cystitis (IC, an inflammatory condition of the bladder lining), but there is no indication that these are the same disease process. The typical patient with prostatitis is in his 30s or early 40s and less likely to have prostate cancer. However, if a patient's prostate specific antigen (PSA) test numbers are not going down or his rectal exam findings (of the prostate) remain palpably abnormal after an acute episode, the author recommends biopsy and full workup. The author also discusses diagnosis issues regarding sexual dysfunction and genital chlamydia infection, recommended course of therapy for men with acute bacterial prostatitis, which patients should have followup, the controversy regarding prostatic massage, and drug therapy.
•
Perplexing Nature of Prostatitis Source: Contemporary Urology. 9(5): 73-74, 77-78, 80. May 1997. Summary: Prostatitis, an infection of the prostate, remains a common and often perplexing problem for the practicing urologist. In this article, the authors present recommendations for differentiating the different types of prostatitis and for the use of new antimicrobials. The authors stress that effective therapy for prostatitis depends upon correct diagnosis and classification of patients into clinically distinct syndromes, which allow the physician a better understanding of the disease process. Prostatitis is classified as bacterial prostatitis (acute and chronic), nonbacterial prostatitis (NBP), or prostatodynia. ABP and CBP are caused more commonly by gram-negative enteric organisms that are usually isolated in urinary tract infections (UTIs). NBP presents similarly to bacterial prostatitis, but as its name implies, bacterial cultures obtained from the urethra, bladder, and prostate are repeatedly negative. In prostatodynia, antimicrobial therapy is not indicated. Antimicrobials discussed include levlofloxacin, ciprofloxacin, ofloxacin, doxycycline, and trimethoprim-sulfamethoxazole. 4 tables. 13 references. (AA-M).
8
Prostatitis
•
Prostatitis Syndromes: A Continuing Enigma for the Family Physician Source: Canadian Family Physician. Volume 37: 921-928. April 1991. Summary: The diagnosis and treatment of prostatitis syndromes can present a challenge for clinicians, especially primary care physicians, and can be a source of frustration to their patients. These related syndromes often have different underlying causes but can exhibit very similar clinical presentations. This article focuses on achieving an accurate early diagnosis in order to ensure a successful treatment outcome. The authors promote an approach for classifying patients at first presentation that involves understanding the etiology and pathophysiology of prostatitis syndromes and using a rigorous diagnostic plan. Syndromes discussed include prostatodynia, acute prostatitis, chronic bacterial prostatitis, and non-bacterial prostatitis. For each syndrome, diagnostic techniques and treatments are described. 3 figures. 1 table. 15 references.
•
Quercetin in Men with Category III Chronic Prostatitis: A Preliminary Prospective, Double-Blind, Placebo-Controlled Trial Source: Urology. 54(6): 960-963. December 1999. Contact: Available from Urology. P.O. Box 2126, Marion, OH 43306-8226. (800) 215-4692. Fax (740) 382-5866. Summary: The National Institutes of Health (NIH) category III chronic prostatitis syndromes (nonbacterial chronic prostatitis and prostatodynia or prostate pain) are common disorders with few effective therapies. Bioflavonoids have recently been shown in an open-label study to improve the symptoms of these disorders in a significant proportion of men. This article reports on a study undertaken to confirm these findings in a prospective randomized, double-blind, placebo controlled trial. The study included 30 men with category IIIa and IIIb chronic pelvic pain syndrome who were randomized in a double blind fashion to receive either placebo or the bioflavonoid quercetin 500 milligrams twice daily for 1 month. The NIH chronic prostatitis symptom score was used to grade symptoms and the quality of life impact at the start and conclusion of the study. In a followup, unblind, open label study, 17 additional men received 1 month of a supplement containing quercetin, as well as bromelain and papain (Prosta-Q), which enhance bioflavonoid absorption. Two patients in the placebo group refused to complete the study because of worsening symptoms, leaving 13 placebo and 15 bioflavonoid patients for evaluation in the blind study. Both the quercetin and placebo groups were similar in age, symptom duration, and initial symptom score. Patients taking placebo had a mean improvement in NIH symptom score from 20.2 to 18.8 (not significant), while those taking the bioflavonoid had a mean improvement from 21.0 to 13.1. Twenty percent of patients taking placebo and 67 percent of patients taking the bioflavonoid had an improvement of symptoms of at least 25 percent. In the 17 patients who received Prosta-Q in the open label study, 82 percent had at least a 25 percent improvement in symptom score. The authors conclude that therapy with the bioflavonoid quercetin is well tolerated and provides significant symptomatic improvement in most men with chronic pelvic pain syndrome. 1 figure. 1 table. 26 references.
•
Validity and Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index Source: Journal of Urology. 169(2): 580-583. February 2003.
Studies
9
Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: The National Institutes of Health Chronic Prostatitis Symptom Index (NIHCPSI) was validated in a sample of men with longstanding prostatitis, but it has not been validated in primary care samples or assessed for responsiveness to change. This article reports on a study that assessed this instrument, including its reliability, validity, and responsiveness to change in a sample of men with pelvic pain visits for health maintenance organization primary care and urology clinics. A total of 261 men with recent primary care or urology clinic visits for pelvic pain and no evidence of specific disease completed the NIH-CPSI and quality of life measures. Validity was demonstrated for the NIH-CPSI pain and quality of life scales through their moderate correlations with other validated measures of these constructs. The NIH-CPSI total scale but not the subscales showed high internal consistency. The pain, quality of life, and total scores were moderately responsive to change, but the urinary symptoms scale was less responsive. The authors conclude that the NIH-CPSI total score appears to be a valid, reliable, responsive measure of prostatitis symptoms in primary and secondary care patients. The findings support the use of the total score as an outcome measure. It may be useful to supplement it with valid, reliable measures of pain intensity and activity interference. 5 tables. 14 references. •
Diagnosis and Treatment of Chronic Abacterial Prostatitis: A Systemic Review Source: Annals of Internal Medicine. 133(5): 367-381. September 5, 2000. Contact: Available from American College of Physicians. American Society of Internal Medicine. 190 North Independence Mall West, Philadelphia, PA 19106-1572. Website: www.acponline.org. Summary: The optimal management of chronic abacterial prostatitis (prostate inflammation not due to a bacterium) is not known. This article reports on a literature review undertaken to assess whether there are accurate, reliable tests available to diagnose chronic abacterial prostatitis and whether there are effective therapies available to treat the condition. For each selected article, two investigators independently extracted key data on study design, patient characteristics, diagnostic test or treatment characteristics, and outcomes. The study included 19 diagnostic test articles and 14 treatment trials. The disparity among studies in design, interventions, and other factors precluded quantitative analysis or pooling of the findings. Diagnostic test articles included 1,384 men (mean age, 33 to 67 years) and evaluated infection; inflammation, immunology, and biochemistry; psychological factors; and ultrasonography. Treatment trials included 570 men (mean age, 38 to 45 years) and evaluated medications used to treat benign prostatic hyperplasia (BPH), anti inflammatory drugs, antibiotics, thermotherapy, and miscellaneous medications. The authors conclude that there is no gold standard diagnostic test for chronic abacterial prostatitis, and that the methodologic quality of available studies of diagnostic tests is low. The few treatment trials are methodologically weak and involved small samples. The routine use of antibiotics and alpha blockers to treat chronic abacterial prostatitis is not supported by the existing evidence. 1 figure. 3 tables. 89 references.
•
Treatment of Prostatitis Source: American Family Physician. 61(10): 3015-3022. May 15, 2000. Contact: Available from American Academy of Family Physicians. 11400 Tomahawk Creek Parkway, Leawood, KS 66211-2672. (800) 274-2237. Website: www.aafp.org.
10
Prostatitis
Summary: The term prostatitis is applied to a series of disorders, ranging from acute bacterial infection of the prostate gland to chronic pain syndromes, in which the prostate gland is inflamed. This article reviews the diagnosis and treatment of prostatitis. Patients present with a variety of symptoms, including urinary obstruction, fever, myalgias (muscle pain), decreased libido or erectile dysfunction, painful ejaculation, and low back or perineal pain. Physical examination often fails to clarify the cause of the pain. Cultures and microscopic examination of urine and prostatic secretions before and after prostatic massage may help differentiate prostatitis caused by infection from prostatitis with other causes. Because the rate of occult (hidden) infection is high, a therapeutic trial of antibiotics is often in order even when patients do not appear to have bacterial prostatitis. If the patient responds to therapy, antibiotics are continued for at least three to four weeks, although some men require treatment for several months. A patient who does not respond might be evaluated for chronic nonbacterial prostatitis, in which nonsteroidal antiinflammatory drugs, alpha blocking agents, anticholinergic agents, or other therapies may provide symptomatic relief. 3 tables. 23 references. •
Prevalence of Prostatitis-like Symptoms in a Community Based Cohort of Older Men Source: Journal of Urology. 168(6): 2467-2471. December 2002. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: This article describes a community based study undertaken to determine the prevalence of prostatitis-like symptoms using questions similar to the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Study subjects (n = 1,541) were a randomly selected sample of Minnesota white men aged 40 to 79 years old who participated in a longitudinal study of lower urinary tract symptoms (LUTS). Of the study group, 182 men (12 percent) had at least one urogenital pain symptom. Pubic pain (76 men, 4.9 percent) and testicular pain (73 men, 4.7 percent) were the most frequent pain symptoms. A total of 34 men with prostatitis-like symptoms (2.2 percent) had higher mean pain, urinary symptom, and quality of life impact scores compared to men who did not. Pain frequency and pain intensity were more strongly associated with prostatitis-like symptoms than urinary symptom score or quality of life impact score. The authors conclude that although urogenital pain is common among community dwelling men, prostatitis-like symptoms based on the modified questions from the NIHCPSI are less common. While pain measures may be useful in distinguishing between men with and without prostatitis-like symptoms, the urinary symptom and quality of life impact scores could partly reflect benign prostatic hyperplasia (BPH). 2 figures. 3 tables. 21 references.
•
Helping Patients Cope with Chronic Prostatitis Source: Patient Care. 34(8): 22-32. April 30, 2000. Contact: Available from Medical Economics. 5 Paragon Drive, Montvale, NJ 07645. (800) 432-4570. Fax (201) 573-4956. Summary: This article describes a new classification system for prostatitis (prostate infection) that can help focus treatment for patients with chronic symptoms. While many patients respond well to treatment for prostatitis, the overall cure rate is low and relapse and recurrence are common. The new diagnostic system, developed in 1995 and endorsed in 1998, has 4 numbered categories and strives to be more descriptive than its predecessor. Category I, acute bacterial prostatitis, and category II, chronic bacterial prostatitis, are defined as they have always been. An important change is evident in
Studies
11
category III, designed as chronic nonbacterial prostatitis or chronic pelvic pain syndrome (CPPS), which encompasses about 90 percent of patients. A new group, category IV, includes patients with asymptomatic prostatitis. Diagnosis begins with a focused history and a physical; the physical assessment should be concentrated on the abdomen, external genitalia, perineum, pelvic area, and the prostate gland. Treatment for patients in category I is straightforward, usually beginning with a short hospital stay. The oral fluoroquinolones are excellent choices for patients with category II prostatitis. Trimethoprim or trimethoprim with sulfamethoxazole may be useful. Therapies used in the treatment of patients with inflammatory CPPS include a trial course, of antibiotics, prostatic massage, NSAIDs, alpha 1 adrenergic blockers, and supportive measures. A patient care algorithm (flowchart) is included. 2 figures. 2 tables. 14 references. •
Cryptic Bacteria in IC and Nonbacterial Prostatitis? Source: Contemporary Urology. 8(2): 53-56. February 1996. Contact: Available from Medical Economics Publishing Inc. Montvale, NJ 07645. (800) 432-4570. Summary: This article describes the authors' methods of diagnosing and treating interstitial cystitis (IC) and nonbacterial prostatitis; the authors also provide evidence that bacterial infection may at times be the causative agent. Both diseases involve chronic inflammation of the genitourinary tract, have no known etiology, and typically respond poorly to treatment. Newer methods of detecting bacteria should provide some definitive answers on the role of infection in these conditions. One sidebar reports on the advances in the detection of nonculturable bacteria. The authors describe the chronic forms of prostatitis, including prostatodynia, chronic bacterial prostatitis, and nonbacterial prostatitis. Men with so-called nonbacterial prostatitis present with the symptoms and signs of chronic bacterial prostatitis, even though regular cultures fail to document bacterial growth. Many investigators hypothesize that this condition frequently has an infectious cause, theorizing that causative organisms are not released into prostatic fluid or urine or will not grow on conventional cultures. Evidence suggests that the inflammation of IC is due, in some patients, to an undetected microbial infection. Direct evidence supporting an infectious cause for IC includes the detection of a higher incidence of bacteria in IC patients compared with controls. Although present research is investigating the role of bacteria in IC, the authors maintain that there are no studies to indicate that longer courses or different antibiotics are effective in eradicating this condition. Therefore, antibiotics are not recommended for patients who fit the NIH criteria for IC. 3 figures. 18 references. (AA-M).
•
Demographic and Clinical Characteristics of Men with Chronic Prostatitis: The National Institutes of Health Chronic Prostatitis Cohort Study Source: Journal of Urology. 168(8): 593-598. August 2002. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: This article describes the study design of the National Institutes of Health Chronic Prostatitis Cohort (CPC) study characterizing men with chronic prostatitis or the chronic pelvic pain syndrome. All 488 men screened into the CPC study before close of recruitment in August 2001 were selected for analysis. The results showed that chronic prostatitis or chronic pelvic pain syndrome is a chronic syndrome affecting men over a wide age group. The majority of CPC study participants are white, well educated,
12
Prostatitis
and affluent. However, lower education, lower income and unemployment were associated with more severe symptoms. Patients most frequently reported pain in the perineum and tenderness in the prostate. The highest self-reported diseases were genitourinary (55 percent), allergies (53 percent), neurological (40 percent), and hematopoietic, lymphatic, or infectious (40 percent). This disease has a significant negative impact on mental and physical domains of quality of life. Almost all patients (95 percent) reported antimicrobial drug use. Of these 488 participants, 280 (57 percent) reported the previous or current use of 5 or more categories of prostatitis related treatments. The authors note that long term follow up of this cohort may answer important questions on the natural treated history of this syndrome. One appendix lists the CPC Study Eligibility Criteria. 7 tables. 20 references. •
New Concepts in the Pathogenesis and Treatment of Prostatitis Source: Current Opinion in Urology. 2(1): 37-43. February 1992. Summary: This article discusses new concepts in the pathogenesis and treatment of prostatitis. The author notes that despite an accepted diagnostic procedure, a standard classification system, and newer generations of antibiotics, prostatitis still causes problems in clinical practice. Topics include the etiology and pathogenesis of prostatitis, the role of history and physical examination in diagnosis, and therapeutic modalities used to treat prostatitis. The author discusses acute and chronic bacterial prostatitis, nonbacterial prostatitis, and prostatodynia. 1 figure. 1 table. 40 annotated references.
•
Treatment of Bacterial Prostatitis Source: American Family Physician. 44(6): 2137-2141. Summary: This article discusses the treatment of bacterial prostatitis. After a review of the four most common types of prostatitis (acute bacterial, chronic bacterial, nonbacterial, and prostatodynia), the author covers the etiology, pathogenesis, and diagnosis of acute and chronic bacterial prostatitis. The author then focuses on the drug therapy used to treat these conditions. The author stresses that careful examination and culture of prostatic fluid to differentiate bacterial from nonbacterial prostatitis is essential for proper diagnosis and treatment. 2 tables. 16 references.
•
Rational Management of Non-Bacterial Prostatitis and Prostatodynia Source: Current Opinion in Urology. 6(1): 53-58. January 1996. Contact: Available from Rapid Science Publishers. 400 Market Street, Suite 750, Philadelphia, PA 19106. (800) 552-5866 or (215) 574-2210. Fax (215) 574-3533. Summary: This article presents a simple approach to the diagnosis and treatment of nonbacterial prostatitis and prostatodynia. The author notes that problems arise when the clinician is confronted with a patient who does not have classic signs and symptoms of bacterial prostatitis. Recent work has shown organisms that are possibly involved in the inflammatory type that are nonculturable, or perhaps not typical of the uropathogens seen generally. The author also considers the possible implications of chlamydia, trachomatis, and ureaplasma urealyticum. Differentiating the specific groups of prostatic syndromes is extremely important when treating these patients. The presence of luekocytes in patients after prostatic examination or massage seems to be the most reliable test that the clinician can do. In these patients, a treatment of antimicrobials, which are active against uropathic organisms and chlamydia, may be worthwhile. The author describes new evidence that suggests the remainder of patients
Studies
13
with noninflammatory prostatitis syndrome should be treated with alpha-blocking agents or anti-inflammatory agents. 1 figure. 60 references. (AA-M). •
Prevalence of Men With National Institutes of Health Category IV Prostatitis and Association With Serum Prostate Specific Antigen Source: Journal of Urology. 169(2): 589-591. February 2003. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: This article reports on a study that evaluated the prevalence and relationship of serum prostate specific antigen (PSA) levels in a screening population of men diagnosed with National Institutes of Health (NIH) category IV prostatitis. In the study, 300 men were evaluated; expressed prostatic secretions were obtained from 227 of the 300 participants. The prevalence of NIH category IV prostatitis was 32.3 percent in this population of men. Patient age, American Urological Association (AUA) symptoms scores, and clinical prostate gland size did not differ between men with or without evidence of prostatitis on expressed prostatic secretion examination. Men with NIH category IV prostatitis had a mean serum PSA level of 2.3 which was significantly higher than those without prostatitis. These data suggest that NIH category IV prostatitis is fairly prevalent among men in the general population who present for prostate cancer screening and appears to contribute to increased serum PSA levels in some men. 1 table. 13 references.
•
Understanding Prostatitis Source: Informer. p. 1, 4. Spring-Summer 1993. Contact: Available from Simon Foundation. P.O. Box 815, Wilmette, IL 60091. (800) 2374666. Summary: This brief article presents an overview of prostatitis. Topics covered include the classification system used for defining prostatitis; the types of prostatitis, including chronic bacterial, acute bacterial, non-bacterial, and prostatodynia; symptoms of prostatitis; treatment methods; and where to find additional information about this condition.
•
Prostatitis: What It Is, How to Cure It Source: American Family Physician. 61(10): 3025-3026. May 15, 2000. Contact: Available from American Academy of Family Physicians. 11400 Tomahawk Creek Parkway, Leawood, KS 66211-2672. (800) 274-2237. Website: www.aafp.org. Summary: This patient education handout offers information about prostatitis, a term that is applied to a series of disorders, ranging from acute bacterial infection of the prostate gland to chronic pain syndromes, in which the prostate gland is inflamed. The prostate is a gland that lies just below the male urinary bladder. The prostate makes a fluid that provides nutrients for sperm; this fluid makes up most of the ejaculate fluid. Patients with prostatitis present with a variety of symptoms, including urinary obstruction, fever, myalgias (muscle pain), decreased libido or erectile dysfunction, painful ejaculation, and low back or perineal pain. The treatment of prostatitis is based on the type of prostatitis diagnosed. Antibiotics are used to treat infections of the prostate. Because the rate of occult (hidden) infection is high, a therapeutic trial of antibiotics is often in order even when patients do not appear to have bacterial
14
Prostatitis
prostatitis. A patient who does not respond to antibiotics might be evaluated for chronic nonbacterial prostatitis, in which nonsteroidal antiinflammatory drugs, alpha blocking agents, anticholinergic agents, or other therapies may provide symptomatic relief. The handout reassures readers that prostatitis does not cause prostate cancer, even though sometimes prostatitis can cause a temporary rise in the man's PSA level (a test used to screen for cancer). 1 figure. •
Diagnosis of Prostatitis: A Review Source: Genitourinary Medicine. 67(4): 279-283. 1991. Summary: This review article addresses the diagnosis of prostatitis. Topics include the anatomy of the prostate and pathogenesis of infection, the diagnosis of acute prostatitis, the diagnosis of chronic prostatitis, examination of the expressed prostatic secretion, laboratory examinations, and other diagnostic techniques. The author notes that infecting organisms can reach the prostate by four routes: ascending from the urethra, descending from the bladder, via the bloodstream, and via the lymphatics. The author stresses that, as clinical features are frequently unhelpful, diagnosis depends on results of special investigations.
Federally Funded Research on Prostatitis The U.S. Government supports a variety of research studies relating to prostatitis. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to prostatitis. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore prostatitis. The following is typical of the type of information found when searching the CRISP database for prostatitis: •
Project Title: A PHASE 1 STUDY/DNA-BASED VACCINE VS PROSTATIC ACID PASE Principal Investigator & Institution: Mcneel, Douglas G.; Medicine; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2007 Summary: (provided by applicant): Dr. McNeel will develop a career in patient-oriented translational research with an emphasis on the immunological treatment of patients with prostate cancer. The goal of this proposal is describe both a career training and mentoring plan through which he will receive training in the proper conduct of human
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
15
subjects research, as well as a translational research plan leading to the conduct of a human vaccine trial for patients with prostate cancer. As part of his career development plan, Dr. McNeel will complete the UW Clinical Investigator Preparatory Pathway (CIPP). This program is an individualized program proviiding didactic and mentored training in the areas of biostatistics and clinical study design, clinical research ethics, leadership and management skills, presentation and teaching skills, scientific writing skills, and expertise within a specific research domain. In addition, he will be mentored directly by Dr. Mark Albertini, a leader in the field of DNA vaccien clinical trials research. His academic and career progress will be followed quarterly by the CIPP Executive Committee as well as Dr. McNeel's faculty mentoring committee at the University of Wisconsin (composed of Drs. Albertini, Sondel, Bryan and Bailey). The other part of this proposal describes a 5-year translational research plan in which Dr. McNeel proposes three aims: 1) to identify the immunological mediators of prostate tissue destruction in a rat model fo inflammatory prostatistics; 2) to identify proteins immunologically recognized in patients with chronic inflammatory prostatis; and 3) to determine in a human clinical vaccine trial the safety and immunological efficacy of a DNA-based vaccine in patients with advanced stage prostate cancer. This clinical trial will target the same antigen, prostatic acid phosphatase, and using the same DNA immunization techniques used to elicit prostatis in the rodent model. This trial will serve as a platform and model for clinical trial evaluation of antigens identified in the second aim of the proposal. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALTERNATIVE VARIABLILITY
THERAPIES
FOR
BPH,
MULTIETHNIC
Principal Investigator & Institution: Kaplan, Steven A.; Professor of Urology, Vice Chair; Urology; Columbia University Health Sciences New York, Ny 10032 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-MAR-2009 Summary: (provided by applicant): Benign prostatic hyperplasia (BPH) is the most common affliction of men over the age of 50. There has been a rapid increase in the use of alternative therapies and specifically, phytotherapuetic agents, to treat BPH. Published studies have focused on the relative efficacy, i.e. symptoms, urinary flow rate and nocturia and side effect profile of these therapies. To date, there have been no studies which have described the natural history of BPH progression in those who are treated with phytotherapeutic agents such as Serenoa repens (Saw palmetto berry) or Pygeurn africanum (African plum tree). Moreover, the natural history of BPH in various age and ethnic groups have been poorly characterized. The Prostate Canter and the The Center for Holistic Urology at The New York Presbyterian Hospital evaluates and treats an ethnically diverse group of more than 3,200 men per year with lower urinary tract symptoms secondary to BPH. It is well positioned to meet the recruitment and patient retention goals as a CETC in this important multi - center, 7 year trial. This trial will provide enormous insight into the progression of BPH and related symptoms in both an untreated population, i.e. placebo versus one treated with phytotherapeutic agents. This is of particular importance because efficacy can be truly determined only with an understanding of the untreated natural history of BPH. Our primary objective is to ascertain if Serenoa repens or Pygeum africanum delays or prevents the clinical progression of BPH. Patients will be classified as 1) Progression of disease as defined by one of the following: rise in baseline AUA Symptom Score of 4 points; urinary retention; incontinence; or recurrent urinary tract infections; 2) Crossover to known therapy, i.e. medical or invasive prior to clinical progression; 3) non - compliance with the coded
16
Prostatitis
medication treatment regimen including patients who elect watchful waiting or open label phytotherapy. Secondary outcomes include comparative efficacy between Serenoa repens and Pygeum africanum as defined by symptoms and urodynamic measurements. Through this full scale BPH trial, we hope to ascertain: A) the effects, if any, of phytotherapeutic agents on the clinical progression of BPH, B) the optimal temporal intervention in the treatment of BPH, C) whether specific ethnic groups manifest various forms of BPH resulting in different rates of progression and differential response to therapy? and, D) whether concomitant prostate conditions such as prostatitis are effected by phytotherapeutic intervention for BPH? Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BASIC SCIENCE TRAINING GRANT IN UROLOGY Principal Investigator & Institution: Lee, Chung; Urology; Northwestern University Office of Sponsored Programs Chicago, Il 60611 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2008 Summary: (provided by applicant): The proposed training program will focus on research in genitoruinary disease. The training will cover the following topics: (1) Mechanism of benign and malignant growth of the prostate, urinary bladder, and kidney. (2) Etiology and treatment of urinary tract infectious diseases and prostatitis. (3) Testicular biology and male reproductive physiology. (4) Endocrinology, diabetes and related male erectile dysfunction. (5) Embryonic development and growth of urogenital organs. (6) Epidemiology and population based studies in urology. These areas are proposed because they represent significant medical problems, which require investment in manpower and expertise in research. The proposed training program will recruit qualified young physician scientists(MD or MD/PhD) and basic scientists(PhD or MD/PhD) to pursue academic careers in urology research. These trainees will work in modem facilities occupied by 14 faculty preceptors in Northwestern University. These preceptors are leading scientists in different disciplines in the field of urology. The proposed training program will recruit six trainees, who belong to three of the following four categories. Category 1 will be post-resident physician scientists, who have completed residency training and will devote one to two years in research. Category 2 will be MD urology resident fellows, who will devote one or two years during their residency solely in research laboratories. Category 3 will be postdoctoral fellows, who have completed PhD or MD/PhD degrees in a basic science field and will devote up to three years of intensive urology research. Category 4 will be pre-doctoral graduate students, who will not be funded by this grant but will study in basic mechanisms in urology diseases and to interact with other trainees. The above four categories of trainees will form a rich interactive environment, that will benefit in a synergistic manner. The opportunity to understand the basic mechanisms of urologic diseases and to work with human clinical materials by applying molecular, biochemical, and epidemiological techniques that are available within this training program will ensure the availability of an adequate outstanding manpower in urology research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BECOMING A MEMBER OF THE CPCRN-FOR PROSTATITIS Principal Investigator & Institution: Berger, Richard E.; Associate Professor; Urology; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2003; Project Start 26-SEP-2003; Project End 28-FEB-2008
Studies
17
Summary: (provided by applicant): The long-term goals of the proposal are to establish a clinical center for the study and treatment of chronic pelvic pain in both genders and to co-operate with and contribute to other investigators in establishing and conducting multicenter clinical trials. In specific, this proposal is concerned with men with chronic male pelvic pain syndrome and with becoming a clinical site for the CPCRN. Our specific aims are to: (1) assist the CPCRN to establish study designs for clinical trials, develop forms, develop clinical definitions, recruit subjects for CPCRN trials, and to analyze and publish data in a co-operative and interactive manner; (2) support and take part in the Urological Chronic Pelvic Pain Syndromes Collaborative Group in a cooperative and interactive manner; (3) develop and conduct ancillary studies, which will provide further understanding of chronic prostatitis. Subjects will be recruited from the practice of Dr. Berger at the University of Washington Medical Center (UWMC) and the outpatient clinics at Group Health Cooperative of Puget Sound (GHC) and the University of Washington Physicians Network (UWPN). Dr. Berger sees approximately 200 new patients with CPPS per year, and GHC sees approximately 250 patients per year with newly diagnosed CPPS. By combining the patient population of both Seattle Medical Centers, we will be able to recruit a mix of previously treated and newly diagnosed patients into CPCRN clinical protocols. The Principal Investigator has a multidisciplinary team, currently performing clinical and laboratory studies in CPPS in men. Over the past four years, the Principal Investigator has enrolled 590 subjects into IRB approved studies of CPPS that have used a variety of methodological perspectives and examined a variety of etiological factors. We believe that we are ideally suited to contribute to the design and implementation of future studies performed by the CPCRN. Furthermore, the same multidisciplinary focus and experience will allow us the flexibility to design and carry out ancillary studies, which will fit with the overall plan of the CPCRN. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHARACTERIZATION & TREATMENT OF CATEGORY III PROSTATITIS Principal Investigator & Institution: Nickel, J Curtis.; Queen's University at Kingston Kingston K7l 3N6, Canada Kingston, Timing: Fiscal Year 2001; Project Start 27-MAR-1998; Project End 30-NOV-2002 Summary: (Taken from the applicant's Abstract) Characterization and Treatment of Category III Prostatitis Background: Chronic abacterial prostatitis and prostatodynia (NIH Category III), remains a frustrating enigma for North American physicians and patients. Our definition of the syndrome is unclear, the etiology is obscure, the relevance of the only objective finding we have (leukocytosis) is unknown, symptoms are highly variable, the natural history of the disease has not been adequately studied and the clinical treatment trials are poorly designed, small and inconclusive. Objectives: To collaboratively develop validated NIH assessment instruments for the study of Category III prostatitis, analyze objective microscopic, microbiological, immunological and molecular biological parameters and develop a long term collaborative multicenter study in which a number of potential standardized treatment protocols could be tested. Research Design: Part 1: Retest, revalidate and revise as necessary the Principal Investigator's published prostatitis specific Symptom Frequency Questionnaire (SFQ) and Symptom Severity Index (SSI) in 100 prostatitis patients presently being studied and 100 age matched control patients. These modified indices would be subsequently used as the basis for a consensus and evidence based NIH prostatitis specific symptom assessment instrument to be tested prospectively in 200 prostatitis and 100 control
18
Prostatitis
patients. Part 2: Analyze objective microscopic, microbiological, immunological and molecular biological aspects of expressed prostatic secretions, semen and urine specimen after prostatic massage in these 300 patients. of potential standardized treatment protocols (conservative, antibiotic, alpha blockade and repetitive prostatic massage; alone or in combination) will be tested in patients enrolled in part l and part 2. Results from this 3 part study will be analyzed and correlated between groups and within groups, both concurrently and sequentially. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHRONIC PROSTATITIS COLLABORATIVE CLINICAL STUDIES Principal Investigator & Institution: O'leary, Michael P.; Assistant Professor; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-1997; Project End 31-AUG-2003 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CHRONIC PROSTATITIS COLLABORATIVE CLINICAL STUDIES Principal Investigator & Institution: Alexander, Richard B.; Professor; Surgery; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2003; Project Start 05-SEP-2003; Project End 28-FEB-2008 Summary: (provided by applicant): Chronic prostatitis/chronic pelvic pain syndrome is a common but poorly understood condition affecting men of all ages. Infection has dominated the thinking about this disease for decades. However, a growing body of evidence provides significant challenge to the notion that infection contributes to symptoms in a significant proportion of patients. Much of this new information was developed by the Chronic Prostatitis Collaborative Research Network (CPCRN), a six year project representing the first NIH-funded collaborative study of chronic prostatitis. The long-term goal of this application is the continuation of our involvement in the Chronic Prostatitis Collaborative Research Network. In addition, we will collaborate with investigators studying interstitial cystitis under an umbrella group, the Urological Chronic Pelvic Pain Syndromes Collaborative Group. We describe the activities at our center over the past 7 years in the study of chronic prostatitis/chronic pelvic pain syndrome and describe the clinical and research infrastructure and expertise that we propose to continue to apply to the study of chronic prostatitis/chronic pelvic pain syndrome as part of this cooperative group. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CHRONIC PROSTATITIS COLLABORATIVE CLINICAL TRIALS Principal Investigator & Institution: Mcnaughton-Collins, Mary F.; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2003; Project Start 05-SEP-2003; Project End 28-FEB-2008 Summary: (provided by applicant): This application reflects a proposal from the Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) / Harvard Medical School to become one of the Clinical Centers of the Chronic Prostatitis Collaborative Research Network (CPCRN) to develop and conduct randomized clinical trials for evaluating novel therapies in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The BWH/MGH Harvard clinical center has a history of successful recruitment and retention of CP/CPPS patients, including a substantial
Studies
19
proportion of Latino patients, from the New England area for CPCRN 1997- 2003 - both for the Chronic Prostatitis Cohort Study and Randomized Clinical Trial. Drs. Mary McNaughton Collins and Michael O'Leary have advanced the field of CP/CPPS by helping to develop and validate the NIH-Chronic Prostatitis Symptom Index, translating the index to Spanish, evaluating the quality of life and resource utilization of men with CP/CPPS, as well as examining the epidemiology and natural history of the condition. Dr. McNaughton Collins has also performed several chronic prostatitis studies as a member of the Patient Outcomes Research Team (PORT) for Prostate Diseases and the Cochrane Collaboration. The BWH/MGH Harvard clinical center has expanded to include a multi-institutional and multi-disciplinary network of coinvestigators and consultants with both content (i.e., chronic prostatitis, pain management) expertise and methodological (i.e., clinical trials, basic science, and outcomes research) training, as well as fresh sources of chronic prostatitis patients, especially newly diagnosed patients and minority patients. The new reservoirs of CP/CPPS patients include: 1) newly diagnosed CP/CPPS patients from primary care practices and medical walk-in units across the two large institutions and their neighborhood health centers, including the BWH internal medicine Spanish clinic; 2) both newly diagnosed and long-term CP/CPPS patients from the MGH Spanish urology clinic, and; 3) both newly diagnosed and long-term patients from Boston Medical Center, which is a large, inner-city academic health center providing care to a large proportion of African American patients. To assist in the recruitment and retention of Latino men, the site now includes 3 Spanish speaking medicine and urology investigators, and the Research Coordinator is taking Spanish classes to become proficient. This proposal includes a clinical trial design for consideration by the CPCRN. The multi-institutional, multi-disciplinary team from the BWH/MGH Harvard clinical center is eager to collaborate on treatment trials and ancillary studies with other CPCRN centers, the NIH/NIDDK scientific team, and the Interstitial Cystitis Clinical Trials Group. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHRONIC PROSTATITIS COLLABORATIVE RESEARCH NETWORK Principal Investigator & Institution: Anderson, Rodney U.; Urology; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2003; Project Start 05-SEP-2003; Project End 28-FEB-2008 Summary: (provided by applicant): This application proposes that Stanford University School of Medicine, Department of Urology, participate as one of several National Clinical Centers in a cooperative effort to develop feasible clinical trials for the study of chronic prostatitis/chronic pelvic pain syndrome. The Principal Investigator intends to participate fully as a member of the steering committee in designing randomized controlled clinical trials and facilitate carrying them out in collaboration with other national center Pl's. The investigative group at Stanford will work in parallel with the centers conducting trials for investigation of interstitial cystitis. A simultaneous application for that effort is being submitted. While the precise pathophysiology and biologic basis of chronic pelvic pain, particularly associated with genitourinary dysfunction, have not been elucidated, a large number of men in the United States continue to suffer immeasurably for many years with this chronic disorder. Multimodal therapy exists as the only management approach and, for the most part, lacks sound scientific justification. The specific aim of this project is to utilize clinical experience from the most experienced and knowledgeable physicians available to design clinical trials of treatment modalities that may provide a favorable therapeutic response among the
20
Prostatitis
many sub-groups of this population of patients. Investigation within these trials will stretch from pharmaceutical to complimentary holistic treatment methods, representing the best of ideas chosen by the participating centers. The Stanford Group intends to contribute experience and expertise with regard to managing chronic prostatitis/chronic pelvic pain syndrome utilizing a neurobehavioral therapy and proposes a clinical trial of targeted physiotherapeutic myofascial release of painful trigger points with progressive relaxation exercises. The psychophysiological vagaries among patients suffering from this disorder have long been appreciated, but poorly defined, and deserve a fresh look with a dedicated "hands on" clinical effort conducted by several investigators simultaneously and with rigorous clinical research design. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHRONIC PROSTATITIS COLLABORATIVE RESEARCH NETWORK Principal Investigator & Institution: Litwin, Mark S.; Associate Professor; Urology; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2003; Project Start 05-SEP-2003; Project End 28-FEB-2008 Summary: (provided by applicant): The goal of this application is to establish a clinical trial center at UCLA, Harbor UCLA Medical Center, and Martin Luther King-Drew Medical Center that will participate in collaborative, multi-site clinical trials sponsored by a newly established NIDDK-sponsored Chronic Prostatitis Collaborative Research Network (CPCRN). As a CPCRN site, UCLA will (1) participate in the design of randomized controlled clinical trials to treat the symptoms associated with chronic prostatitis, also known as chronic pelvic pain syndrome (CPPS) (2) develop and conduct ancillary studies, which will provide further understanding of CPPS (3) determine if there is a different response to therapy between sub-groups of patients, including newly diagnosed and chronic, long-term patients with CPPS (4) recruit sufficient numbers of patients with CCPS, including an adequate number of newly diagnosed cases, into these clinical trials (5) jointly work with other CPCRN investigators, including a Data Coordinating Center, to analyze and interpret the results of the trials (6) participate in a newly established Urological Chronic Pelvic Pain Syndromes Collaborative Group to facilitate the efficient conduct of clinical trials in both interstitial cystitis and chronic prostatitis The study will develop a clinically relevant definition of the urologic chronic pelvic pain syndromes, based on the clinical findings from these and other related clinical studies. The UCLA site has demonstrated experience in recruiting minority subjects to participate in research studies, including clinical trials, for CPPS and other urologic conditions. The UCLA site will build upon its experience as a charter site in the first CPCRN to achieve the goals set out by the second. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CHRONIC PROSTATITIS CRC Principal Investigator & Institution: Krieger, John N.; Professor of Urology; Urology; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2003; Project Start 05-SEP-2003; Project End 28-FEB-2008 Summary: (provided by applicant): Prostatitis is a chronic, disabling condition affecting untold numbers of men of all ages and ethnic origins. We will participate in the Chronic Prostatitis Collaborative Research Network (CPCRN). Long-term goals are to prevent and effectively treat this condition. Specific aims are to cooperate and interact with the other clinical centers, the Data Coordinating Center (DCC) and NIDDK staff to: 1)
Studies
21
establish a collaborative group of clinical trial centers with expertise in chronic pelvic pain, clinical pain management, and chronic prostatitis 2) design randomized controlled clinical trials to treat the symptoms associated with chronic prostatitis 3) develop and conduct ancillary studies, which will provide further understanding of chronic prostatitis 4) determine if there is a different response to therapy between sub-groups of patients, including newly diagnosed and chronic, long-term patients 5) recruit a sufficient numbers of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), including an adequate number of newly diagnosed cases 6) jointly work with other CPCRN investigators, including the DCC, to analyze and interpret trial results 7) participate in the Urological Chronic Pelvic Pain Syndromes Collaborative Group (UCPPSCG) and 8) develop a clinically relevant definition of the urologic chronic pelvic pain syndromes, based on the clinical findings from these and other related clinical studies. Previous success in CP/CPPS studies allows us to meet the special requirements for this research including: the ability to recruit (and retain a high proportion of) at least 4-6 participants each month during years 2-4, the ability to recruit newly diagnosed cases, willingness to participate in a collaborative and interactive manner to develop the study protocols (both clinical trial and ancillary studies) and carry out the CPCRN trials, and willingness to participate in the UCPPSCG. We propose the following trial concept for consideration. Prior studies focused on refractory cases from tertiary referral centers. We propose to test the hypothesis that treatment outcomes in newly diagnosed cases are substantially better than in tertiary referral cases. We will screen the general population in Penang, Malaysia for new cases to compare with chronic cases from UW and other tertiary centers. Following clinical evaluation, CP/CPPS patients will be enrolled in a randomized clinical trial with a factorial design comparing alpha-blocker therapy, nonsteroidal anti-inflammatory therapy (or other therapies selected by the CPCRN), the combination, or placebo. Potential outcomes include: symptom indexes (e.g., the NIH-CPSI), urodynamics and inflammation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLINICAL TRIAL DEVELOPMENT IN CHRONIC PELVIC PAIN SYNDR* Principal Investigator & Institution: Shoskes, Daniel A.; Professor; Cleveland Clinic Foundation 9500 Euclid Ave Cleveland, Oh 44195 Timing: Fiscal Year 2003; Project Start 05-SEP-2003; Project End 28-FEB-2008 Summary: (provided by applicant): Chronic Pelvic Pain Syndrome (CPPS) is a prevalent multifactorial disorder with variable and often disappointing response to therapy. There is evidence for infection, inflammation and neuromuscular spasm as the underlying cause in different patients despite identical clinical presentation. Large multicenter clinical trials are required to help delineate effective therapies and to identify which patients have the highest chance of success for a particular intervention. The Chronic Prostatitis Clinic at the Cleveland Clinic Florida has a high volume of patients, both newly diagnosed and longstanding. We have done numerous clinical trials in chronic prostatitis with rapid enrolment, 100% accrual of set targets and high rates of retention. We have a team of clinical specialists in allied fields important to the understanding of this condition, including experts in erectile dysfunction, rectal dysfunction, chronic pain management, complementary therapies (acupuncture, phytotherapy) and neuropsychology. We also maintain a basic science laboratory which would be equipped to perform any necessary molecular or biochemical ancillary studies such as real time PCR, oxidative stress markers, cytokines and genetic polymorphisms. Through our participation in the CPCRN and first NIH chronic prostatitis randomized clinical
22
Prostatitis
trial, we have demonstrated the ability to work collaboratively and to participate in study design and execution. As an example of a potential clinical trial, a study of water induced thermotherapy is outlined. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DATA COORDINATING CENTER FOR CPCRN AND ICCRN Principal Investigator & Institution: Landis, J R.; Professor; Biostatistics and Epidemiology; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 28-FEB-2008 Summary: (provided by applicant): This is an application from the Center for Clinical Epidemiology and Biostatistics (CCEB) at the University of Pennsylvania Medical Center to serve as the Data Coordinating Center (DCC) for the Chronic Prostatitis Collaborative Research Network (CPCRN) and the Interstitial Cystitis Clinical Research Network (ICCRN). The proposed DCC will provide administrative, biostatistical, data management and research computing leadership for randomized clinical trials (RCTs) within each of these two collaborative networks. In addition, the DCC will serve as a central link among 20 clinical centers, potentially overlapping for both the CPCRN and ICCRN at a few sites, within the Urological Chronic Pelvic Pain Syndromes Collaborative Group (UCPPSCG), the overarching organization formed to facilitate common protocol and data collection procedures across these two networks. With supplemental funding, the DCC would also provide design, analysis and data coordination support for ancillary studies, as approved by the UCPPSCG. The proposed DCC is uniquely positioned with experience-based scientific, technical and administrative leadership to coordinate new RCTs for the UCPPSCG, currently serving as the DCC for the CPCRN (1997-2003) and the ICCTG (1998-2004), with 10 Clinical Research Centers (CRCs) within each network, as well as the previously funded Interstitial Cystitis Data Base (ICDB) Study (1993-1998). To support these multicenter RCTs, the DCC will provide the technical expertise necessary to design and implement data collection, quality assurance (QA), and reporting via a secure World Wide Web (www)-based data management system (DMS), deployed at the CRCs on existing hardware, to facilitate data entry, verification, validation and query resolution, and data transmission over the internet to servers at the DCC. This DMS will support subject screening and enrollment, randomization and data collection at the CRCs, and tracking of subjects and data at the DCC. The DCC will execute procedures for data security and access, QA, storage, back-up, disaster recovery, and will provide periodic monitoring and QA reports. The DCC will provide the scientific design and analysis, logistical and administrative support by organizing meetings of Steering Committees, coordinating development and distribution of RCT Protocols and Manuals of Operations, and providing the NIDDK Program Office, Steering Committees, and the Data and Safety Monitoring Board (DSMB) with interim and final statistical analyses, and collaboration on all scientific publications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DIAGNOSTIC CHALLENGES IN IC (AND MALE CPPS) Principal Investigator & Institution: Dimitrakov, Jordan D.; Queen's University at Kingston Kingston K7l 3N6, Canada Kingston, Timing: Fiscal Year 2003; Project Start 20-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): The etiology and pathogenesis of interstitial cystitis (IC) and its related condition in men, chronic prostatitis/chronic pelvic pain syndrome
Studies
23
(CP/CPPS) has remained elusive. This has hampered development of mechanistic treatment strategies for these common, chronic and distressing medical conditions. We believe that IC and perhaps CP/CPPS are a spectrum of complex but inter-related genetic and acquired diseases resulting from the interaction of several genes regulating immune/inflammatory and neurogenic parameters and environmental factors/circumstances or exposure, culminating in the combination of pain, frequency, urgency and sexual specific symptoms. New research has delineated the dynamic and powerful association of the immune and neurogenic system in pain activation. An immune-modulated neurogenic model of IC illuminating the action of immune derived substances and pain related substances might be important in discovering the determinants of pain, voiding dysfunction and gender specific sexual problems. This inter-related dynamic model of IC disease pathogenesis could be explored for potential avenues leading to novel diagnostic and treatment strategies. We plan to identify and evaluate the sensitivity and specificity of several novel nerve and inflammation related markers in the diagnosis and follow up of IC (and CP/CPPS). By correlating the levels of urine immune and pain related substances to disease mechanisms, severity and progression, we may be able to create a human disease specific model for diagnosis and treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EFFECTS OF STRETCH ON IC AND NORMAL UROTHELIA Principal Investigator & Institution: Chai, Toby C.; Associate Professor; Surgery; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2001; Project Start 15-JUN-2001; Project End 31-MAY-2006 Summary: (Adapted from the Applicant's Abstract): Interstitial cystitis (IC) patients typically present with extreme urinary frequency, urgency and pelvic pain. It has a 10:1 female:male predominance. Since the pathophysiologic picture of IC is unclear, cure remains elusive and treatment options are largely ineffectual. Even the diagnosis of IC is controversial. An objective diagnostic criterion is the cystoscopic appearance of glomerulations after bladder hydrodistention (stretch) under anesthesia. Recent data disputed the diagnostic specificity of this procedure because hydrodistention of control bladders resulted in glomerulations. Based on the investigators' preliminary data which showed that IC urothelia responded to stretch significantly differently than controls in cystoscopic appearance, levels of urinary heparin binding epidermal growth factor-like growth factor (HB-EGF), antiproliferative activity (APF), and adenosine triphosphate (ATP), they propose to test these hypotheses: 1. Bladder glomerulations, which appear after hydrodistention, are specific for NIH-IC symptoms criteria (NISC). 2. Male patients with chronic non-bacterial prostatitis (prostatitis class III or chronic pelvic pain syndrome, CPPS) and NISC have post-hydrodistention glomerulations whereas males with CPPS and no NISC do not. This observation would further strengthen the association of glomerulations with NISC. 3. Some NISC patients improve symptomatically after hydrodistention and degree of improvement correlates with changes in urinary markers (APF, HB-EGF and ATP). 4. In vitro stretch of IC urothelial cells results in increased ATP, HBEGF and decreased APF activity compared to stretch of control cells. 5. There is increased expression of P2X1 and P2X3 ATP receptors in IC compared to control bladder urothelium and suburothelium. This project is unique because it links clinical and laboratory data to test the central hypothesis that IC urothelia respond differently to stretch. Only human samples will be used to provide optimal clinical relevance. Findings from this study will clarify the current diagnostic dilemma regarding specificity of glomerulations for diagnosing IC and determine the
24
Prostatitis
therapeutic efficacy of hydrodistention. Furthermore, this study will explore the exciting new discovery that ATP released by stretched IC cells is significantly higher compared to controls. ATP may mediate nociception in the bladder. Urothelial stretch thus appears to be an important consideration in diagnosis, treatment and pathophysiology of IC. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EPIDEMIOLOGY OF CHRONIC PELVIC PAIN Principal Investigator & Institution: Clemens, J Quentin.; Assistant Professor; Urology; Northwestern University Office of Sponsored Programs Chicago, Il 60611 Timing: Fiscal Year 2001; Project Start 15-SEP-2001; Project End 31-AUG-2006 Summary: (Provided by Applicant): The primary aim of this application is to obtain novel information about chronic pelvic pain of bladder origin (CPPBO) in order to determine the magnitude of the problem and its cost to society. This study builds on our ongoing collaborative work with the NIH Chronic Prostatitis Collaborative Clinical Research Study, in which demographics, risk factors, quality of life, and health resource utilization are being evaluated in men with chronic voiding symptoms and pelvic pain. These studies are ongoing, and we will utilize similar methods in men and women in order to obtain consistent data for comparison between the sexes. The specific aims are: 1) to assess the prevalence and incidence of CPPBO. A clinically useful definition of the syndrome will be described, and this definition will be used to assess the prevalence of the syndrome in a large, diverse patient population. Using the same definition, the incidence of new cases will subsequently be determined over a three-year time period; 2) to determine risk factors for the development of CPPBO. A case-control study will be performed using age- and gender-matched controls in order to evaluate for medical conditions and lifestyle factors which are associated with the syndrome; and 3) to evaluate the effect of CPPBO on patient quality of life and health resource utilization. To conduct this study, two populations will be utilized. A database of patients from the Kaiser Permanente Foundation Hospitals in Oregon will be used to assess population prevalence and incidence rates and direct medical costs. Questionnaires will be mailed to a random sample of the Kaiser Permanente patients to obtain detailed information about symptoms and quality of life (QOL). In addition, patients diagnosed with CPPBO at the Northwestern Memorial Faculty Foundation Urology Clinic will undergo a more extensive questionnaire evaluation to analyze medical and lifestyle risk factors for the presence of CPPBO and to obtain additional QOL and health resource utilization information. Answers from the Urology clinic patients will be compared with those of age-and gender-matched controls in a case-control study design. This project will provide novel, population-based epidemiologic information about chronic pelvic pain of bladder origin in both men and women, and will help to further define the public health burden of this extremely common condition. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMMUNOLOGIC THERAPY OF PROSTATE CANCER Principal Investigator & Institution: Chatta, Gurkamal S.; Medicine; University of Arkansas Med Scis Ltl Rock 4301 W Markham St Little Rock, Ar 72205 Timing: Fiscal Year 2001; Project Start 04-APR-1997; Project End 01-MAY-2002 Summary: Prostate cancer is currently the commonest cancer in men. Sixty percent of new cases at the time of diagnosis are not organ confined. Once prostate cancer is far advanced, the impact of therapy has been marginal. Additional methods to intervene therapeutically in advanced disease are needed. One potential novel intervention would
Studies
25
be T cell vaccines and/or T cell therapy directed against prostate specific antigens. There is increasing evidence, that there is an existent immune response to cancer in many patients and that some of the antigens recognized by autologous B cells and T cells are diffentiation antigens. What remains to be determined is whether immune responses against diffentiation antigens can be manipulated to confer protection against the cancer. A major theoretical problem with targeting T cell therapy against differentiation antigens is that eliciting or boosting such immunity can result in destructive autoimmunity. However, if autoimmunity is elicited against tissues with dispensable function, (i.e., the prostate gland in patients with prostate cancer), the destructive autoimmunity might eradicate cancer cells originating in the nominated tissue. Others have shown that immunizing rodents to homogenate prostate tissue can induce T cell mediated autoimmune prostatitis. However, the target antigens are unknown, and the autoimmunity has been observed to be self limited. Issues that need to be elucidated before attempting to develop the use of autoimmune prostatitis as therapy in humans for prostate cancer include: 1) which prostate- specific proteins can serve as targets for T cell attack, 2) how to prospectively and effectively circumvent tolerance to prostate self proteins, and, 3) how to sustain the destructiveness of autoimmune prostatitis. Current grant proposes to examine these issues in a rat model. The prototype antigen selected for study is prostatic acid phosphatase (PAP), a known tumor marker for human prostate cancer. Rat PAP, a 50kD secreted glycoprotein made exclusively by prostatic epithelial cells, is 79 percent homologous to human PAP. Thus, principles elucidated in the rat model might be applicable to the human situation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTERSTITIAL CYSTITIS CLINICAL RESEARCH NETWORK Principal Investigator & Institution: Payne, Christopher K.; Associate Professor; Urology; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 28-FEB-2008 Summary: (provided by applicant): This application proposes that Stanford University Center for Female Urology and NeuroUrology participate as one of several National Clinical Centers in a cooperative effort to develop clinical trials for the study of interstitial cystitis (IC). The Principal Investigator intends to participate fully as a member of the steering committee in designing and carrying out multicenter randomized controlled clinical trials (RCTs). The investigative group at Stanford will work in parallel with the centers conducting trials for investigation of chronic prostatitis. A simultaneous application for that effort is being submitted. This is a critical juncture for IC research. While appreciation of the prevalence and impact of the disease is growing, little headway has been made in identifying the underlying etiology or finding reliably effective treatment. More importantly, the very definition of IC and pelvic pain syndromes is under active debate--are all patients with pelvic pain simply varying manifestations of a single underlying disorder or are there important clinical distinctions between IC, vulvadynia, chronic prostatitis, and pelvic floor dysfunction? The relevance of standard diagnostic tools has been challenged. Bladder distention under anesthesia may be neither sensitive nor specific. Neither urodynamic testing nor bladder biopsy provides specific diagnostic information. A simple office trial of intravesical potassium instillation purported to identify IC totally failed to predict response to therapy in a RCT. These and other critical issues will only be settled by carefully designed, large scale RCTs. The ICCRN should focus on the following specific aims: 1) determining the clinical utility of currently diagnostic tests for IC and evaluating new tests 2) developing evidence based algorithms for the work-up of IC
26
Prostatitis
patients involved in clinical research 3) developing relevant clinical protocols that involve the entire spectrum of IC patients 4) to test novel therapies for IC as they become available. Stanford is ideally suited for this project due to a long history of interest in IC, a Principal Investigator with recognized expertise in clinical research, an ethnically diverse patient base, and demonstrable success recruiting patients for IC research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTERSTITIAL CYSTITIS CLINICAL RESEARCH NETWORK Principal Investigator & Institution: Burks, David A.; Senior Staff Urologists; Urology; Case Western Reserve Univ-Henry Ford Hsc Research Administraion Cfp-046 Detroit, Mi 48202 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 28-FEB-2008 Summary: (provided by applicant): Interstitial cystitis is a chronic debilitating disease characterized by urinary frequency, urgency and bladder pain. Despite the first descriptions of this disease by Guy Hunner in 1914, it still remains "The Great Enigma." The disease continues to defy a consensus definition, a definable pathophysiology or a reliably effective treatment. Multiple theories of pathogenesis have spawned a myriad of mostly ineffective treatments. Many physicians either doubt, or are unaware of the existence of this disease causing significant delay in diagnosis for many patients, especially men and children, where the disease is most poorly characterized. Since 1987 the NIH has begun a systematic, evidence-based effort to define interstitial cystitis determine its biochemical and clinical characteristics and evaluate novel therapies. Beginning with the NIDDK Workshop and Consensus Conference, the definition of interstitial cystitis has evolved from a restrictive instrument used for research papers, to a more inclusive criteria developed by the Interstitial Cystitis Data Base Group. The Interstitial Cystitis Clinical Trials Group proved that a collaborative multi-center group could recruit patients into rigorous, novel treatment protocols. The major objective of this grant is to develop the Interstitial Cystitis Clinical Research Network to continue the evolution in characterizing this disease. We propose evaluating a novel therapy, IPD1151T, an immune system modulator with possible efficacy in interstitial cystitis patients. A published pilot study showed significant improvement in symptom scores with minimal side effects. The ICCRN will work in collaboration with the Chronic Prostatitis Clinical Research Network to investigate interstitial cystitis as a subset of chronic pelvic pain disorders of the bladder. A coordinated effort to develop common patient evaluation and treatment protocols, will allow an overarching analysis of these urologic pain syndromes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INTERSTITIAL CYSTITIS CLINICAL RESEARCH NETWORK (ICCRN) Principal Investigator & Institution: Kreder, Karl J.; Professor; Urology; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 28-FEB-2008 Summary: (provided by applicant): The long-term objectives and specific aims of this proposal are to establish the University of Iowa Interstitial Cystitis Research Group as a clinical center in the Interstitial Cystitis Clinical Research Network (ICCRN). The purpose of this network is to establish a collaborative group of centers with expertise in pelvic pain and interstitial cystitis to conduct controlled clinical trials that will provide
Studies
27
further understanding of interstitial cystitis. Additionally this network will participate in the Urologic-Chronic Pelvic Pain Syndromes Collaborative Group to conduct trials in chronic prostatitis. A concept protocol using low dose BCG and interferon-alpha(alpha) is included in this proposal. The recruitment, marketing and retention strategies outlined in the following sections will ensure enrollment of between four and six patients per month as well as maximize this center's ability to recruit minority populations. This center has all the clinical and laboratory support as stated in the protocol. The following sections outline innovative methods to recruit both male and female interstitial cystitis patients as well as multiple strategies to ensure long term compliance and completion of all scheduled follow-up visits. In summary, this proposal outlines what we believe are the outstanding credentials of the University of Iowa Interstitial Cystitis Research Group to serve as a Clinical Center in the multi-institutional Interstitial Cystitis Clinical Research Network (ICCRN). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTERSTITIAL CYSTITIS CLINICAL RESEARCH NETWORK (ICCRN) Principal Investigator & Institution: Sant, Grannum R.; New England Medical Center Hospitals 750 Washington St Boston, Ma 021111533 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 28-FEB-2008 Summary: (provided by applicant): The objectives of this proposal are the initiation and development of the Interstitial Cystitis Clinical Research Network (ICCRN) and the performance of randomized controlled multicenter clinical trials for the treatment of interstitial cystitis (IC). These objectives will be achieved by: (a) development and design of medical treatment protocols for IC and a manual of operations in conjunction with a Steering Committee consisting of the Clinical Centers, the Data Coordinating Center and the NIDDK Project Scientist. (b) recruitment and retention of patients who meet agreed upon Clinical Trials entry criteria The Specific Aims of the proposal are: (a) to assess the therapeutic effectiveness of drug (approved, investigational, other) and non-drug treatment of IC in well-characterized cohorts of IC patients (newly diagnosed, chronic, minority populations) (b) to utilize validated and meaningful treatment outcome measures (eg., SF-36 health-related quality of life; the O'Leary-Sant Symptom/Problem Index, global response assessment (GRA) (c) recruitment of a minimum of 50 patients/year for 4 years (total 200 patients). The Principal Investigator (Dr. Grannum R. Sant, has a 20 year experience in the diagnosis and treatment of IC and has a large IC patient population within his clinical practice. (d) there will be an initial 12 month period of collaborative protocol/manual of operations development, followed by 48 months of patient recruitment with concurrent data analysis and reporting. (e) coordinate protocol development and clinical outcomes analyses with the Chronic Prostatitis Clinical Research Network (CPCRN) under the umbrella of the Urological Chronic Pain Syndromes Collaborative Network (UCPPSCG). The data obtained from these randomized controlled studies will define the effectiveness of various therapies for IC and improve the quality of life of patients suffering from IC. The collaboration with the UCPPSCG will better define the urological pelvic pain syndromes (male and female) and lead to better classification and treatment outcomes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
28
Prostatitis
•
Project Title: INTERSTITIAL CYSTITIS CLINICAL RESEARCH NETWORK (ICCRN) Principal Investigator & Institution: Hanno, Phillip M.; Surgery; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 28-FEB-2008 Summary: (provided by applicant): This is an application from the Division of Urology of the University of Pennsylvania Health System (UPHS) to participate as a clinical site for the Interstitial Cystitis Clinical Research Network (ICCRN). The UPHS clinical site encompasses the core group of highly talented and experienced investigators who worked as a part of the Interstitial Cystitis Data Base Study and in the Interstitial Cystitis Clinical Trials Group (ICCTG), currently in its 5th year. The Div of Urology of the UPHS and the Univ of Pennsylvania has demonstrated their support and commitment to research on IC by actively participating in ICCTG #1 and #2. The Division of Urology of the UPHS Center, supports the broad research goals of the NIDDK with regard to interstitial cystitis (IC) and related disorders, through the following specific aims: Aim 1: To maintain our IC clinical network pertaining to all aspects of patient care, including recruiting and retaining patients with an appropriate age, race, and gender representation; providing high quality care; monitoring and ensuring safety; and coaching and encouraging subjects to be compliant with study protocols. Aim 2: To collaborate and provide scientific expertise on IC in all phases of the clinical trials and associated basic science or clinical additions to the core studies to aid in the discovery of new ways to determine the etiology, most efficient diagnosis, and best treatments of IC. Aim 3: To conduct objective, controlled, scientifically validated studies in order to determine the overall utility and efficacy of a variety of novel therapies for IC. A Central component is to continuously review and refine entry criteria as well as outcome parameters as additional scientific evidence becomes available. Aim 4: To work together as part of the Urological Chronic Pelvic Pain Syndromes Collaborative Group (UCPPSCG) with the following goals: (1) to shorten the period of protocol development, (2) to collect common information to permit comparisons of the clinical characteristics of these two conditions, (3) to facilitate decisions on treatments to be evaluated, and (4) to increase the rate of accrual of study participants. Aim 5: To develop a suitable clinical definition of IC, a clinically and scientifically based assessment of where the disease falls in the spectrum of chronic pelvic pain, pelvic floor dysfunction, and prostatitis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS FOR ACQUIRED CHANGES IN PROSTATE GROWTH REGU* Principal Investigator & Institution: Bushman, Wade A.; Professor; Surgery; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2008 Summary: The impact of aging on prostate growth regulation is central to efforts to elucidate the genesis of BPH and identify factors which contribute to prostate cancer initiation and progression. Three growth perturbing influences afflict the prostate of the aging male: tonic androgen stimulation, oxidative stress, and environmental exposure to chemical or toxic compounds. Each of these influences alone can disrupt normal growth regulation but the compounding effect of these influences is likely to be much larger. Acting in combination over the lifespan of an individual, these influences are postulated to degrade the normal growth regulatory mechanisms charged with maintaining growth
Studies
29
homeostasis. The unifying hypothesis of this O'Brien Center proposal is that aging and the environment produce acquired changes in prostate growth control that predispose to neoplasia. This proposal examines the pathways and mechanisms that mediate those effects. The proposed Center embraces seven research subprojects. Four subprojects will examine how androgen stimulation produces oxidative stress, elucidate how changes in cellular redox state produces epigenetic changes in gene regulation and growth regulation, and examine the effect of oxidative stress on gene imprinting. Three subprojects examine chemical influences on prostate growth. One examines the mechanism of action of green tea; a second focuses on the plantalkaloid sensitive hedgehog signaling pathway; and a third project, an NIEHS merit award included as a non-reviewed project, examines the effect of dioxin on prostate development. Two DR/P&F projects selected from a total of 9 submitted preproposals address the immunology of androgen withdrawal induced prostatitis and the potential to design small molecule inhibitors of key signal transduction pathways based on peptide motif analysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR ANALYSIS OF PATHOGENS IN OTITIS MEDIA BY PCR Principal Investigator & Institution: Ehrlich, Garth D.; Executive Director; AlleghenySinger Research Institute 320 E North Ave Pittsburgh, Pa 15212 Timing: Fiscal Year 2001; Project Start 01-DEC-1993; Project End 28-FEB-2003 Summary: (Adapted from the Applicant's Abstract) The proposal by Ehrlich and colleagues, "Molecular Analysis of Pathogens in Otitis Media by PCR," is a nonoverlapping continuation research application. The investigations planned will attempt to capitalize on and extend this group's findings dealing with infectious agents in otitis media (OM) currently funded as 5R01 DC02148-03 (Ehrlich), expiration date 11/30/97. Ehrlich's group has documented the presence of bacterial DNA and H. influenzae transcripts in culture-negative, otitis media with effusions (OME). This demonstration is a departure from one theory regarding the etiology of effusion in OM which holds that bacterial products, but not live bacteria, are responsible for causing the effusion. An experimental chinchilla animal model was developed and supported the PCR-based findings and suggested that antibiotic-treated bacteria may persist in a culture-sterile, but PCR-positive state for weeks. This continuing application will concentrate on the molecular biology of H. influenzae and factors which may lead to the development of OME. The central hypothesis which will be explored is whether OME is initiated and maintained by the establishment of biofilms. Biofilms are networks of adherent, or sessile, bacteria distinct from free-floating, or planktonic, forms. Biofilms have been implicated in causing contamination of implantable devices, "sterile" arthritis, and prostatitis. Biofilm formation results from the coordinated expression of sets of genes that are induced upon bacterial attachment. Once formed, multiple species can live in specific microenvironments protected from the external environment and display extraordinary tolerance to antibiotics. This tolerance is primarily attributable to the reduced metabolic activity and lowered rates of cell division of sessile bacteria when compared to planktonic forms. To test these hypotheses the researchers will compare, through differential gene expression, the metabolic activity of free-floating bacteria, biofilm bacteria, and viable, culture-negative organisms from middle-ear effusions. To further characterize the transcriptionally active, effusion-derived H. influenzae, pulse chase experiments using RIPAs will be employed to evaluate levels of protein synthesis in the animal OM model. The focus will also be directed to other infectious agents that
30
Prostatitis
have been implicated in OME, including M. catarrhalis and S. pneumoniae, and OME will be assessed for the presence of the corresponding bacterial mRNA species using RTPCR. In a second series of experiments, the sterile OME-derived H. influenzae mRNAs will be screened for possible transcripts encoding inflammatory mediators. In a third series of experiments, attempts will be made to characterize the genes involved in H. influenzae biofilm formation and compared with the established biofilm-forming agent P. aeruginosa. A combined final series of experiments will attempt to determine the mechanism(s) that regulate or trigger the formation of biofilms and to correlate different models of mutational2 induction with the consequences of antibiotic therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTISPECTRAL BACTERIAL IDENTIFICATION Principal Investigator & Institution: Robles, Steven J.; Kairos Scientific, Inc. 10225 Barnes Canyon Rd, #a110 San Diego, Ca 92121 Timing: Fiscal Year 2001; Project Start 01-APR-1999; Project End 31-AUG-2004 Summary: During Phase 1, a multispectral optical technique was developed to simultaneously classify individual bacterial cells within mixed populations. Multispectral Bacterial Identification (mBID) combines innovations in microscopy with a software analysis program to measure and categorize the fluorescence signals from multiplexed 16S ribosomal RNA probes hybridized to populations of different bacteria. Software was developed to identity individual bacteria at the level of species within these mixed populations. In Phase 2, we plan to couple this new multispectral technology to existing identification technologies that utilize 16S rRNA sequence alignment. Using this integrated identification protocol, bacteria that may be associated with chronic conditions (e.g., prostatitis and vaginosis) will be identified first by analyzing their 16S rDNA sequences and then by visualizing them with fluorescent probes hybridized to their 16S rRNA in situ. Phase 2 activities will also include a merger of many of the steps required in both sequence-based and spectral-based ID. A major focus of this work will be to further automate the Phase 1 prototype instrument in terms of acquisition and radiometric processing of multispectral image stacks. These efforts will facilitate a single technology platform for multispectral rRNA-based bacterial ID that is generally applicable to populations of (unculturable) bacteria growing within consortia and biofilms, with applications in both clinical and environmental microbiology. PROPOSED COMMERCIAL APPLICATIONS: We shall provide an integrated technology platform to the general microbiology research community for rRNA-based identification of multiple bacterial species in a single sample. In Phase 3, this technology could be used in clinical research laboratories to follow diseases that may be caused by bacterial consortia or biofilms. The size of the in vitro microbiology diagnostic market was recently estimated by Market Data International to be $1.4 billion. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PATHOGENESIS OF NON BACTERIAL CHRONIC PROSTATITIS Principal Investigator & Institution: Albertsen, Peter C.; University of Connecticut Sch of Med/Dnt Bb20, Mc 2806 Farmington, Ct 060302806 Timing: Fiscal Year 2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
Project Title: REGULATORY PROGRESSION
MECHANISMS
OF
PROSTATE
31
TUMOR
Principal Investigator & Institution: Heston, Warren D.; Staff & Director; Cleveland Clinic Foundation 9500 Euclid Ave Cleveland, Oh 44195 Timing: Fiscal Year 2001; Project Start 30-SEP-1993; Project End 31-AUG-2003 Summary: Abnormal conditions or the prostate constitute a major medical problem in the United States. Prostatitis, benign enlargement (BPH), and malignant growth of the prostate (CaP), will effect the lives of most men over the age of 50. BPH is a bothersome abnormal growth that fortunately is readily treated by a variety of options. Prostate cancer, if detected early is curable. However, metastatic disease can be fatal, as there is currently no available curative therapy for metastatic prostate cancer. In addition, because of the extreme heterogeneity with regard to the biologic potential of prostatic cancer, there is debate on the approach to therapy, even with localized disease. There is a lack of consensus and viable approaches to management and therapy for CaP. This reflects our lack of knowledge regarding the biologic determinants responsible for this spectrum of behavior at a level that would provide appropriate therapeutic intervention. This O'Brien Urology Center project will focus its attention on determining changes in the cellular phenotype that is associated with disease progression from normal to premalignant lesions, to localized cancer, and to distant disseminated disease. In this project we will center on three areas related to cellular signaling and cell cycle programming as it related to benign and malignant prostate growth. The first project will focus its research efforts on cell cycle regulation in prostate cancer progression. The second project will examine alterations in PKC isozyme signaling in metastatic progression and in apoptotic cell death. The third project will examine the role of PSM antigen as a folate hydrolase in the biology of the prostate and its evolution to cancer. These projects and the recruitment of developmental programs to the Center are designed to provide an understanding of the biology of progression of CaP and developing strong rational for innovative interventional strategies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RHO-MODIFYING CYTOTOXIC NECROTIZING FACTOR OF E. COLI Principal Investigator & Institution: O'brien, Alison D.; Professor of Microbiology & Immunol; Henry M. Jackson Fdn for the Adv Mil/Med Rockville, Md 20852 Timing: Fiscal Year 2002; Project Start 30-SEP-1995; Project End 30-APR-2007 Summary: Cytotoxic necrotizing factor type 1 (CNF1) is a member of a family of bacterial toxins that target the Rho family of small GTP-binding proteins in mammalian cells. CNF1 deamidates a single glutamine residue in RhoA, Cdc42, and Rac1 but not in Ras. This deamidation results in the constitutive activation of these GTPases which can trigger actin stress fiber formation, multinucleation, or cell death, depending on the target cell and dose of toxin. CNF1 is frequently produced by Escherichia coli strains that cause urinary tract infections (UTIs), such as cystitis, prostatitis, and pyelonephritis. In support of this epidemiological connection, we recently showed that CNF1 not only induces apoptosis in 5637 human uroepithelial cells but also provides a growth advantage to uropathogenic E. coli (UPEC) in a mouse model of ascending UTI when compared to CNF1-negative isogenic mutants. Additionally, we found that CNF1 enhances the degree of inflammation and resulting tissue damage in bladders of infected mice and in prostates of rats challenged intraurethrally with CNF1-producing UPEC. Finally, we discovered that CNF1- producing UPEC survive better than CNF1-
32
Prostatitis
negative isogenic mutants in the presence of human polymorphonuclear leukocytes (PMNs). Taken together, these findings have led us to propose the following hypothesis. CNF1 enhances the pathogenicity of UPEC by: i.) promoting uroepithelial cell shedding; ii.) evoking a large influx of PMNs while providing toxin-producing E. coli protection against PMN-mediated killing, and; iii.) facilitating deeper invasion of the bladder or prostate by the infecting strain. The specific aims designed to test this theory are to: 1.) further define the role that CNF1 plays in the pathogenesis of UPEC-mediated cystitis in the mouse and prostatitis in the rat by analyzing the interaction of CNF1 or CNF1expressing UPEC with PMNs from these animals and by defining the CNF1-mediated cytokine response that evokes PMN influx; 2) investigate the cellular and cytokine responses of a human bladder organoid to CNF1 or a CNF1-producing UPEC strain; 3.) identify the functional receptor for CNF1 by sequential biochemical and molecular approaches, and; 4.) continue to evaluate CNF1 structure and function by characterizing the CNF1 epitopes recognized by neutralizing monoclonal antibodies and by analyzing chimeric molecules comprised of portions of CNF1 and the related toxins CNF2, Pasteurella multocida toxin, and the Bordetella dermonecrotic toxin. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TARGETED CTL MEDIATED IMMUNITY FOR PROSTATE CANCER Principal Investigator & Institution: Frelinger, John G.; Professor; Microbiology and Immunology; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2001; Project Start 01-SEP-1996; Project End 31-AUG-2003 Summary: (Adapted from investigator's abstract): A loner term goal of this work is to test the hypothesis that a tissue-specific and developmentally regulated antigen may be used for the effective immuno-therapy of prostate cancer. Prostate cancer is the second leading cause of cancer deaths in men and an important disease of the aged. A serious limitation in the past has been the lack of defined and authentic tumor antigens, which would be applicable to humans, yet have the experimental advantages of an animal model. To address these issues the investigators have developed transgenic mice that express human prostate specific antigen (hPSA) in a pattern remarkably similar to humans. In this project they will examine how the specific expression of hPSA in the prostate affects the cell-mediated immune, response to PSA. Using a novel molecular approach, they will determine which PSA epitopes are recognized in the PSAexpressing mice compared to non-transgenic mice. These studies will test the hypothesis that the PSA-CD transgenic mice, in which PSA is a self-antigen, are tolerant to one or more immuno-dominant epitopes, but are capable of responding to this antigen via recognition of a different subset of PSA epitopes that are normally subdominant or cryptic. The PSA epitopes for both CD4 and CD8 cells restricted to mouse class I molecules, as well as those presented by the human HLA-A2 class I molecule, will be determined. They believe they have incorporated a method for not only identifying, but also improving upon tumor-antigen epitopes. Altered peptide ligands with improved MHC binding or improved recognition by the T cell receptor will be created and tested for their ability to stimulate protective responses against tumors expressing native hPSA. Further, using this model they will explore if a vigorous response to PSA results in autoimmune prostatitis. Finally, these results will be incorporated into immunotherapy strategies using mice that develop prostate cancer spontaneously. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
33
Project Title: VIRULENCE FACTORS OF CHLAMYDIAE Principal Investigator & Institution: Wyrick, Priscilla B.; Professor; Microbiology; East Tennessee State University Box 70565 Johnson City, Tn 37601 Timing: Fiscal Year 2001; Project Start 01-APR-1995; Project End 31-MAR-2005 Summary: Chlamydia trachomatis serovars D-K are the most common cause, in the USA and worldwide, of bacterially-acquired sexually transmitted diseases and their sequelae, including prostatitis, epididymitis, pelvic inflammatory disease, ectopic pregnancy and sterility. Chlamydial diseases are insidious and they constitute significant primary, secondary and tertiary health concerns in which women bear a special burden because of their increased risk of adverse reproductive consequences. The goal of this laboratory for 25 years has been to try to understand the basic biology of chlamydial growth in its host epithelial cell in order to understand the infectious process and to permit dissection of the cellular and molecular consequences of persistent infection, since the majority of chlamydial tubal disease appears to result from chronic subclinical, persistent infection. This proposal is a continuation of on-going efforts to understand the crucial attachment/entry steps, the signals in chlamydiae-infected epithelial cells which trigger neutrophil chemotaxis--since a prolonged inflammatory response to persistent chlamydial antigens is believed to be responsible for the damage and sequelae, and hormone modulation of entry and signaling of neutrophils. In Aim 1, the chlamydial envelope-associated hsp70 and its co- chaperonins GrpE and DnaJ will be incorporated into liposomes, along with known and suspected adhesins, to define the role of hsp70 in entry and, in Aim 2, help identify the receptor which functions with newly identified, estrogen-responsive receptor accessory proteins. Also in Aim 2, the swine C. trachomatis S45 isolate- swine genital tissue model of infection will be developed to dissect hormone modulation of entry and neutrophil signaling (Aim 3). In Aim 3, a comparison will be made of chlamydial and chemokine signals triggering neutrophil chemotaxis to polarized HeLa cells normally and persistently infected with noninvasive, asymptomatic serovar E versus invasive, symptomatic serovar L2. Finally, in Aim 4, cryo-electron microscopy and density gradients will be used to show that chlamydial antigen secretion and trafficking can occur via vesicles pinched off from the chlamydial inclusion. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “prostatitis” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for prostatitis in the PubMed Central database: 3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
34
Prostatitis
•
Chronic Prostatitis Due to Yersinia pseudotuberculosis. by Naiel B, Raul R.; 1998 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104649
•
Cytotoxic Necrotizing Factor Type 1-Positive Escherichia coli Causes Increased Inflammation and Tissue Damage to the Prostate in a Rat Prostatitis Model. by Rippere-Lampe KE, Lang M, Ceri H, Olson M, Lockman HA, O'Brien AD.; 2001 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=98788
•
Differences in Virulence Factors among Clinical Isolates of Escherichia coli Causing Cystitis and Pyelonephritis in Women and Prostatitis in Men. by Ruiz J, Simon K, Horcajada JP, Velasco M, Barranco M, Roig G, Moreno-Martinez A, Martinez JA, Jimenez de Anta T, Mensa J, Vila J.; 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=154654
•
Diverse and Related 16S rRNA-Encoding DNA Sequences in Prostate Tissues of Men with Chronic Prostatitis. by Riley DE, Berger RE, Miner DC, Krieger JN.; 1998 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104894
•
Prevalence of Corynebacterial 16S rRNA Sequences in Patients with Bacterial and "Nonbacterial" Prostatitis. by Tanner MA, Shoskes D, Shahed A, Pace NR.; 1999 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84971
•
Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. by Krieger JN, Riley DE, Roberts MC, Berger RE.; 1996 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229469
•
Prostatitis. by Domingue GJ Sr, Hellstrom WJ.; 1998 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88899
•
Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis. by Wolfson JS, Hooper DC.; 1989 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=172733
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with prostatitis, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “prostatitis” (or
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
Studies
35
synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for prostatitis (hyperlinks lead to article summaries): •
A case of imported melioidosis presenting as prostatitis. Author(s): Heyse AM, Dierick J, Vanhouteghem H, Ameye F, Baert D, Burvenich P, Wauters G. Source: Infection. 2003 January; 31(1): 60-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12590337&dopt=Abstract
•
A new high frequency electrostimulation device to treat chronic prostatitis. Author(s): John H, Ruedi C, Kotting S, Schmid DM, Fatzer M, Hauri D. Source: The Journal of Urology. 2003 October; 170(4 Pt 1): 1275-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14501740&dopt=Abstract
•
A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. Author(s): Nickel JC, Pontari M, Moon T, Gittelman M, Malek G, Farrington J, Pearson J, Krupa D, Bach M, Drisko J; Rofecoxib Prostatitis Investigator Team. Source: The Journal of Urology. 2003 April; 169(4): 1401-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12629372&dopt=Abstract
•
A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index. Author(s): Litwin MS. Source: Urology. 2002 December; 60(6 Suppl): 14-8; Discussion 18-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521581&dopt=Abstract
•
A study of the use of norfloxacin in prostatitis. Author(s): Sheikh MA, Naqvi SA. Source: Chemioterapia. 1987 June; 6(2 Suppl): 529-30. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3334615&dopt=Abstract
•
Acupuncture ameliorates symptoms in men with chronic prostatitis/chronic pelvic pain syndrome. Author(s): Chen R, Nickel JC. Source: Urology. 2003 June; 61(6): 1156-9; Discussion 1159. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12809886&dopt=Abstract
•
Acupuncture treatment in 102 cases of chronic prostatitis. Author(s): Ge SH, Meng FY, Xu BR. Source: J Tradit Chin Med. 1988 June; 8(2): 99-100. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3412022&dopt=Abstract
36
Prostatitis
•
Acute and chronic prostatitis: diagnosis and treatment. Author(s): Meares EM Jr. Source: Infectious Disease Clinics of North America. 1987 December; 1(4): 855-73. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3333662&dopt=Abstract
•
Acute prostatitis: which antibiotic to use first? Author(s): Becopoulos T, Georgoulias D, Stathakis H, Kosmidis J. Source: Chemioterapia. 1987 June; 6(2 Suppl): 527-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3509490&dopt=Abstract
•
Advanced therapy for prostatitis: minimally invasive and invasive therapies. Author(s): El-Hakim A, Shah DK, Smith AD. Source: Curr Urol Rep. 2003 August; 4(4): 320-6. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12882727&dopt=Abstract
•
Aetiology of chronic prostatitis. Author(s): Skerk V, Schonwald S, Krhen I, Markovinovic L, Beus A, Kuzmanovic NS, Kruzic V, Vince A. Source: International Journal of Antimicrobial Agents. 2002 June; 19(6): 471-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12135835&dopt=Abstract
•
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Author(s): Mehik A, Alas P, Nickel JC, Sarpola A, Helstrom PJ. Source: Urology. 2003 September; 62(3): 425-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12946740&dopt=Abstract
•
Allopurinol for chronic prostatitis. Author(s): McNaughton CO, Wilt T. Source: Cochrane Database Syst Rev. 2002; (4): Cd001041. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12519549&dopt=Abstract
•
Alpha-blockers: an effective treatment for prostatitis? Author(s): Caropreso D, Moon TD. Source: Curr Urol Rep. 2000 August; 1(2): 148-54. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12084329&dopt=Abstract
•
An evidence-based approach to the treatment of prostatitis: is it possible? Author(s): Doble A. Source: Curr Urol Rep. 2000 August; 1(2): 142-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12084328&dopt=Abstract
Studies
37
•
An overview of holistic medicine and complementary and alternative medicine for the prevention and treatment of BPH, prostatitis, and prostate cancer. Author(s): McClure MW. Source: World Journal of Urology. 2002 November; 20(5): 273-84. Epub 2002 September 28. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12522583&dopt=Abstract
•
Antimicrobial therapy for bacterial and nonbacterial prostatitis. Author(s): Fowler JE Jr. Source: Urology. 2002 December; 60(6 Suppl): 24-6; Discussion 26. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521585&dopt=Abstract
•
Antimicrobials for the treatment of bacterial prostatitis. Historical developments and current trends. Author(s): Baumuller A. Source: Scand J Urol Nephrol Suppl. 1987; 104: 97-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3326159&dopt=Abstract
•
Application of real-time polymerase chain reaction technology to detect prostatic bacteria in patients with chronic prostatitis/chronic pelvic pain syndrome. Author(s): Takahashi S, Riley DE, Krieger JN. Source: World Journal of Urology. 2003 June; 21(2): 100-4. Epub 2003 May 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12743735&dopt=Abstract
•
Azithromycin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Author(s): Skerk V, Schonwald S, Krhen I, Strapac Z, Markovinovic L, Kruzic V, Puntaric A, Vrsalovic R, Vukovic J. Source: Journal of Chemotherapy (Florence, Italy). 2001 December; 13(6): 664-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11806631&dopt=Abstract
•
Bacille-Calmette-Guerin vaccine-induced granulomatous prostatitis: another hypoechoic nonneoplastic lesion. Author(s): Torres GM, Kaude JV, Drylie D. Source: Ajr. American Journal of Roentgenology. 1990 July; 155(1): 195-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2112849&dopt=Abstract
•
Bacteria in the chronic prostatitis-chronic pelvic pain syndrome: molecular approaches to critical research questions. Author(s): Krieger JN, Riley DE. Source: The Journal of Urology. 2002 June; 167(6): 2574-83. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11992091&dopt=Abstract
38
Prostatitis
•
Bacterial dna sequences in prostate tissue from patients with prostate cancer and chronic prostatitis. Author(s): Krieger JN, Riley DE, Vesella RL, Miner DC, Ross SO, Lange PH. Source: The Journal of Urology. 2000 October; 164(4): 1221-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10992370&dopt=Abstract
•
Bacterial localization in antibiotic-refractory chronic bacterial prostatitis. Author(s): Nickel JC, Costerton JW. Source: The Prostate. 1993; 23(2): 107-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8378186&dopt=Abstract
•
Bacterial prostatitis caused by Staphylococcus saprophyticus. Author(s): Pfau A. Source: Urology. 1983 January; 21(1): 102-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6823695&dopt=Abstract
•
Bacterial prostatitis caused by Staphylococcus saprophyticus. Author(s): Carson CC, McGraw VD, Zwadyk P. Source: Urology. 1982 June; 19(6): 576-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7090104&dopt=Abstract
•
Bacterial prostatitis in patients infected with the human immunodeficiency virus. Author(s): Leport C, Rousseau F, Perronne C, Salmon D, Joerg A, Vilde JL. Source: The Journal of Urology. 1989 February; 141(2): 334-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2643725&dopt=Abstract
•
Bacterial prostatitis: an unusual cause of total urinary incontinence and its surgical management. Author(s): Duvie SO. Source: The Journal of Urology. 1988 January; 139(1): 139-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3336079&dopt=Abstract
•
Bacterial prostatitis: diagnosis and treatment. Author(s): Drach GW. Source: Ariz Med. 1983 May; 40(5): 329-32. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6870575&dopt=Abstract
•
Bacterial prostatitis: new methods of treatment. Author(s): Aagaard J, Madsen PO. Source: Urology. 1991; 37(3 Suppl): 4-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2003343&dopt=Abstract
Studies
39
•
Bacterial prostatitis: treatment with carbenicillin indanyl sodium. Author(s): Mobley DF. Source: Invest Urol. 1981 July; 19(1): 31-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7019153&dopt=Abstract
•
Bacterial prostatitis: urine and spermatic fluid culture. Author(s): Lacquaniti S, Fulcoli V, Weir JM, Pisanti F, Servello C, Destito A. Source: Arch Ital Urol Androl. 2000 April; 72(1): 21-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10875162&dopt=Abstract
•
BCG-induced granulomatous prostatitis: a comparative ultrasound and pathologic study. Author(s): Miyashita H, Troncoso P, Babaian RJ. Source: Urology. 1992 April; 39(4): 364-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1557848&dopt=Abstract
•
Benign prostatomegaly, carcinoma and prostatitis. Author(s): Brown RB. Source: Aust Fam Physician. 1986 December; 15(12): 1551, 1553-4, 1556-7 Passim. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2432868&dopt=Abstract
•
Bladder carcinoma presenting as prostatitis syndrome. Author(s): Luzzi GA, Cranston D. Source: Bju International. 2000 April; 85(6): 774-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10759683&dopt=Abstract
•
Burkitt's lymphoma mimicking prostatitis. Author(s): Boe S, Nielsen H, Ryttov N. Source: The Journal of Urology. 1981 June; 125(6): 891-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7241700&dopt=Abstract
•
Can decreased phagocytosis and killing of autologous gram-positive bacteria explain the finding of gram-positive bacteria in “non-bacterial prostatitis”? Author(s): Wedren H, Holm SE, Bergman B. Source: Acta Pathol Microbiol Immunol Scand [b]. 1987 February; 95(1): 75-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3565020&dopt=Abstract
•
Chronic bacterial prostatitis: 10 years of experience with local antibiotics. Author(s): Baert L, Leonard A. Source: The Journal of Urology. 1988 October; 140(4): 755-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3047435&dopt=Abstract
40
Prostatitis
•
Chronic bacterial prostatitis: problems in diagnosis and therapy. Author(s): Drach GW, Nolan PE Jr. Source: Urology. 1986 February; 27(2 Suppl): 26-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3946049&dopt=Abstract
•
Chronic prostatitis and chronic pelvic pain in men: aetiology, diagnosis and management. Author(s): Luzzi GA. Source: Journal of the European Academy of Dermatology and Venereology : Jeadv. 2002 May; 16(3): 253-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12195565&dopt=Abstract
•
Chronic prostatitis caused by Trichomonas vaginalis--diagnosis and treatment. Author(s): Skerk V, Schonwald S, Granic J, Krhen I, Barsic B, Marekovic I, Roglic S, Desnica B, Zeljko Z. Source: Journal of Chemotherapy (Florence, Italy). 2002 October; 14(5): 537-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12462437&dopt=Abstract
•
Chronic prostatitis. Author(s): Gingell JC. Source: British Medical Journal (Clinical Research Ed.). 1987 October 17; 295(6604): 998. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3119140&dopt=Abstract
•
Chronic prostatitis. Author(s): Batstone GR, Doble A, Batstone D. Source: Current Opinion in Urology. 2003 January; 13(1): 23-9. Review. Erratum In: Curr Opin Urol.2003 March; 13(2): 177. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12490812&dopt=Abstract
•
Chronic prostatitis. Author(s): Schaeffer A, Stern J. Source: Clin Evid. 2002 June; (7): 788-95. Review. No Abstract Available. Update In: http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12230704&dopt=Abstract
•
Chronic prostatitis/chronic pelvic pain pyndrome): seminal markers of inflammation. Author(s): Ludwig M, Vidal A, Diemer T, Pabst W, Failing K, Weidner W. Source: World Journal of Urology. 2003 June; 21(2): 82-5. Epub 2003 April 11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12690515&dopt=Abstract
Studies
41
•
Chronic prostatitis: epidemiology and role of infection. Author(s): Krieger JN, Ross SO, Riley DE. Source: Urology. 2002 December; 60(6 Suppl): 8-12; Discussion 13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521579&dopt=Abstract
•
Chronic prostatitis: symptom survey with follow-up clinical evaluation. Author(s): Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, Yap HW, Krieger JN. Source: Urology. 2003 January; 61(1): 60-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12559266&dopt=Abstract
•
Chronic prostatitis: what we know, what we do not know, and what we should do! Author(s): Lobel B, Rodriguez A. Source: World Journal of Urology. 2003 June; 21(2): 57-63. Epub 2003 May 28. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12774173&dopt=Abstract
•
Classification (traditional and National Institutes of Health) and demographics of prostatitis. Author(s): Schaeffer AJ. Source: Urology. 2002 December; 60(6 Suppl): 5-6; Discussion 6-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521577&dopt=Abstract
•
Clinical evaluation of the man with chronic prostatitis/chronic pelvic pain syndrome. Author(s): Nickel JC. Source: Urology. 2002 December; 60(6 Suppl): 20-2; Discussion 22-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521583&dopt=Abstract
•
Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Author(s): Skerk V, Schonwald S, Krhen I, Banaszak A, Begovac J, Strugar J, Strapac Z, Vrsalovic R, Vukovic J, Tomas M. Source: International Journal of Antimicrobial Agents. 2003 May; 21(5): 457-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12727080&dopt=Abstract
•
Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Author(s): Skerk V, Schonwald S, Krhen I, Markovinovic L, Barsic B, Marekovic I, Roglic S, Zeljko Z, Vince A, Cajic V. Source: Journal of Chemotherapy (Florence, Italy). 2002 August; 14(4): 384-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12420857&dopt=Abstract
42
Prostatitis
•
Comprehensive therapy for chronic bacterial prostatitis: report of 52 cases. Author(s): Zhou DQ, Wen HT, Tan WL. Source: Di Yi June Yi Da Xue Xue Bao. 2002 April; 22(4): 368-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12390750&dopt=Abstract
•
Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. Author(s): Kurzer E, Kaplan S. Source: European Urology. 2002 August; 42(2): 163-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12160588&dopt=Abstract
•
Counting leukocytes in expressed prostatic secretions from patients with chronic prostatitis/chronic pelvic pain syndrome. Author(s): Krieger JN, Ross SO, Deutsch LA, Fritsche TR, Riley DE. Source: Urology. 2003 July; 62(1): 30-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12837417&dopt=Abstract
•
Cytologic evaluation of urine is important in evaluation of chronic prostatitis. Author(s): Nickel JC, Ardern D, Downey J. Source: Urology. 2002 August; 60(2): 225-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12137814&dopt=Abstract
•
Demographic and clinical characteristics of men with chronic prostatitis: the national institutes of health chronic prostatitis cohort study. Author(s): Schaeffer AJ, Landis JR, Knauss JS, Propert KJ, Alexander RB, Litwin MS, Nickel JC, O'Leary MP, Nadler RB, Pontari MA, Shoskes DA, Zeitlin SI, Fowler JE Jr, Mazurick CA, Kishel L, Kusek JW, Nyberg LM; Chronic Prostatitis Collaborative Research Network Group. Source: The Journal of Urology. 2002 August; 168(2): 593-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12131316&dopt=Abstract
•
Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Author(s): Propert KJ, Alexander RB, Nickel JC, Kusek JW, Litwin MS, Landis JR, Nyberg LM, Schaeffer AJ; Chronic Prostatitis Collaborative Research Network. Source: Urology. 2002 June; 59(6): 870-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12031372&dopt=Abstract
•
Detecting urethral and prostatic inflammation in patients with chronic prostatitis. Author(s): Krieger JN, Jacobs R, Ross SO. Source: Urology. 2000 February; 55(2): 186-91; Discussion 191-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10688076&dopt=Abstract
Studies
43
•
Detection and follow-up of Wegener's prostatitis by transrectal ultrasound. Author(s): Menown IB, McKane WR, Kennedy JA, Kelly IM, Maclennan BA, Best BG, Walsh MY. Source: British Journal of Rheumatology. 1998 July; 37(7): 805-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9714370&dopt=Abstract
•
Detection of chlamydia trachomatis by polymerase chain reaction assay in nonbacterial prostatitis. Author(s): Guo H, Lu G, Zhang Q, Xiong X. Source: Chinese Medical Journal. 1997 March; 110(3): 177-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9594334&dopt=Abstract
•
Diagnosing and treating chronic prostatitis: do urologists use the four-glass test? Author(s): McNaughton Collins M, Fowler FJ Jr, Elliott DB, Albertsen PC, Barry MJ. Source: Urology. 2000 March; 55(3): 403-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10699621&dopt=Abstract
•
Diagnosing the prostatitis patient: the dilemma continues. Author(s): Potts JM. Source: Curr Urol Rep. 2002 August; 3(4): 319-23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12149164&dopt=Abstract
•
Diagnosis and follow-up of acute bacterial prostatitis and orchiepididymitis detected by In-111-labeled leukocyte imaging. Author(s): Mateos JJ, Lomena F, Velasco M, Horcajada JP, Ortega M, Fuertes S, Pons F. Source: Clinical Nuclear Medicine. 2003 May; 28(5): 403-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12702940&dopt=Abstract
•
Diagnosis and management of acute and chronic prostatitis. Author(s): Shoskes DA, Katske F, Kim S. Source: Urologic Nursing : Official Journal of the American Urological Association Allied. 2001 August; 21(4): 255-8, 261-2; Quiz 263-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11998455&dopt=Abstract
•
Diagnosis and management of chronic prostatitis by primary care providers. Author(s): Lovejoy B. Source: Journal of the American Academy of Nurse Practitioners. 2001 July; 13(7): 31721; Quiz 322-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11930605&dopt=Abstract
44
Prostatitis
•
Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. Author(s): McNaughton Collins M, MacDonald R, Wilt TJ. Source: Annals of Internal Medicine. 2000 September 5; 133(5): 367-81. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10979882&dopt=Abstract
•
Diagnosis and treatment of prostatitis in Canada. Author(s): Nickel JC, Nigro M, Valiquette L, Anderson P, Patrick A, Mahoney J, Buckley R, Corcos J, Hosking D. Source: Urology. 1998 November; 52(5): 797-802. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9801102&dopt=Abstract
•
Diagnostic dilemmas in the interpretation of fine-needle aspirates of granulomatous prostatitis. Author(s): Garcia Solano J, Sanchez Sanchez C, Montalban Romero S, Perez-Guillermo M. Source: Diagnostic Cytopathology. 1998 March; 18(3): 215-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9523142&dopt=Abstract
•
Differences in virulence factors among clinical isolates of Escherichia coli causing cystitis and pyelonephritis in women and prostatitis in men. Author(s): Ruiz J, Simon K, Horcajada JP, Velasco M, Barranco M, Roig G, MorenoMartinez A, Martinez JA, Jimenez de Anta T, Mensa J, Vila J. Source: Journal of Clinical Microbiology. 2002 December; 40(12): 4445-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12454134&dopt=Abstract
•
Distal urethral web: a risk factor in prostatitis. Author(s): Vega RE. Source: Prostate Cancer and Prostatic Diseases. 2002; 5(3): 180-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12496978&dopt=Abstract
•
Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: results of a national survey of physician visits. Author(s): Collins MM, Stafford RS, O'Leary MP, Barry MJ. Source: Urology. 1999 May; 53(5): 921-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10223484&dopt=Abstract
•
Distribution of chronic prostatitis in radical prostatectomy specimens with upregulation of bcl-2 in areas of inflammation. Author(s): Gerstenbluth RE, Seftel AD, MacLennan GT, Rao RN, Corty EW, Ferguson K, Resnick MI. Source: The Journal of Urology. 2002 May; 167(5): 2267-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11956490&dopt=Abstract
Studies
45
•
Diverse and related 16S rRNA-encoding DNA sequences in prostate tissues of men with chronic prostatitis. Author(s): Riley DE, Berger RE, Miner DC, Krieger JN. Source: Journal of Clinical Microbiology. 1998 June; 36(6): 1646-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9620394&dopt=Abstract
•
Does the chronic prostatitis/pelvic pain syndrome differ from nonbacterial prostatitis and prostatodynia? Author(s): Krieger JN, Jacobs RR, Ross SO. Source: The Journal of Urology. 2000 November; 164(5): 1554-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11025703&dopt=Abstract
•
Dynamics of spermatogenesis, hormonal and immune response of patients suffering from chronic prostatitis and sterility under bitemporal treatment with an ultra-high frequency electric field. Author(s): Bogolyubov VM, Karpukhin IV, Bobkova AS, Razuvayev AV, Kozhinova EV. Source: International Urology and Nephrology. 1986; 18(1): 89-97. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3087902&dopt=Abstract
•
Editorial: Emerging concepts in the management of prostatitis/chronic pelvic pain syndrome. Author(s): Schaeffer AJ. Source: The Journal of Urology. 2003 February; 169(2): 597-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12544315&dopt=Abstract
•
Effective office management of chronic prostatitis. Author(s): Nickel JC. Source: The Urologic Clinics of North America. 1998 November; 25(4): 677-84. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10026774&dopt=Abstract
•
Effects of sodium pentosanpolysulphate on symptoms related to chronic nonbacterial prostatitis. A double-blind randomized study. Author(s): Wedren H. Source: Scandinavian Journal of Urology and Nephrology. 1987; 21(2): 81-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2441458&dopt=Abstract
•
Efficacy of treatment and recurrence rate of leukocytospermia in infertile men with prostatitis. Author(s): Branigan EF, Muller CH. Source: Fertility and Sterility. 1994 September; 62(3): 580-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7520396&dopt=Abstract
46
Prostatitis
•
Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Author(s): Alexander RB, Ponniah S, Hasday J, Hebel JR. Source: Urology. 1998 November; 52(5): 744-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9801092&dopt=Abstract
•
Emphysematous prostatitis and cystitis secondary to Candida albicans. Author(s): Bartkowski DP, Lanesky JR. Source: The Journal of Urology. 1988 May; 139(5): 1063-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3361647&dopt=Abstract
•
Eosinophilic prostatitis and prostatic specific antigen. Author(s): Liu S, Miller PD, Holmes SA, Christmas TJ, Kirby RS. Source: British Journal of Urology. 1992 January; 69(1): 61-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1371086&dopt=Abstract
•
Eosinophilic prostatitis simulating invasive prostatic carcinoma: CT appearance. Author(s): Gibney RG, Hicken P, Nichols DM. Source: Canadian Association of Radiologists Journal = Journal L'association Canadienne Des Radiologistes. 1988 March; 39(1): 48-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2966170&dopt=Abstract
•
Epidemiologic association between prostatitis and prostate cancer. Author(s): Dennis LK, Lynch CF, Torner JC. Source: Urology. 2002 July; 60(1): 78-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12100928&dopt=Abstract
•
Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. Author(s): Mehik A, Hellstrom P, Lukkarinen O, Sarpola A, Jarvelin M. Source: Bju International. 2000 September; 86(4): 443-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10971269&dopt=Abstract
•
Epidemiology of prostatitis. Author(s): Roberts RO, Jacobsen SJ. Source: Curr Urol Rep. 2000 August; 1(2): 135-41. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12084327&dopt=Abstract
•
Epidemiology of prostatitis: new evidence for a world-wide problem. Author(s): Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH. Source: World Journal of Urology. 2003 June; 21(2): 70-4. Epub 2003 April 24. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12712363&dopt=Abstract
Studies
47
•
Escherichia coli virulence factors and serotypes in acute bacterial prostatitis. Author(s): Terai A, Yamamoto S, Mitsumori K, Okada Y, Kurazono H, Takeda Y, Yoshida O. Source: International Journal of Urology : Official Journal of the Japanese Urological Association. 1997 May; 4(3): 289-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9255669&dopt=Abstract
•
Estrogen treatment of abacterial chronic prostatitis. Author(s): Mackenzie AR. Source: Urology. 1986 June; 27(6): 574-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3716064&dopt=Abstract
•
Etiology: where does prostatitis stop and interstitial cystitis begin? Author(s): Eisenberg ER, Moldwin RM. Source: World Journal of Urology. 2003 June; 21(2): 64-9. Epub 2003 May 28. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12774174&dopt=Abstract
•
Evaluation of 42 patients with chronic abacterial prostatitis: are there any underlying correctable pathologies? Author(s): Atilla MK, Sargin H, Odabas O, Yilmaz Y, Aydin S. Source: International Urology and Nephrology. 1998; 30(4): 463-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9821050&dopt=Abstract
•
Evaluation of non-invasive clinical samples in chronic chlamydial prostatitis by using in situ hybridization. Author(s): Gumus B, Sengil AZ, Solak M, Fistik T, Alibey E, Cakmak EA, Yeter M. Source: Scandinavian Journal of Urology and Nephrology. 1997 October; 31(5): 449-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9406305&dopt=Abstract
•
Evaluation of seminal plasma parameters in patients with chronic prostatitis or leukocytospermia. Author(s): Ludwig M, Kummel C, Schroeder-Printzen I, Ringert RH, Weidner W. Source: Andrologia. 1998; 30 Suppl 1: 41-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9629442&dopt=Abstract
•
Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion. Author(s): Persson BE, Ronquist G. Source: The Journal of Urology. 1996 March; 155(3): 958-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8583617&dopt=Abstract
48
Prostatitis
•
Expression of Bcl-2 on leukocytes in prostatic fluid from patients with acute and chronic prostatitis. Author(s): Abe H, Nishimura T, Asoh S, Ohta S. Source: Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy. 2003 June; 9(2): 156-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12825115&dopt=Abstract
•
Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction. Author(s): Spivey JM, Cummings DM, Pierson NR. Source: Pharmacotherapy. 1996 March-April; 16(2): 314-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8820479&dopt=Abstract
•
Fears, sexual disturbances and personality features in men with prostatitis: a population-based cross-sectional study in Finland. Author(s): Mehik A, Hellstrom P, Sarpola A, Lukkarinen O, Jarvelin MR. Source: Bju International. 2001 July; 88(1): 35-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11446842&dopt=Abstract
•
Female prostatitis. Author(s): Gittes RF. Source: The Urologic Clinics of North America. 2002 August; 29(3): 613-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12476524&dopt=Abstract
•
Female prostatitis? Author(s): Russi MF. Source: The Western Journal of Medicine. 1996 September; 165(3): 161. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8909177&dopt=Abstract
•
Female prostatitis? Author(s): Peterson NE. Source: The Western Journal of Medicine. 1996 September; 165(3): 161. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8909176&dopt=Abstract
•
Female urethral syndrome. A female prostatitis? Author(s): Gittes RF, Nakamura RM. Source: The Western Journal of Medicine. 1996 May; 164(5): 435-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8686301&dopt=Abstract
Studies
49
•
Few patients with “chronic prostatitis” have significant bladder outlet obstruction. Author(s): Mayo ME, Ross SO, Krieger JN. Source: Urology. 1998 September; 52(3): 417-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9730453&dopt=Abstract
•
Fine needle aspiration cytology of granulomatous prostatitis induced by BCG immunotherapy of bladder cancer. Author(s): Stilmant M, Siroky MB, Johnson KB. Source: Acta Cytol. 1985 November-December; 29(6): 961-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3866459&dopt=Abstract
•
Fine needle aspiration cytology of granulomatous prostatitis. Author(s): Miralles TG, Gosalbez F, Menendez P, Perez-Rodriguez A, Folgueras V, Cabanilles DL. Source: Acta Cytol. 1990 January-February; 34(1): 57-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2296841&dopt=Abstract
•
Gardnerella vaginalis and prostatitis. Author(s): Maskell R. Source: Lancet. 1981 September 12; 2(8246): 581-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6116022&dopt=Abstract
•
Getting beyond chronic nonbacterial prostatitis. Author(s): Ross SO. Source: Urologic Nursing : Official Journal of the American Urological Association Allied. 1995 June; 15(2): 61-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7597451&dopt=Abstract
•
Granulomatous prostatitis and poorly differentiated prostate carcinoma. Their distinction with the use of immunohistochemical methods. Author(s): Presti B, Weidner N. Source: American Journal of Clinical Pathology. 1991 March; 95(3): 330-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1996542&dopt=Abstract
•
Granulomatous prostatitis due to Mycobacterium avium complex. Author(s): Mikolich DJ, Mates SM. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 1992 February; 14(2): 589-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1554847&dopt=Abstract
50
Prostatitis
•
Granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy of bladder cancer. Author(s): Oates RD, Stilmant MM, Freedlund MC, Siroky MB. Source: The Journal of Urology. 1988 October; 140(4): 751-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3418796&dopt=Abstract
•
Granulomatous prostatitis induced by capsule-deficient cryptococcal infection. Author(s): Milchgrub S, Visconti E, Avellini J. Source: The Journal of Urology. 1990 February; 143(2): 365-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2299734&dopt=Abstract
•
Granulomatous prostatitis on needle biopsy. Author(s): Oppenheimer JR, Kahane H, Epstein JI. Source: Archives of Pathology & Laboratory Medicine. 1997 July; 121(7): 724-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9240909&dopt=Abstract
•
Granulomatous prostatitis with vasculitis. A sequel to transurethral prostatic resection. Author(s): Kopolovic J, Rivkind A, Sherman Y. Source: Archives of Pathology & Laboratory Medicine. 1984 September; 108(9): 732-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6547826&dopt=Abstract
•
Granulomatous prostatitis. Author(s): Gonzalez Tuero J, Alonso de la Campa J, Perez Lacort L, Fernandez Madrigal F, Abascal Garcia J, Abascal Garcia R. Source: Urologia Internationalis. 1988; 43(2): 97-101. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3388640&dopt=Abstract
•
Granulomatous prostatitis. Special reference to radiologic findings. Author(s): Ney C, Miller HL, Levy JL. Source: Urology. 1983 March; 21(3): 320-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6188265&dopt=Abstract
•
Granulomatous prostatitis: a clinicopathological study. Author(s): Bryan RL, Newman J, Campbell A, Fitzgerald G, Kadow C, O'Brien JM. Source: Histopathology. 1991 November; 19(5): 453-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1721891&dopt=Abstract
•
Granulomatous prostatitis: a hypoechoic lesion of the prostate. Author(s): Rubenstein JB, Swayne LC, Magidson JG, Furey CA. Source: Urol Radiol. 1991; 13(2): 119-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1897068&dopt=Abstract
Studies
51
•
Granulomatous prostatitis: a spectrum including nonspecific, infectious, and spindle cell lesions. Author(s): Stanley MW, Horwitz CA, Sharer W, Uke E, Kaye K, Burton L. Source: Diagnostic Cytopathology. 1991; 7(5): 508-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1954830&dopt=Abstract
•
Granulomatous prostatitis: distinction among allergic, nonspecific, and posttransurethral resection lesions. Author(s): Epstein JI, Hutchins GM. Source: Human Pathology. 1984 September; 15(9): 818-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6432674&dopt=Abstract
•
Haemophilus influenzae prostatitis. Author(s): Goetz MB, Craig WA. Source: Jama : the Journal of the American Medical Association. 1982 June 11; 247(22): 3118. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6978949&dopt=Abstract
•
Heat therapy in the treatment of prostatitis. Author(s): Zeitlin SI. Source: Urology. 2002 December; 60(6 Suppl): 38-40; Discussion 41. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521593&dopt=Abstract
•
Hemophilus parainfluenzae prostatitis in a homosexual man with chronic lymphadenopathy syndrome and HTLV-III infection. Author(s): Clairmont GJ, Zon LI, Groopman JE. Source: The American Journal of Medicine. 1987 January; 82(1): 175-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3799681&dopt=Abstract
•
Herbal and complementary medicine in chronic prostatitis. Author(s): Shoskes DA, Manickam K. Source: World Journal of Urology. 2003 June; 21(2): 109-13. Epub 2003 April 29. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12720037&dopt=Abstract
•
High-resolution protein patterns of human expressed prostatic secretion: a new tool for the diagnosis of prostatitis. Author(s): Balerna M, Colpi GM, Campana A, Roveda L, Tommasini-Degna A, Zanollo A. Source: Archives of Andrology. 1982 March; 8(2): 97-105. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7073394&dopt=Abstract
52
Prostatitis
•
HLA antigens and sacro-iliitis in chronic prostatitis. Author(s): Moller P, Vinje O, Fryjordet A. Source: Scandinavian Journal of Rheumatology. 1980; 9(3): 138-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7455619&dopt=Abstract
•
HLA phenotypes and joint affection in psoriasis, acute anterior uveitis and chronic prostatitis. Author(s): Moller P, Berg K, Vinje O. Source: Clinical Genetics. 1981 April; 19(4): 266-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7196814&dopt=Abstract
•
How common is prostatitis? A national survey of physician visits. Author(s): Collins MM, Stafford RS, O'Leary MP, Barry MJ. Source: The Journal of Urology. 1998 April; 159(4): 1224-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9507840&dopt=Abstract
•
IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. Author(s): Nadler RB, Koch AE, Calhoun EA, Campbell PL, Pruden DL, Bennett CL, Yarnold PR, Schaeffer AJ. Source: The Journal of Urology. 2000 July; 164(1): 214-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10840462&dopt=Abstract
•
IL-1ra versus IL-1 levels in prostatic fluid from prostatitis patients. Author(s): Nishimura T, Abe H, Ito H, Ikeda K, Oka F, Yamamoto M. Source: Urologia Internationalis. 1998; 60(2): 92-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9563146&dopt=Abstract
•
Imaging prostatitis with Tc-99m ciprofloxacin. Author(s): Choe W, Chung MH, Kim WH, Kim S, Kan Ryu J, Jin Kang K, Suh JK. Source: Clinical Nuclear Medicine. 2002 July; 27(7): 527-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12072785&dopt=Abstract
•
Immunocytochemical detection of chlamydial antigen in both the urethral scraping and prostatic aspirate in a case of abacterial prostatitis. Author(s): Kobayashi TK, Araki H, Sawaragi I. Source: Acta Cytol. 1988 March-April; 32(2): 270-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3279715&dopt=Abstract
Studies
53
•
Immunohistochemical demonstration of Chlamydial antigens in association with prostatitis. Author(s): Shurbaji MS, Gupta PK, Myers J. Source: Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. 1988 September; 1(5): 348-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2467288&dopt=Abstract
•
Immunosuppression and sperm antibody formation in men with prostatitis. Author(s): Witkin SS, Zelikovsky G. Source: J Clin Lab Immunol. 1986 September; 21(1): 7-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3543373&dopt=Abstract
•
Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. Author(s): LaFontaine PD, Middleman BR, Graham SD Jr, Sanders WH. Source: Urology. 1997 March; 49(3): 363-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9123699&dopt=Abstract
•
Incidental lymphocytic prostatitis. Selective involvement with nonmalignant glands. Author(s): Blumenfeld W, Tucci S, Narayan P. Source: The American Journal of Surgical Pathology. 1992 October; 16(10): 975-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1415905&dopt=Abstract
•
Increased intraprostatic pressure in patients with chronic prostatitis. Author(s): Mehik A, Hellstrom P, Lukkarinen O, Sarpola A, Alfthan O. Source: Urological Research. 1999 August; 27(4): 277-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10460899&dopt=Abstract
•
Increased prostate-specific antigen in subclinical prostatitis: the role of aggressiveness and extension of inflammation. Author(s): Yaman O, Gogus C, Tulunay O, Tokatli Z, Ozden E. Source: Urologia Internationalis. 2003; 71(2): 160-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12890953&dopt=Abstract
•
Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. Author(s): Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Source: Journal of Immunology (Baltimore, Md. : 1950). 1997 October 1; 159(7): 3113-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9317107&dopt=Abstract
54
Prostatitis
•
Inflammation and anti-inflammatory therapy in chronic prostatitis. Author(s): A Pontari M. Source: Urology. 2002 December; 60(6 Suppl): 29-33; Discussion 33-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521589&dopt=Abstract
•
Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Author(s): Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E. Source: European Urology. 2000 April; 37(4): 404-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10765070&dopt=Abstract
•
Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. Author(s): Zhang W, Sesterhenn IA, Connelly RR, Mostofi FK, Moul JW. Source: The Journal of Urology. 2000 January; 163(1): 131-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10604330&dopt=Abstract
•
Influence of environmental factors on chronic prostatitis-like symptoms in young men: results of a community-based survey. Author(s): Ku JH, Kim ME, Lee NK, Park YH. Source: Urology. 2001 December; 58(6): 853-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11744444&dopt=Abstract
•
Interleukin-10 levels in seminal plasma: implications for chronic prostatitis-chronic pelvic pain syndrome. Author(s): Miller LJ, Fischer KA, Goralnick SJ, Litt M, Burleson JA, Albertsen P, Kreutzer DL. Source: The Journal of Urology. 2002 February; 167(2 Pt 1): 753-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11792966&dopt=Abstract
•
Interventions for chronic abacterial prostatitis. Author(s): McNaughton C, Mac Donald R, Wilt T. Source: Cochrane Database Syst Rev. 2001; (1): Cd002080. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11279750&dopt=Abstract
•
Intravesical potassium sensitivity in patients with prostatitis. Author(s): Parsons CL, Albo M. Source: The Journal of Urology. 2002 September; 168(3): 1054-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12187221&dopt=Abstract
Studies
55
•
Is there a role for transrectal microwave hyperthermia of the prostate in the treatment of abacterial prostatitis and prostatodynia? Author(s): Montorsi F, Guazzoni G, Bergamaschi F, Galli L, Consonni P, Matozzo V, Barbieri L, Rigatti P. Source: The Prostate. 1993; 22(2): 139-46. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8456052&dopt=Abstract
•
Isolated candidal prostatitis. Author(s): Elert A, von Knobloch R, Nusser R, Heidenreich A, Hofmann R. Source: The Journal of Urology. 2000 January; 163(1): 244. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10604365&dopt=Abstract
•
Laboratory findings in chronic prostatitis--with special reference to immunological and microbiological aspects. Author(s): Vinje O, Fryjordet A, Bruu AL, Moller P, Mellbye OJ, Kass E. Source: Scandinavian Journal of Urology and Nephrology. 1983; 17(3): 291-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6648377&dopt=Abstract
•
Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study. Author(s): Schaeffer AJ, Knauss JS, Landis JR, Propert KJ, Alexander RB, Litwin MS, Nickel JC, O'Leary MP, Nadler RB, Pontari MA, Shoskes DA, Zeitlin SI, Fowler JE Jr, Mazurick CA, Kusek JW, Nyberg LM; Chronic Prostatitis Collaborative Research Network Study Group. Source: The Journal of Urology. 2002 September; 168(3): 1048-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12187220&dopt=Abstract
•
Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls. Author(s): Nickel JC, Alexander RB, Schaeffer AJ, Landis JR, Knauss JS, Propert KJ; Chronic Prostatitis Collaborative Research Network Study Group. Source: The Journal of Urology. 2003 September; 170(3): 818-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12913707&dopt=Abstract
•
Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Author(s): Nickel JC, Downey J, Clark J, Casey RW, Pommerville PJ, Barkin J, Steinhoff G, Brock G, Patrick AB, Flax S, Goldfarb B, Palmer BW, Zadra J. Source: Urology. 2003 October; 62(4): 614-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14550427&dopt=Abstract
56
Prostatitis
•
Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Author(s): Bundrick W, Heron SP, Ray P, Schiff WM, Tennenberg AM, Wiesinger BA, Wright PA, Wu SC, Zadeikis N, Kahn JB. Source: Urology. 2003 September; 62(3): 537-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12946763&dopt=Abstract
•
Local transrectal enzymatic treatment for chronic nonbacterial prostatitis and prostatodynia: initial clinical experience. Author(s): Kerbl K, Zisch R. Source: Tech Urol. 2000 March; 6(1): 22-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10708143&dopt=Abstract
•
Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. Author(s): Naber KG; European Lomefloxacin Prostatitis Study Group. Source: International Journal of Antimicrobial Agents. 2002 July; 20(1): 18-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12127707&dopt=Abstract
•
Longitudinal studies of prostatic fluid immunoglobulin in men with bacterial prostatitis. Author(s): Fowler JE Jr, Mariano M. Source: The Journal of Urology. 1984 February; 131(2): 363-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6699975&dopt=Abstract
•
Longitudinal study of macrophages in prostatic fluid from nonbacterial prostatitis patients. Author(s): Nishimura T, Kanamori S, Yoshida K, Akimoto M, Kawai H. Source: Urology. 1981 September; 18(3): 255-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6169184&dopt=Abstract
•
Long-term antibiotic treatment of chronic bacterial prostatitis. Effect on bacterial flora. Author(s): Bergman B, Wedren H, Holm SE. Source: British Journal of Urology. 1989 May; 63(5): 503-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2786439&dopt=Abstract
•
Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. Author(s): Shoskes DA, Hakim L, Ghoniem G, Jackson CL. Source: The Journal of Urology. 2003 April; 169(4): 1406-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12629373&dopt=Abstract
Studies
57
•
Low levels of IL-1ra versus IL-1 levels in prostatic fluid are not a cause of prolongation of prostatitis. Author(s): Nishimura T, Abe H, Ito H, Ikeda K, Oka F, Yamamoto M. Source: Nippon Ika Daigaku Zasshi. 1996 December; 63(6): 502-3. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8987370&dopt=Abstract
•
Management of chronic prostatitis in Genitourinary Medicine clinics in the United Kingdom's North Thames Region 2000. Author(s): Dale A, Wilson J, Forster G, Daniels D, Brook G. Source: International Journal of Std & Aids. 2001 April; 12(4): 256-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11319977&dopt=Abstract
•
Management of chronic prostatitis-chronic pelvic pain syndrome. Author(s): Anderson RU. Source: The Urologic Clinics of North America. 2002 February; 29(1): 235-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12109351&dopt=Abstract
•
Management of prostatitis. Author(s): Gurunadha Rao Tunuguntla HS, Evans CP. Source: Prostate Cancer and Prostatic Diseases. 2002; 5(3): 172-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12496977&dopt=Abstract
•
Managing prostatitis in the elderly. Author(s): Cunha BA, Marx J, Gingrich D. Source: Geriatrics. 1991 January; 46(1): 60-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1985069&dopt=Abstract
•
Measurement of immunoglobulins in seminal fluid with modified nephelometry--an alternative diagnostic tool for chronic prostatitis. Author(s): Kastner C, Jakse G. Source: Prostate Cancer and Prostatic Diseases. 2003; 6(1): 86-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12664071&dopt=Abstract
•
Measurement of urinary antibodies to crude bacterial antigen in patients with chronic bacterial prostatitis. Author(s): Shortliffe LM, Elliott K, Sellers RG. Source: The Journal of Urology. 1989 March; 141(3): 632-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2918607&dopt=Abstract
58
Prostatitis
•
Minocycline in chronic abacterial prostatitis: a double-blind prospective trial. Author(s): Simmons PD, Thin RN. Source: British Journal of Urology. 1985 February; 57(1): 43-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3882181&dopt=Abstract
•
Molecular epidemiological evidence for ascending urethral infection in acute bacterial prostatitis. Author(s): Terai A, Ishitoya S, Mitsumori K, Ogawa O. Source: The Journal of Urology. 2000 December; 164(6): 1945-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11061888&dopt=Abstract
•
Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. Author(s): Horcajada JP, Vila J, Moreno-Martinez A, Ruiz J, Martinez JA, Sanchez M, Soriano E, Mensa J. Source: The Journal of Antimicrobial Chemotherapy. 2002 January; 49(1): 55-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11751767&dopt=Abstract
•
Mullerian duct cyst masquerading as chronic prostatitis: diagnosis with magnetic resonance imaging using a phased array surface coil. Author(s): Fowler JE Jr, Peters JJ, Hamrick-Turner J. Source: Urology. 1995 April; 45(4): 676-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7716853&dopt=Abstract
•
Mycotic prostatitis. Author(s): Schwarz J. Source: Urology. 1982 January; 19(1): 1-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7058573&dopt=Abstract
•
Na-tartrate in the treatment of chronic nonbacterial prostatitis. Author(s): Dunzendorfer U, Kruschwitz K, Feller H, Milbradt R. Source: Andrologia. 1983 March-April; 15(2): 135-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6859559&dopt=Abstract
•
National institutes of Health Chronic Prostatitis Symptom Index for Japanese men. Author(s): Kunishima Y, Matsukawa M, Takahashi S, Itoh N, Hirose T, Furuya S, Takatsuka K, Mori M, Tsukamoto T. Source: Urology. 2002 July; 60(1): 74-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12100927&dopt=Abstract
Studies
59
•
Necrotising granulomatous prostatitis after transurethral resection. Author(s): Haboubi NY, Khan MK, Ali HH. Source: Journal of Clinical Pathology. 1984 January; 37(1): 103-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6707216&dopt=Abstract
•
Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome. Author(s): Miller LJ, Fischer KA, Goralnick SJ, Litt M, Burleson JA, Albertsen P, Kreutzer DL. Source: Urology. 2002 April; 59(4): 603-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11927336&dopt=Abstract
•
Neuromuscular dysfunction in nonbacterial prostatitis. Author(s): Hellstrom WJ, Schmidt RA, Lue TF, Tanagho EA. Source: Urology. 1987 August; 30(2): 183-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3497475&dopt=Abstract
•
New antimicrobial treatment of urinary tract infections and prostatitis. Author(s): Sawyer DW, Mandell GL. Source: Semin Urol. 1985 November; 3(4): 281-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3843701&dopt=Abstract
•
NIH consensus definition and classification of prostatitis. Author(s): Krieger JN, Nyberg L Jr, Nickel JC. Source: Jama : the Journal of the American Medical Association. 1999 July 21; 282(3): 236-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10422990&dopt=Abstract
•
Non-bacterial prostatitis. Author(s): Persson BE, Ronquist G. Source: Lancet. 1996 September 14; 348(9029): 761. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8806324&dopt=Abstract
•
Nonbacterial prostatitis: a comprehensive review. Author(s): de la Rosette JJ, Debruyne FM. Source: Urologia Internationalis. 1991; 46(2): 121-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2053217&dopt=Abstract
60
Prostatitis
•
Non-specific eosinophilic granulomatous prostatitis responded favorably to an antimicrobial agent and a hydrocortisone. Author(s): Ohkawa M, Yamaguchi K, Kobayashi M. Source: International Journal of Urology : Official Journal of the Japanese Urological Association. 2001 October; 8(10): 578-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11737489&dopt=Abstract
•
Non-specific granulomatous prostatitis treated with steroids. Author(s): Saha PK, Hyakutake H, Nomata K, Yushita Y, Kanetake H, Saito Y. Source: Hinyokika Kiyo. 1991 August; 37(8): 927-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1957740&dopt=Abstract
•
Nonspecific granulomatous prostatitis. Author(s): Matsumoto T, Sakamoto N, Kimiya K, Kumazawa J, Miyazaki N, Hasegawa Y. Source: Urology. 1992 May; 39(5): 420-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1580029&dopt=Abstract
•
Non-specific granulomatous prostatitis. Author(s): Beneke GR, Kandzari SJ. Source: W V Med J. 1981 March; 77(3): 55-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6958124&dopt=Abstract
•
Nonspecific simple eosinophilic granulomatous prostatitis with eosinophilia in peripheral blood. A case report. Author(s): Sugiura H, Hayashi M, Shimamura M, Matsubara F. Source: Acta Pathol Jpn. 1987 December; 37(12): 1973-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3445753&dopt=Abstract
•
Norfloxacin in prostatitis: correlation between HPLC tissue concentrations and clinical results. Author(s): Bologna M, Vaggi L, Flammini D, Carlucci G, Forchetti CM. Source: Drugs Exp Clin Res. 1985; 11(2): 95-100. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3836122&dopt=Abstract
•
Novel complications with HTLV-1-associated myelopathy/tropical spastic paraparesis: interstitial cystitis and persistent prostatitis. Author(s): Nomata K, Nakamura T, Suzu H, Yushita Y, Kanetake H, Sawada T, Ikeda S, Hino S, Nagataki S, Saito Y. Source: Japanese Journal of Cancer Research : Gann. 1992 June; 83(6): 601-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1353753&dopt=Abstract
Studies
61
•
Ofloxacin in the management of complicated urinary tract infections, including prostatitis. Author(s): Cox CE. Source: The American Journal of Medicine. 1989 December 29; 87(6C): 61S-68S. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2690622&dopt=Abstract
•
On chronic prostatitis with special studies of Staphylococcus epidermidis. Author(s): Wedren H. Source: Scand J Urol Nephrol Suppl. 1989; 123: 1-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2483757&dopt=Abstract
•
On the relevance of gram-positive bacteria in prostatitis. Author(s): Bergman B. Source: Infection. 1994; 22 Suppl 1: S22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8050786&dopt=Abstract
•
Outcome of antibiotic therapy with ciprofloxacin in chronic bacterial prostatitis. Author(s): Weidner W, Ludwig M, Brahler E, Schiefer HG. Source: Drugs. 1999; 58 Suppl 2: 103-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10553717&dopt=Abstract
•
Overview summary statement. Diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Author(s): Schaeffer AJ, Datta NS, Fowler JE Jr, Krieger JN, Litwin MS, Nadler RB, Nickel JC, Pontari MA, Shoskes DA, Zeitlin SI, Hart C; Chronic Prostatitis Collaborative Research Network. Source: Urology. 2002 December; 60(6 Suppl): 1-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521576&dopt=Abstract
•
Phytotherapy and other alternative forms of care for the patient with prostatitis. Author(s): Shoskes DA. Source: Curr Urol Rep. 2002 August; 3(4): 330-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12149166&dopt=Abstract
•
Phytotherapy in chronic prostatitis. Author(s): Shoskes DA. Source: Urology. 2002 December; 60(6 Suppl): 35-7; Discussion 37. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521591&dopt=Abstract
62
Prostatitis
•
Practical approach to bacteriologic investigation of chronic prostatitis. Author(s): Fowler JE Jr. Source: Urology. 1985 November; 26(5 Suppl): 17-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3904136&dopt=Abstract
•
Prevalence of prostatitis-like symptoms in a community based cohort of older men. Author(s): Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. Source: The Journal of Urology. 2002 December; 168(6): 2467-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12441942&dopt=Abstract
•
Prevalence of prostatitis-like symptoms in Singapore: a population-based study. Author(s): Tan JK, Png DJ, Liew LC, Li MK, Wong ML. Source: Singapore Med J. 2002 April; 43(4): 189-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12188063&dopt=Abstract
•
Prostatic calculi do not influence the level of serum prostate specific antigen in men without clinically detectable prostate cancer or prostatitis. Author(s): Lee SE, Ku JH, Park HK, Jeong CK, Kim SH. Source: The Journal of Urology. 2003 September; 170(3): 745-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12913688&dopt=Abstract
•
Prostatitis and aspiration biopsy cytology of prostate. Author(s): Maksem JA, Johenning PW, Galang CF. Source: Urology. 1988 September; 32(3): 263-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3413918&dopt=Abstract
•
Prostatitis and male infertility: evidence and links. Author(s): Schoor RA. Source: Curr Urol Rep. 2002 August; 3(4): 324-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12149165&dopt=Abstract
•
Prostatitis and pruritus. Author(s): Usatine RP. Source: The Journal of Family Practice. 2003 April; 52(4): 287-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12681089&dopt=Abstract
•
Prostatitis versus pelvic pain syndrome: immunologic studies. Author(s): Maake C, John H. Source: Curr Urol Rep. 2003 August; 4(4): 327-34. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12882728&dopt=Abstract
Studies
63
•
Prostatitis. Author(s): Stewart C. Source: Emergency Medicine Clinics of North America. 1988 August; 6(3): 391-402. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3292218&dopt=Abstract
•
Prostatitis. Author(s): Hammond L. Source: Aust Fam Physician. 1987 August; 16(8): 1173. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3675354&dopt=Abstract
•
Prostatitis. Author(s): Madsen PO, Gasser TC. Source: Infection. 1986 November-December; 14(6): 253-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3818103&dopt=Abstract
•
Prostatitis. Author(s): Shortliffe LM. Source: Primary Care. 1985 December; 12(4): 787-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3853240&dopt=Abstract
•
Prostatitis. A continuing enigma. Author(s): Pfau A. Source: The Urologic Clinics of North America. 1986 November; 13(4): 695-715. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3535211&dopt=Abstract
•
Prostatitis: ancient history and new horizons. Author(s): Krieger JN, Weidner W. Source: World Journal of Urology. 2003 June; 21(2): 51-3. Epub 2003 April 30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12721753&dopt=Abstract
•
Prostatitis: diagnosis and classification. Author(s): Nickel JC. Source: Curr Urol Rep. 2003 August; 4(4): 259-60. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12882715&dopt=Abstract
•
Prostatitis: the role of antibiotic treatment. Author(s): Wagenlehner FM, Naber KG. Source: World Journal of Urology. 2003 June; 21(2): 105-8. Epub 2003 April 10. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12687400&dopt=Abstract
64
Prostatitis
•
Prostatitis-like symptoms: one year later. Author(s): Nickel JC, Downey JA, Nickel KR, Clark JM. Source: Bju International. 2002 November; 90(7): 678-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12410746&dopt=Abstract
•
Psychological problems in young men with chronic prostatitis-like symptoms. Author(s): Ku JH, Jeon YS, Kim ME, Lee NK, Park YH. Source: Scandinavian Journal of Urology and Nephrology. 2002; 36(4): 296-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12201923&dopt=Abstract
•
Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. Author(s): McNaughton Collins M, Pontari MA, O'Leary MP, Calhoun EA, Santanna J, Landis JR, Kusek JW, Litwin MS; Chronic Prostatitis Collaborative Research Network. Source: Journal of General Internal Medicine : Official Journal of the Society for Research and Education in Primary Care Internal Medicine. 2001 October; 16(10): 656-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11679032&dopt=Abstract
•
Quantitative culture of ureaplasma urealyticum in patients with chronic prostatitis or prostatosis. Author(s): Weidner W, Brunner H, Krause W. Source: The Journal of Urology. 1980 November; 124(5): 622-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7452788&dopt=Abstract
•
Quantitative studies on the role of Ureaplasma urealyticum in non-gonococcal urethritis and chronic prostatitis. Author(s): Brunner H, Weidner W, Schiefer HG. Source: Yale J Biol Med. 1983 September-December; 56(5-6): 545-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6679147&dopt=Abstract
•
Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Author(s): Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Source: Urology. 1999 December; 54(6): 960-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10604689&dopt=Abstract
•
Questionnaire survey of urologists and primary care physicians' diagnostic and treatment practices for prostatitis. Author(s): Moon TD. Source: Urology. 1997 October; 50(4): 543-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9338729&dopt=Abstract
Studies
65
•
Rapidly progressing adenocarcinoma of the prostate presenting as prostatitis. Author(s): Henderson CG, Griewe GL, Siegel TS, Peppas DS, Esther TA, Moul JW. Source: The Journal of Urology. 2002 August; 168(2): 638-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12131329&dopt=Abstract
•
Re: Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. Author(s): Shafik A. Source: The Journal of Urology. 1999 January; 161(1): 230-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10037409&dopt=Abstract
•
Re: Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel doubleblind controlled study. Author(s): Nickel JC, Siemens DR, Lundie MJ. Source: The Journal of Urology. 1997 February; 157(2): 628-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8996380&dopt=Abstract
•
Re: Demographic and clinical characteristics of men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort study. Author(s): Shafik A. Source: The Journal of Urology. 2003 April; 169(4): 1476; Author Reply 1476. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12629394&dopt=Abstract
•
Re: Isolation of Chlamydia trachomatis from the prostatic cells in patients affected by nonacute abacterial prostatitis. Author(s): Weidner W, Schiefer HG. Source: The Journal of Urology. 1986 September; 136(3): 690. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3735556&dopt=Abstract
•
Re: Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study. Author(s): Merkle W. Source: The Journal of Urology. 2000 July; 164(1): 129. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10840468&dopt=Abstract
•
Re: The chronic prostatitis-chronic pelvic pain syndrome can be characterized by prostatic tissue pressure measurements. Author(s): Barbalias GA. Source: The Journal of Urology. 2002 August; 168(2): 663. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12131342&dopt=Abstract
66
Prostatitis
•
Re: Transurethral microwave thermotherapy for nonbacterial prostatitis: a randomized double-blind sham controlled study using new prostatitis specific assessment questionnaires. Author(s): Issa MM. Source: The Journal of Urology. 1997 February; 157(2): 629. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8996381&dopt=Abstract
•
Reappraisal of antibiotic susceptibility tests in the management of chronic bacterial prostatitis. Author(s): Kazanci G, Buyukalpelli R. Source: European Urology. 1988; 14(5): 398-401. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3049111&dopt=Abstract
•
Recent developments in diagnosis and therapy of the prostatitis syndromes. Author(s): Dimitrakov J, Diemer T, Ludwig M, Weidner W. Source: Current Opinion in Urology. 2001 January; 11(1): 87-91. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11148752&dopt=Abstract
•
Recommendations for the evaluation of patients with prostatitis. Author(s): Nickel JC. Source: World Journal of Urology. 2003 June; 21(2): 75-81. Epub 2003 April 09. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12684835&dopt=Abstract
•
Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Author(s): Hasui Y, Marutsuka K, Asada Y, Ide H, Nishi S, Osada Y. Source: The Prostate. 1994 August; 25(2): 91-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7518599&dopt=Abstract
•
Relevance of male accessory gland infection for subsequent fertility with special focus on prostatitis. Author(s): Weidner W, Krause W, Ludwig M. Source: Human Reproduction Update. 1999 September-October; 5(5): 421-32. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10582781&dopt=Abstract
•
Relief by botulinum toxin of voiding dysfunction due to prostatitis. Author(s): Maria G, Destito A, Lacquaniti S, Bentivoglio AR, Brisinda G, Albanese A. Source: Lancet. 1998 August 22; 352(9128): 625. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9746032&dopt=Abstract
Studies
67
•
Repetitive prostatic massage therapy for chronic refractory prostatitis: the Philippine experience. Author(s): Nickel JC, Downey J, Feliciano AE Jr, Hennenfent B. Source: Tech Urol. 1999 September; 5(3): 146-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10527258&dopt=Abstract
•
Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Author(s): Nickel JC, Nyberg LM, Hennenfent M. Source: Urology. 1999 August; 54(2): 229-33. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10443716&dopt=Abstract
•
Role of alpha-blockers in the treatment of chronic prostatitis. Author(s): Datta NS. Source: Urology. 2002 December; 60(6 Suppl): 27-8; Discussion 28. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521587&dopt=Abstract
•
Role of Chlamydia trachomatis and mycoplasmas in chronic prostatitis. A review. Author(s): Weidner W, Schiefer HG, Krauss H. Source: Urologia Internationalis. 1988; 43(3): 167-73. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3051621&dopt=Abstract
•
Role of ejaculation in the treatment of chronic non-bacterial prostatitis. Author(s): Yavascaoglu I, Oktay B, Simsek U, Ozyurt M. Source: International Journal of Urology : Official Journal of the Japanese Urological Association. 1999 March; 6(3): 130-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10226823&dopt=Abstract
•
Routine prostatitis? A case report of long-term foreign body in the prostatic urethra. Author(s): Adams GW Jr, Hudson HC. Source: The Journal of Urology. 1986 September; 136(3): 682-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3525868&dopt=Abstract
•
Scrotal calcinosis presenting with prostatitis-like symptoms. Author(s): Tsai YS, Tzai TS, Lin JS, Tong YC. Source: Urology. 2002 January; 59(1): 138. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11796310&dopt=Abstract
•
Semen parameters in men with and without proven chronic prostatitis. Author(s): Weidner W, Jantos C, Schiefer HG, Haidl G, Friedrich HJ. Source: Archives of Andrology. 1991 May-June; 26(3): 173-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1872650&dopt=Abstract
68
Prostatitis
•
Semen quality and chronic abacterial prostatitis. Author(s): Schlegel PN. Source: Urology. 1992 April; 39(4): 395. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1557858&dopt=Abstract
•
Seminal fluid findings in men with nonbacterial prostatitis and prostatodynia. Author(s): Krieger JN, Berger RE, Ross SO, Rothman I, Muller CH. Source: Journal of Andrology. 1996 May-June; 17(3): 310-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8792222&dopt=Abstract
•
Seminal oxidative stress in patients with chronic prostatitis. Author(s): Pasqualotto FF, Sharma RK, Potts JM, Nelson DR, Thomas AJ, Agarwal A. Source: Urology. 2000 June; 55(6): 881-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10840100&dopt=Abstract
•
Seminal plasma zinc analysis and bacteriological cultures in chronic staphylococcal prostatitis. Author(s): Evliyaoglu Y, Kumbur H. Source: International Urology and Nephrology. 1995; 27(3): 341-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7591601&dopt=Abstract
•
Seminal secretory capacity of the male accessory sex glands in chronic pelvic pain syndrome (CPPS)/chronic prostatitis with special focus on the new prostatitis classification. Author(s): Ludwig M, Vidal A, Diemer T, Pabst W, Failing K, Weidner W. Source: European Urology. 2002 July; 42(1): 24-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12121725&dopt=Abstract
•
Seminal vesiculography in chronic bacterial prostatitis. Author(s): Baert L, Leonard A, D'Hoedt M, Vandeursen R. Source: The Journal of Urology. 1986 October; 136(4): 844-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3761444&dopt=Abstract
•
Sequential changes in the prostatic fluid level of latamoxef in patients with acute bacterial prostatitis. Author(s): Itoh M, Katoh N, Ono Y, Ohshima S, Miyake K. Source: Urologia Internationalis. 1995; 55(2): 101-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8533190&dopt=Abstract
Studies
69
•
Serum prostate specific antigen levels in non-specific granulomatous prostatitis. Author(s): Speights VO Jr, Brawn PN. Source: British Journal of Urology. 1996 March; 77(3): 408-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8814847&dopt=Abstract
•
Short course oral prednisolone therapy in chronic abacterial prostatitis and prostatodynia: case reports of three responders and one non-responder. Author(s): Bates S, Talbot M. Source: Sexually Transmitted Infections. 2000 October; 76(5): 398-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11141861&dopt=Abstract
•
Sickness impact of chronic nonbacterial prostatitis and its correlates. Author(s): Wenninger K, Heiman JR, Rothman I, Berghuis JP, Berger RE. Source: The Journal of Urology. 1996 March; 155(3): 965-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8583619&dopt=Abstract
•
Sperm angiotensin-converting enzyme activity in Chernobyl victims and patients with chronic prostatitis. Author(s): Sakharov IYu, Evdokimov VV, Atochina EA. Source: Andrologia. 1996 September-October; 28(5): 259-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8893093&dopt=Abstract
•
Staphylococcus saprophyticus in males with symptoms of chronic prostatitis. Author(s): Bergman B, Wedren H, Holm SE. Source: Urology. 1989 November; 34(5): 241-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2815444&dopt=Abstract
•
Stress cause of prostatitis. Author(s): Rudnick DH. Source: Urology. 1985 September; 26(3): 320-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4035856&dopt=Abstract
•
Stress prostatitis. Author(s): Miller HC. Source: Urology. 1988 December; 32(6): 507-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3201657&dopt=Abstract
•
Stress prostatitis. Author(s): Goldstein AM, Padma-Nathan H. Source: Urology. 1989 May; 33(5): 449. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2775375&dopt=Abstract
70
Prostatitis
•
Study of macrophages in prostatic fluid from nonbacterial prostatitis patients. V. Relation between activation of macrophages and stage of prostatitis. Author(s): Nishimura T, Terashima Y, Hattori T, Satoh M, Yoshida K, Akimoto M. Source: Urologia Internationalis. 1991; 46(1): 15-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2024364&dopt=Abstract
•
Symptomatic granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy for bladder cancer. Author(s): Noor MA, Biyabani SR, Burney IA, Talatia J. Source: J Pak Med Assoc. 2002 December; 52(12): 578-80. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12627909&dopt=Abstract
•
Symptoms and inflammation in chronic prostatitis/chronic pelvic pain syndrome. Author(s): Krieger JN, Ross SO, Penson DF, Riley DE. Source: Urology. 2002 December; 60(6): 959-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12475649&dopt=Abstract
•
Terazosin helpful in patients with chronic prostatitis. Author(s): Slawson D. Source: American Family Physician. 2003 May 15; 67(10): 2206-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12776975&dopt=Abstract
•
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. Author(s): Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, Yap HW, Krieger JN. Source: The Journal of Urology. 2003 February; 169(2): 592-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12544314&dopt=Abstract
•
The characterization of bacterial and nonbacterial prostatitis by prostatic immunoglobulins. Author(s): Shortliffe LM, Wehner N. Source: Medicine; Analytical Reviews of General Medicine, Neurology, Psychiatry, Dermatology, and Pediatrics. 1986 November; 65(6): 399-414. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3537628&dopt=Abstract
•
The clinical spectrum of granulomatous prostatitis: a report of 200 cases. Author(s): Stillwell TJ, Engen DE, Farrow GM. Source: The Journal of Urology. 1987 August; 138(2): 320-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3599248&dopt=Abstract
Studies
71
•
The enigma of prostatitis. Recent advances in classification and management. Author(s): Chou DS, Manyak MJ. Source: Adv Nurse Pract. 2001 November; 9(11): 63-4, 69-70, 73. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12420503&dopt=Abstract
•
The Finnish version of The National Institutes Of Health Chronic Prostatitis Symptom Index correlates well with the visual pain scale: translation and results of a modified linguistic validation study. Author(s): Leskinen MJ, Mehik A, Sarpola A, Tammela TL, Jarvelin MR. Source: Bju International. 2003 August; 92(3): 251-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12887478&dopt=Abstract
•
The impact of chronic prostatitis/chronic pelvic pain syndrome on patients. Author(s): McNaughton Collins M. Source: World Journal of Urology. 2003 June; 21(2): 86-9. Epub 2003 April 02. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12682773&dopt=Abstract
•
The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. Author(s): Carver BS, Bozeman CB, Williams BJ, Venable DD. Source: The Journal of Urology. 2003 February; 169(2): 589-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12544313&dopt=Abstract
•
The role of cytokines in prostatitis. Author(s): Jang TL, Schaeffer AJ. Source: World Journal of Urology. 2003 June; 21(2): 95-9. Epub 2003 May 29. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12783173&dopt=Abstract
•
Therapeutic results with mezlocillin in acute prostatitis. Author(s): Comi L, Aymar T, Morelli F. Source: Chemioterapia. 1987 June; 6(2 Suppl): 528-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3509491&dopt=Abstract
•
Total and free serum prostate specific antigen levels during the first month of acute prostatitis. Author(s): Game X, Vincendeau S, Palascak R, Milcent S, Fournier R, Houlgatte A. Source: European Urology. 2003 June; 43(6): 702-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12767374&dopt=Abstract
72
Prostatitis
•
Transrectal prostatic ultrasonography in acute bacterial prostatitis: findings and clinical implications. Author(s): Horcajada JP, Vilana R, Moreno-Martinez A, Alvarez-Vijande R, Bru C, Bargallo X, Bunesch L, Martinez JA, Mensa J. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(2): 114-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12693562&dopt=Abstract
•
Treatment of bacterial prostatitis. Comparison of cephalexin and minocycline. Author(s): Paulson DF, Zinner NR, Resnick MI, Childs SJ, Love T, Madsen PO. Source: Urology. 1986 April; 27(4): 379-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3515737&dopt=Abstract
•
Treatment of blastomycetes induced chronic prostatitis with ketoconazole (Nizoral). Author(s): Koranyi E, Torok I, Kottasz S, Brousil E. Source: Ther Hung. 1987; 35(4): 218-21. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3447307&dopt=Abstract
•
Treatment of chronic bacterial prostatitis with ciprofloxacin. Author(s): Langemeyer TN, Ferwerda WH, Hoogkamp-Korstanje JA, de Leur EJ, van Oort H, Schipper JJ, van der Wal T. Source: Pharm Weekbl Sci. 1987 December 11; 9 Suppl: S78-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3325933&dopt=Abstract
•
Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. Author(s): Weidner W, Schiefer HG, Dalhoff A. Source: The American Journal of Medicine. 1987 April 27; 82(4A): 280-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3555048&dopt=Abstract
•
Treatment of chronic prostatitis: intraprostatic antibiotic injections under echography control. Author(s): Jimenez-Cruz JF, Tormo FB, Gomez JG. Source: The Journal of Urology. 1988 May; 139(5): 967-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3283385&dopt=Abstract
•
Treatment response to conventional and novel therapies in chronic prostatitis. Author(s): Shoskes DA. Source: Curr Urol Rep. 2003 August; 4(4): 311-5. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12882725&dopt=Abstract
Studies
73
•
TUR-prostatitis. Histological and immunohistochemical observations on a special type of granulomatous prostatitis. Author(s): Helpap B, Vogel J. Source: Pathology, Research and Practice. 1986 June; 181(3): 301-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3748877&dopt=Abstract
•
Two-balloon and four-channel silicone rubber catheter for drug injection in the treatment of chronic bacterial prostatitis. Author(s): Cheng HJ, Huang GG. Source: European Urology. 1987; 13(1-2): 116-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3582440&dopt=Abstract
•
Ultrasonographic findings in patients with nonbacterial prostatitis. Author(s): de la Rosette JJ, Karthaus HF, Debruyne FM. Source: Urologia Internationalis. 1992; 48(3): 323-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1589926&dopt=Abstract
•
Ureaplasma urealyticum in the urogenital tract of patients with chronic prostatitis or related symptomatology. Author(s): Ohkawa M, Yamaguchi K, Tokunaga S, Nakashima T, Fujita S. Source: British Journal of Urology. 1993 December; 72(6): 918-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8306156&dopt=Abstract
•
Uridine, xanthine and urate concentrations in prostatic fluid and seminal plasma of patients with prostatitis. Author(s): Persson BE, Sjoman M, Niklasson F, Ronquist G. Source: European Urology. 1991; 19(3): 253-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1855533&dopt=Abstract
•
Urinary plasma protein patterns in acute prostatitis. Author(s): Everaert K, Delanghe J, Vanderkelen M, Cornelis K, De Wachter S, Viaene A, De Ruyck E, Clarysse B, Oosterlinck W. Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 2003 January; 41(1): 79-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12636054&dopt=Abstract
•
Urinary tract infection in urology, including acute and chronic prostatitis. Author(s): Pewitt EB, Schaeffer AJ. Source: Infectious Disease Clinics of North America. 1997 September; 11(3): 623-46. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9378927&dopt=Abstract
74
Prostatitis
•
Urodynamic evidence of vesical neck obstruction in men with misdiagnosed chronic nonbacterial prostatitis and the therapeutic role of endoscopic incision of the bladder neck. Author(s): Kaplan SA, Te AE, Jacobs BZ. Source: The Journal of Urology. 1994 December; 152(6 Pt 1): 2063-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7966675&dopt=Abstract
•
Urovirulence determinants in Escherichia coli strains causing prostatitis. Author(s): Andreu A, Stapleton AE, Fennell C, Lockman HA, Xercavins M, Fernandez F, Stamm WE. Source: The Journal of Infectious Diseases. 1997 August; 176(2): 464-9. Erratum In: J Infect Dis 1997 November; 176(5): 1416. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9237713&dopt=Abstract
•
US case of the day. Granulomatous prostatitis resulting from BCG therapy. Author(s): Rifkin MD, Tessler FN, Tublin ME, Ross JS. Source: Radiographics : a Review Publication of the Radiological Society of North America, Inc. 1998 November-December; 18(6): 1605-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9821203&dopt=Abstract
•
Use of antibiotics in chronic prostatitis syndromes. Author(s): Shoskes DA. Source: Can J Urol. 2001 June; 8 Suppl 1: 24-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11442994&dopt=Abstract
•
Use of fibrin sealant in the treatment of prostatic cutaneous fistula in a case of Pseudomonas prostatitis. Author(s): Felipetto R, Vigano L, Cecchi M, Florentini L, Minervini R. Source: International Urology and Nephrology. 1995; 27(5): 563-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8775040&dopt=Abstract
•
Use of quinolones in treatment of prostatitis and lower urinary tract infections. Author(s): Andriole VT. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 1991 April; 10(4): 342-50. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1864295&dopt=Abstract
•
Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. Author(s): Gul O, Eroglu M, Ozok U. Source: International Urology and Nephrology. 2001; 32(3): 433-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11583367&dopt=Abstract
Studies
75
•
Validity and responsiveness of the national institutes of health chronic prostatitis symptom index. Author(s): Turner JA, Ciol MA, Von Korff M, Berger R. Source: The Journal of Urology. 2003 February; 169(2): 580-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12544311&dopt=Abstract
•
Value of intraprostatic injection of zinc and vitamin C and of ultrasound application in infertile men with chronic prostatitis. Author(s): Fahim MS, Ibrahim HH, Girgis SM, Essa HA, Hanafi S. Source: Archives of Andrology. 1985; 14(1): 81-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3901948&dopt=Abstract
•
Value of the prostatic LDH levels in the diagnosis of bacterial prostatitis. Author(s): Becopoulos T, Stavropoulos N, Kastriotis J, Sinaniotis K, Gourgiotis D, Syriopoulou V. Source: European Urology. 1989; 16(3): 223-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2744058&dopt=Abstract
•
Value of urine cytology in screening patients with prostatitis syndromes. Author(s): de la Rosette JJ, Hubregtse MR, Wiersma AM, Debruyne FM. Source: Acta Cytol. 1993 September-October; 37(5): 710-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8362583&dopt=Abstract
•
Variability of the symptoms of chronic abacterial prostatitis/chronic pelvic pain syndrome during intermittent therapy with rectal prednisolone foam for ulcerative colitis. Author(s): Talbot M, Bates S. Source: International Journal of Std & Aids. 2001 November; 12(11): 752-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11589817&dopt=Abstract
•
Virulence characteristics of Escherichia coli in acute bacterial prostatitis. Author(s): Mitsumori K, Terai A, Yamamoto S, Ishitoya S, Yoshida O. Source: The Journal of Infectious Diseases. 1999 October; 180(4): 1378-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10479177&dopt=Abstract
•
Voiding dysfunction associated with “chronic bacterial prostatitis”. Author(s): Ghobish A. Source: European Urology. 2002 August; 42(2): 159-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12160587&dopt=Abstract
76
Prostatitis
•
Wegener's granulomatosis presenting as granulomatous prostatitis causing urinary retention. Author(s): Hussain SF, Baker JT, De Bolla AR. Source: British Journal of Urology. 1990 January; 65(1): 104. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2310918&dopt=Abstract
•
Wegener's granulomatosis presenting as lower back pain with prostatitis and ureteral obstruction. Author(s): Middleton G, Karp D, Lee E, Cush J. Source: The Journal of Rheumatology. 1994 March; 21(3): 566-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8006905&dopt=Abstract
•
Wegener's granulomatosis presenting as prostatitis. Author(s): Murty GE, Powell PH. Source: British Journal of Urology. 1991 January; 67(1): 107-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1993268&dopt=Abstract
•
X Chromosomal short tandem repeat polymorphisms near the phosphoglycerate kinase gene in men with chronic prostatitis. Author(s): Riley DE, Krieger JN. Source: Biochimica Et Biophysica Acta. 2002 January 2; 1586(1): 99-107. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11781154&dopt=Abstract
•
Xanthogranulomatous prostatitis. Author(s): Miekos E, Wlodarczyk W, Szram S. Source: International Urology and Nephrology. 1986; 18(4): 433-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3818220&dopt=Abstract
77
CHAPTER 2. NUTRITION AND PROSTATITIS Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and prostatitis.
Finding Nutrition Studies on Prostatitis The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “prostatitis” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7
Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
78
Prostatitis
The following information is typical of that found when using the “Full IBIDS Database” to search for “prostatitis” (or a synonym): •
62 cases of chronic prostatitis treated by rectal ionintroduction of TCM suppository. Author(s): Shijiazhuang Railway Central Hospital, Hebei Province. Source: Chen, Z J-Tradit-Chin-Med. 1996 March; 16(1): 15-7 0254-6272
•
Acupuncture treatment in 102 cases of chronic prostatitis. Source: Ge, S H Meng, F Y Xu, B R J-Tradit-Chin-Med. 1988 June; 8(2): 99-100 0254-6272
•
Antibacterial effect of intraprostatic zinc injection in a rat model of chronic bacterial prostatitis. Author(s): Department of Urology, St. Vincent Hospital, Catholic University Medical College, 93 Ji-dong, Paldal-gu, Suwon 442-723, Seoul, South Korea. Source: Cho, Y H Lee, S J Lee, J Y Kim, S W Lee, C B Lee, W Y Yoon, M S Int-JAntimicrob-Agents. 2002 June; 19(6): 576-82 0924-8579
•
Chronic prostatitis and chronic pelvic pain in men: aetiology, diagnosis and management. Author(s): Wycombe Hospital, High Wycombe, HP11 2TT, UK.
[email protected] Source: Luzzi, G A J-Eur-Acad-Dermatol-Venereol. 2002 May; 16(3): 253-6 0926-9959
•
Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response. Author(s): Harbor-University of California-Los Angeles Medical Center, Torrance, California, USA. Source: Shahed, A R Shoskes, D A J-Urol. 2001 November; 166(5): 1738-41 0022-5347
•
Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome: association with diagnosis and treatment response. Author(s): Cleveland Clinic Florida, Weston and Nova Southeastern University, Fort Lauderdale, Florida, USA. Source: Shoskes, Daniel A Albakri, Qussay Thomas, Kim Cook, Daniel J-Urol. 2002 July; 168(1): 331-5 0022-5347
•
Development of rat prostatitis model by oral administration of isoflavone and its characteristics. Author(s): Department of Urology, Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, C.P.O. Box 8044, Seoul 120-752, Korea. Source: Kwon, S M Kim, S I Chun, D C Cho, N H Chung, B C Park, B W Hong, S J Yonsei-Med-J. 2001 August; 42(4): 395-404 0513-5796
•
Effect of cernitin pollen-extract on experimental nonbacterial prostatitis in rats. Author(s): Department of Urology, Faculty of Medicine, University of Tokyo, Japan.
[email protected] Source: Kamijo, T Sato, S Kitamura, T Prostate. 2001 October 1; 49(2): 122-31 0270-4137
•
Eosinophilic prostatitis simulating invasive prostatic carcinoma: CT appearance. Author(s): Department of Radiology, University of British Columbia, North Vancouver. Source: Gibney, R G Hicken, P Nichols, D M Can-Assoc-Radiol-J. 1988 March; 39(1): 4850 0846-5371
•
Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction. Author(s): Department of Family Medicine, East Carolina University School of Medicine, Greenville, North Carolina 27858-4354, USA.
Nutrition
79
Source: Spivey, J M Cummings, D M Pierson, N R Pharmacotherapy. 1996 Mar-April; 16(2): 314-6 0277-0008 •
Intravesical potassium sensitivity in patients with prostatitis. Author(s): Division of Urology, University of California San Diego Medical Center, San Diego, CA 92103, USA. Source: Parsons, C L Albo, M J-Urol. 2002 September; 168(3): 1054-7 0022-5347
•
Local transrectal enzymatic treatment for chronic nonbacterial prostatitis and prostatodynia: initial clinical experience. Author(s): Department of Urology, University of Vienna, Austria. Source: Kerbl, K Zisch, R Tech-Urol. 2000 March; 6(1): 22-5 1079-3259
•
Non-specific eosinophilic granulomatous prostatitis responded favorably to an antimicrobial agent and a hydrocortisone. Author(s): Department of Urology, Kanazawa Municipal Hospital, Kanazawa, Japan. Source: Ohkawa, M Yamaguchi, K Kobayashi, M Int-J-Urol. 2001 October; 8(10): 578-80 0919-8172
•
Phytotherapy and other alternative forms of care for the patient with prostatitis. Author(s): Department of Urology, Cleveland Clinic Florida, 2950 Cleveland Clinic Boulevard, Weston, FL 33331, USA.
[email protected] Source: Shoskes, D A Curr-Urol-Repage 2002 August; 3(4): 330-4 1527-2737
•
Phytotherapy for chronic prostatitis. Author(s): St. Luke's/Roosevelt Hospital Center, 111 Amsterdam Avenue at 114th Street, New York, NY 10025, USA.
[email protected] Source: Lowe, F C Fagelman, E Curr-Urol-Repage 2000 August; 1(2): 164-6 1527-2737
•
Phytotherapy in chronic prostatitis. Author(s): Cleveland Clinic Florida, Weston, Florida, USA. Source: Shoskes, D A Urology. 2002 December; 60(6 Suppl): 35-7; discussion 37 15279995
•
Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Author(s): Institute for Male Urology, Encino, California, USA. Source: Shoskes, D A Zeitlin, S I Shahed, A Rajfer, J Urology. 1999 December; 54(6): 9603 0090-4295
•
Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Author(s): Department of Urology, Georg-August-University, Gottingen, Germany. Source: Rugendorff, E W Weidner, W Ebeling, L Buck, A C Br-J-Urol. 1993 April; 71(4): 433-8 0007-1331
•
Sovremennye metody diagnostiki i lecheniia prostatita. [Current methods of diagnosis and treatment of prostatitis] Source: Klimenko, P M Klin-Khir. 1999; (7): 33-5
•
Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. Author(s): Department of Population Dynamics, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD 21205. Source: Sharma, O P Adlercreutz, H Strandberg, J D Zirkin, B R Coffey, D S Ewing, L L J-Steroid-Biochem-Mol-Biol. 1992 November; 43(6): 557-64 0960-0760
80
Prostatitis
•
The effect of prostaglandin E1 on in vitro transcription of sperm chromatin, isolated from patients with azoospermia, teratospermia and chronic prostatitis. Author(s): Institute of Molecular Biology, Bulg. Acad. Sci., Sofia, Bulgaria. Source: Pironcheva, G Miteva, K Russev, G C Vaisberg, C Zlatarev, S Z-Naturforsch-[C]. 1998 May-June; 53(5-6): 421-4 0341-0382
•
Treatment of 133 cases of chronic prostatitis by seminal consolidation and turbidity excretion. Source: Zhu, Y K J-Tradit-Chin-Med. 1989 December; 9(4): 272-4 0254-6272
•
Treatment of chronic abacterial prostatitis: a review. Source: Evans, D T Int-J-STD-AIDS. 1994 May-June; 5(3): 157-64 0956-4624
•
Treatment of nonspecific chronic prostatitis with Qian Lie Xian Yan Suppository suppository in 104 cases. Author(s): Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine and Pharmacy, Beijing 100700. Source: Jia, Y Li, Y Li, J Sun, M J-Tradit-Chin-Med. 2001 June; 21(2): 90-2 0254-6272
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Nutrition
81
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMD®Health: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
The following is a specific Web list relating to prostatitis; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Vitamins Vitamin C Source: Healthnotes, Inc.; www.healthnotes.com
•
Minerals Quercetin Source: Healthnotes, Inc.; www.healthnotes.com Zinc Source: Healthnotes, Inc.; www.healthnotes.com Zinc Source: Integrative Medicine Communications; www.drkoop.com Zinc Source: Prima Communications, Inc.www.personalhealthzone.com
•
Food and Diet Berries Source: Healthnotes, Inc.; www.healthnotes.com Pumpkin Seeds Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,176,00.html
83
CHAPTER 3. ALTERNATIVE MEDICINE AND PROSTATITIS Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to prostatitis. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to prostatitis and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “prostatitis” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to prostatitis: •
62 cases of chronic prostatitis treated by rectal ionintroduction of TCM suppository. Author(s): Chen Z. Source: J Tradit Chin Med. 1996 March; 16(1): 15-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8758702&dopt=Abstract
•
A new high frequency electrostimulation device to treat chronic prostatitis. Author(s): John H, Ruedi C, Kotting S, Schmid DM, Fatzer M, Hauri D. Source: The Journal of Urology. 2003 October; 170(4 Pt 1): 1275-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14501740&dopt=Abstract
•
Acupuncture ameliorates symptoms in men with chronic prostatitis/chronic pelvic pain syndrome. Author(s): Chen R, Nickel JC.
84
Prostatitis
Source: Urology. 2003 June; 61(6): 1156-9; Discussion 1159. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12809886&dopt=Abstract •
Acupuncture treatment in 102 cases of chronic prostatitis. Author(s): Ge SH, Meng FY, Xu BR. Source: J Tradit Chin Med. 1988 June; 8(2): 99-100. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3412022&dopt=Abstract
•
Acute and chronic bacterial prostatitis: a review of treatment approaches. Author(s): Kot T, Pettit-Young N. Source: Compr Ther. 1990 August; 16(8): 54-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2173653&dopt=Abstract
•
Advanced therapy for prostatitis: minimally invasive and invasive therapies. Author(s): El-Hakim A, Shah DK, Smith AD. Source: Curr Urol Rep. 2003 August; 4(4): 320-6. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12882727&dopt=Abstract
•
Aetiology of chronic prostatitis. Author(s): Skerk V, Schonwald S, Krhen I, Markovinovic L, Beus A, Kuzmanovic NS, Kruzic V, Vince A. Source: International Journal of Antimicrobial Agents. 2002 June; 19(6): 471-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12135835&dopt=Abstract
•
Amebic prostatitis. Author(s): Goff DA, Davidson RA. Source: Southern Medical Journal. 1984 August; 77(8): 1053-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6087468&dopt=Abstract
•
An overview of holistic medicine and complementary and alternative medicine for the prevention and treatment of BPH, prostatitis, and prostate cancer. Author(s): McClure MW. Source: World Journal of Urology. 2002 November; 20(5): 273-84. Epub 2002 September 28. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12522583&dopt=Abstract
•
Application of millimeter waves in treating chronic prostatitis patients. Author(s): Matveev AG. Source: Crit Rev Biomed Eng. 2001; 29(3): 482-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11730107&dopt=Abstract
Alternative Medicine 85
•
Chlamydia trachomatis in 'abacterial' prostatitis: microbiological, cytological and serological studies. Author(s): Weidner W, Arens M, Krauss H, Schiefer HG, Ebner H. Source: Urologia Internationalis. 1983; 38(3): 146-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6346628&dopt=Abstract
•
Chlamydial and ureaplasmal infections in patients with nonbacterial chronic prostatitis. Author(s): Badalyan RR, Fanarjyan SV, Aghajanyan IG. Source: Andrologia. 2003 October; 35(5): 263-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14535852&dopt=Abstract
•
Chronic prostatitis and chronic pelvic pain in men: aetiology, diagnosis and management. Author(s): Luzzi GA. Source: Journal of the European Academy of Dermatology and Venereology : Jeadv. 2002 May; 16(3): 253-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12195565&dopt=Abstract
•
Chronic prostatitis. Author(s): Mobley DF. Source: Southern Medical Journal. 1974 February; 67(2): 219-24. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4590619&dopt=Abstract
•
Chronic prostatitis/chronic pelvic pain pyndrome): seminal markers of inflammation. Author(s): Ludwig M, Vidal A, Diemer T, Pabst W, Failing K, Weidner W. Source: World Journal of Urology. 2003 June; 21(2): 82-5. Epub 2003 April 11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12690515&dopt=Abstract
•
Chronic prostatitis: psychosomatic incidence. Author(s): Mendlewicz J, Schulman CC, De Schutter B, Wilmotte J. Source: Psychotherapy and Psychosomatics. 1971; 19(1): 118-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5146341&dopt=Abstract
•
Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Author(s): Skerk V, Schonwald S, Krhen I, Banaszak A, Begovac J, Strugar J, Strapac Z, Vrsalovic R, Vukovic J, Tomas M. Source: International Journal of Antimicrobial Agents. 2003 May; 21(5): 457-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12727080&dopt=Abstract
•
Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis.
86
Prostatitis
Author(s): Skerk V, Schonwald S, Krhen I, Markovinovic L, Barsic B, Marekovic I, Roglic S, Zeljko Z, Vince A, Cajic V. Source: Journal of Chemotherapy (Florence, Italy). 2002 August; 14(4): 384-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12420857&dopt=Abstract •
Comparison of expressed prostatic secretions with urine after prostatic massage--a means to diagnose chronic prostatitis/inflammatory chronic pelvic pain syndrome. Author(s): Ludwig M, Schroeder-Printzen I, Ludecke G, Weidner W. Source: Urology. 2000 February; 55(2): 175-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10688073&dopt=Abstract
•
Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response. Author(s): Shahed AR, Shoskes DA. Source: The Journal of Urology. 2001 November; 166(5): 1738-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11586213&dopt=Abstract
•
Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome: association with diagnosis and treatment response. Author(s): Shoskes DA, Albakri Q, Thomas K, Cook D. Source: The Journal of Urology. 2002 July; 168(1): 331-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12050565&dopt=Abstract
•
Development of rat prostatitis model by oral administration of isoflavone and its characteristics. Author(s): Kwon SM, Kim SI, Chun DC, Cho NH, Chung BC, Park BW, Hong SJ. Source: Yonsei Medical Journal. 2001 August; 42(4): 395-404. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11519081&dopt=Abstract
•
Diagnosis of chronic prostatitis: overview and update. Author(s): Thin RN. Source: International Journal of Std & Aids. 1997 August; 8(8): 475-81. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9259494&dopt=Abstract
•
Does the chronic prostatitis/pelvic pain syndrome differ from nonbacterial prostatitis and prostatodynia? Author(s): Krieger JN, Jacobs RR, Ross SO. Source: The Journal of Urology. 2000 November; 164(5): 1554-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11025703&dopt=Abstract
•
Effect of cernitin pollen-extract on experimental nonbacterial prostatitis in rats. Author(s): Kamijo T, Sato S, Kitamura T.
Alternative Medicine 87
Source: The Prostate. 2001 October 1; 49(2): 122-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11582591&dopt=Abstract •
Emotional aspects of chronic prostatitis. Author(s): LEWIN KK. Source: Geriatrics. 1963 April; 18: 261-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13930315&dopt=Abstract
•
Heat therapy in the treatment of prostatitis. Author(s): Zeitlin SI. Source: Urology. 2002 December; 60(6 Suppl): 38-40; Discussion 41. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521593&dopt=Abstract
•
Herbal and complementary medicine in chronic prostatitis. Author(s): Shoskes DA, Manickam K. Source: World Journal of Urology. 2003 June; 21(2): 109-13. Epub 2003 April 29. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12720037&dopt=Abstract
•
Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy. Author(s): Liu KJ, Chatta GS, Twardzik DR, Vedvick TS, True LD, Spies AG, Cheever MA. Source: Journal of Immunology (Baltimore, Md. : 1950). 1997 July 1; 159(1): 472-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9200488&dopt=Abstract
•
Inflammation and anti-inflammatory therapy in chronic prostatitis. Author(s): A Pontari M. Source: Urology. 2002 December; 60(6 Suppl): 29-33; Discussion 33-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521589&dopt=Abstract
•
Local transrectal enzymatic treatment for chronic nonbacterial prostatitis and prostatodynia: initial clinical experience. Author(s): Kerbl K, Zisch R. Source: Tech Urol. 2000 March; 6(1): 22-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10708143&dopt=Abstract
•
Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. Author(s): Shoskes DA, Hakim L, Ghoniem G, Jackson CL. Source: The Journal of Urology. 2003 April; 169(4): 1406-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12629373&dopt=Abstract
88
Prostatitis
•
Management of chronic prostatitis-chronic pelvic pain syndrome. Author(s): Anderson RU. Source: The Urologic Clinics of North America. 2002 February; 29(1): 235-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12109351&dopt=Abstract
•
Management of prostatitis. Author(s): Gurunadha Rao Tunuguntla HS, Evans CP. Source: Prostate Cancer and Prostatic Diseases. 2002; 5(3): 172-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12496977&dopt=Abstract
•
Measurement of urinary antibodies to crude bacterial antigen in patients with chronic bacterial prostatitis. Author(s): Shortliffe LM, Elliott K, Sellers RG. Source: The Journal of Urology. 1989 March; 141(3): 632-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2918607&dopt=Abstract
•
Neuromuscular dysfunction in nonbacterial prostatitis. Author(s): Hellstrom WJ, Schmidt RA, Lue TF, Tanagho EA. Source: Urology. 1987 August; 30(2): 183-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3497475&dopt=Abstract
•
Phytotherapy and other alternative forms of care for the patient with prostatitis. Author(s): Shoskes DA. Source: Curr Urol Rep. 2002 August; 3(4): 330-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12149166&dopt=Abstract
•
Phytotherapy for chronic prostatitis. Author(s): Lowe FC, Fagelman E. Source: Curr Urol Rep. 2000 August; 1(2): 164-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12084332&dopt=Abstract
•
Phytotherapy in chronic prostatitis. Author(s): Shoskes DA. Source: Urology. 2002 December; 60(6 Suppl): 35-7; Discussion 37. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521591&dopt=Abstract
•
Practical approach to the management of prostatitis. Author(s): Nickel JC. Source: Tech Urol. 1995 Fall; 1(3): 162-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9118386&dopt=Abstract
Alternative Medicine 89
•
Prevalence of chronic prostatitis in men with premature ejaculation. Author(s): Screponi E, Carosa E, Di Stasi SM, Pepe M, Carruba G, Jannini EA. Source: Urology. 2001 August; 58(2): 198-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11489699&dopt=Abstract
•
Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. Author(s): Potts JM. Source: The Journal of Urology. 2000 November; 164(5): 1550-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11025702&dopt=Abstract
•
Prostatitis unplugged? Prostatic massage revisited. Author(s): Nickel JC, Alexander R, Anderson R, Krieger J, Moon T, Neal D, Schaeffer A, Shoskes D. Source: Tech Urol. 1999 March; 5(1): 1-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10374787&dopt=Abstract
•
Prostatitis. Author(s): RAINES SL. Source: J Med Assoc State Ala. 1964 October; 34: 99-102. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14198396&dopt=Abstract
•
Prostatitis: are the gram-positive organisms pathogenic? Author(s): Jimenez-Cruz JF, Martinez Ferrer M, Allona Almagro A, De Rafael L, NavioNino S, Baquero Mochales M. Source: European Urology. 1984; 10(5): 311-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6519134&dopt=Abstract
•
Prostatitis: Man's hidden infection. Author(s): Drach GW. Source: The Urologic Clinics of North America. 1975 October; 2(3): 499-520. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=52931&dopt=Abstract
•
Prostatitis; an evaluation of laboratory procedures and of the effectiveness of nitrofurantoin. Author(s): BARNES RW, HADLEY HL. Source: Calif Med. 1965 January; 102: 11-3. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14243849&dopt=Abstract
•
Prostatitis--an increasing clinical problem for diagnosis and management. Author(s): Leigh DA.
90
Prostatitis
Source: The Journal of Antimicrobial Chemotherapy. 1993 July; 32 Suppl A: 1-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8407691&dopt=Abstract •
Pseudodyssynergia (contraction of the external sphincter during voiding) misdiagnosed as chronic nonbacterial prostatitis and the role of biofeedback as a therapeutic option. Author(s): Kaplan SA, Santarosa RP, D'Alisera PM, Fay BJ, Ikeguchi EF, Hendricks J, Klein L, Te AE. Source: The Journal of Urology. 1997 June; 157(6): 2234-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9146624&dopt=Abstract
•
Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Author(s): Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Source: Urology. 1999 December; 54(6): 960-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10604689&dopt=Abstract
•
Repetitive prostatic massage therapy for chronic refractory prostatitis: the Philippine experience. Author(s): Nickel JC, Downey J, Feliciano AE Jr, Hennenfent B. Source: Tech Urol. 1999 September; 5(3): 146-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10527258&dopt=Abstract
•
Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Author(s): Rugendorff EW, Weidner W, Ebeling L, Buck AC. Source: British Journal of Urology. 1993 April; 71(4): 433-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8499988&dopt=Abstract
•
Significance of Chlamydia trachomatis in “abacterial” prostatitis. Author(s): Krauss H, Schiefer HG, Weidner W, Arens M, Ebner H. Source: Zentralbl Bakteriol Mikrobiol Hyg [a]. 1983 July; 254(4): 545-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6372332&dopt=Abstract
•
Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. Author(s): Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS, Ewing LL. Source: The Journal of Steroid Biochemistry and Molecular Biology. 1992 November; 43(6): 557-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1419891&dopt=Abstract
Alternative Medicine 91
•
Studies on the role of Ureaplasma urealyticum and Mycoplasma hominis in prostatitis. Author(s): Brunner H, Weidner W, Schiefer HG. Source: The Journal of Infectious Diseases. 1983 May; 147(5): 807-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6842018&dopt=Abstract
•
Symptoms and inflammation in chronic prostatitis/chronic pelvic pain syndrome. Author(s): Krieger JN, Ross SO, Penson DF, Riley DE. Source: Urology. 2002 December; 60(6): 959-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12475649&dopt=Abstract
•
The characterization of bacterial and nonbacterial prostatitis by prostatic immunoglobulins. Author(s): Shortliffe LM, Wehner N. Source: Medicine; Analytical Reviews of General Medicine, Neurology, Psychiatry, Dermatology, and Pediatrics. 1986 November; 65(6): 399-414. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3537628&dopt=Abstract
•
The chronic prostatitis syndromes. Author(s): Thin RN. Source: J R Army Med Corps. 1997 October; 143(3): 155-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9403823&dopt=Abstract
•
The NIH Consensus concept of chronic prostatitis/chronic pelvic pain syndrome compared with traditional concepts of nonbacterial prostatitis and prostatodynia. Author(s): Krieger JN, Ross SO, Deutsch L, Riley DE. Source: Curr Urol Rep. 2002 August; 3(4): 301-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12149161&dopt=Abstract
•
The possible role of anaerobic bacteria in chronic prostatitis. Author(s): Szoke I, Torok L, Dosa E, Nagy E, Scultety S. Source: International Journal of Andrology. 1998 June; 21(3): 163-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9669200&dopt=Abstract
•
The Pre and Post Massage Test (PPMT): a simple screen for prostatitis. Author(s): Nickel JC. Source: Tech Urol. 1997 Spring; 3(1): 38-43. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9170224&dopt=Abstract
•
The role of Chlamydia trachomatis in patients with non-bacterial prostatitis. Author(s): Mutlu N, Mutlu B, Culha M, Hamsioglu Z, Demirtas M, Gokalp A.
92
Prostatitis
Source: Int J Clin Pract. 1998 November-December; 52(8): 540-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10622051&dopt=Abstract •
The value of endotoxin concentrations in expressed prostatic secretions for the diagnosis and classification of chronic prostatitis. Author(s): Li LJ, Shen ZJ, Lu YL, Fu SZ. Source: Bju International. 2001 October; 88(6): 536-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11678746&dopt=Abstract
•
Transurethral radiofrequency hot balloon thermal therapy in chronic nonbacterial prostatitis. Author(s): Nickel JC, Siemens DR, Johnston B. Source: Tech Urol. 1998 September; 4(3): 128-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9800889&dopt=Abstract
•
Treatment of 133 cases of chronic prostatitis by seminal consolidation and turbidity excretion. Author(s): Zhu YK. Source: J Tradit Chin Med. 1989 December; 9(4): 272-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2630815&dopt=Abstract
•
Treatment of chronic abacterial prostatitis: a review. Author(s): Evans DT. Source: International Journal of Std & Aids. 1994 May-June; 5(3): 157-64. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8061085&dopt=Abstract
•
Treatment of chronic prostatitis and prostatodynia with pollen extract. Author(s): Buck AC, Rees RW, Ebeling L. Source: British Journal of Urology. 1989 November; 64(5): 496-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2692777&dopt=Abstract
•
Treatment of chronic prostatitis with laser acupuncture. Author(s): Chen C, Gao Z, Liu Y, Shen L. Source: J Tradit Chin Med. 1995 March; 15(1): 38-41. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7783460&dopt=Abstract
•
Treatment of nonspecific chronic prostatitis with Qian Lie Xian Yan Suppository suppository in 104 cases. Author(s): Jia Y, Li Y, Li J, Sun M. Source: J Tradit Chin Med. 2001 June; 21(2): 90-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11498910&dopt=Abstract
Alternative Medicine 93
•
Treatment of prostatitis. Author(s): Stevermer JJ, Easley SK. Source: American Family Physician. 2000 May 15; 61(10): 3015-22, 3025-6. Erratum In: Am Fam Physician 2001 June 1; 63(11): 2129. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10839552&dopt=Abstract
•
Treatment response to conventional and novel therapies in chronic prostatitis. Author(s): Shoskes DA. Source: Curr Urol Rep. 2003 August; 4(4): 311-5. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12882725&dopt=Abstract
•
Ureaplasma urealyticum in the urogenital tract of patients with chronic prostatitis or related symptomatology. Author(s): Ohkawa M, Yamaguchi K, Tokunaga S, Nakashima T, Fujita S. Source: British Journal of Urology. 1993 December; 72(6): 918-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8306156&dopt=Abstract
•
Use of prostatic massage in combination with antibiotics in the treatment of chronic prostatitis. Author(s): Shoskes DA, Zeitlin SI. Source: Prostate Cancer and Prostatic Diseases. 1999 May; 2(3): 159-162. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12496826&dopt=Abstract
•
Value of intraprostatic injection of zinc and vitamin C and of ultrasound application in infertile men with chronic prostatitis. Author(s): Fahim MS, Ibrahim HH, Girgis SM, Essa HA, Hanafi S. Source: Archives of Andrology. 1985; 14(1): 81-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3901948&dopt=Abstract
•
Zinc concentration in human prostatic fluid: normal, chronic prostatitis, adenoma and cancer. Author(s): Zaichick VY, Sviridova TV, Zaichick SV. Source: International Urology and Nephrology. 1996; 28(5): 687-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9061429&dopt=Abstract
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
94
Prostatitis
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com®: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMD®Health: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to prostatitis; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Benign Prostatic Hyperplasia Alternative names: Prostate Enlargement Source: Prima Communications, Inc.www.personalhealthzone.com Male Infertility Source: Healthnotes, Inc.; www.healthnotes.com Prostate Infection Source: Integrative Medicine Communications; www.drkoop.com Prostatitis Source: Healthnotes, Inc.; www.healthnotes.com Prostatitis Source: Integrative Medicine Communications; www.drkoop.com
•
Alternative Therapy Hydrotherapy Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,705,00.html
Alternative Medicine 95
•
Chinese Medicine Qianlieshu Wan Alternative names: Qianlieshu Pills Source: Pharmacopoeia Commission of the Ministry of Health, People's Republic of China Hyperlink: http://www.newcenturynutrition.com/cgilocal/patent_herbs_db/db.cgi?db=default&Chinese=Qianlieshu%20Wan&mh=10& sb=---&view_records=View+Records
•
Herbs and Supplements Bromelain Source: Healthnotes, Inc.; www.healthnotes.com Corn Silk Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca Horsetail Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca Pau D’arco Alternative names: Tabebuia avellanedae, Tabebuia impestiginosa Source: Healthnotes, Inc.; www.healthnotes.com Pollen Source: Healthnotes, Inc.; www.healthnotes.com Pygeum Alternative names: African Prune; Pygeum africanum Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Pygeum Alternative names: Prunus africanum, Pygeum africanum Source: Healthnotes, Inc.; www.healthnotes.com Pygeum Source: Prima Communications, Inc.www.personalhealthzone.com Saw Palmetto Alternative names: Serenoa serrulata, Serenoa repens, Sabal serrulata Source: Healthnotes, Inc.; www.healthnotes.com Saw Palmetto Source: Prima Communications, Inc.www.personalhealthzone.com
96
Prostatitis
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
97
CHAPTER 4. PATENTS ON PROSTATITIS Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.8 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “prostatitis” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on prostatitis, we have not necessarily excluded non-medical patents in this bibliography.
Patents on Prostatitis By performing a patent search focusing on prostatitis, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We will tell you how to obtain this information later in the chapter. The following is an 8Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
98
Prostatitis
example of the type of information that you can expect to obtain from a patent search on prostatitis: •
Combined hyperthermia and dilation catheter Inventor(s): Burton; John H. (Minnetonka, MN), Cook; Timothy C. (Wayzata, MN), Tihon; Claude (Eden Prairie, MN) Assignee(s): American Medical Systems, Inc. (Minnetonka, MN) Patent Number: 5,496,271 Date filed: June 16, 1993 Abstract: An apparatus and method for treatment of conditions in which it is desired to simultaneously hyperthermally treat diseased target tissue in a patient and dilate a lumen of a patient which is compressed and/or obstructed by the diseased target tissue and/or surrounding tissue is disclosed. The apparatus generally includes a catheter for insertion into a lumen of the patient, such as in the prostatic urethra; an antenna for applying microwave or radio frequency energy to the selected target tissue to produce hyperthermal effects therein, thereby causing therapeutic alteration of the selected target tissue cells; a dilation balloon for simultaneously dilating the lumen of the patient and for compressing tissue to restrict blood flow to said tissue, thereby reducing the heat sink effect of blood-supplied tissue absorbing heat energy applied thereto, enabling both greater uniformity of heating in selected target diseased tissue and a reduction in the amount of power required to supply an effective level of energy to the selected target diseased tissue; and a fixation balloon for securing the apparatus during treatment. The apparatus and method are particularly adapted to the treatment of diseases of the prostate, such as benign prostatic hypertrophy (BPH), prostatitis and prostatic cancer, as well as in the treatment of certain tumors of the esophagus and the gastro-intestinal tract. Excerpt(s): This invention relates to an apparatus and method for the treatment of conditions in which it is desired to simultaneously hyperthermally treat diseased target tissue in a patient and dilate a lumen of a patient which is being compressed and obstructed by diseased tissue and/or surrounding tissue, especially as such a state exists in diseases of the prostate, including benign prostatic hypertrophy (BPH), and in other conditions of the prostate, such as prostatitis, and prostatic cancer, as well as in certain tumors of the esophagus and the gastro-intestinal tract. In particular, the invention relates to a catheter featuring the combined use of microwave or radio frequency hyperthermia and balloon dilation. Prostatic disease is one of the most common diseases in men in the United States. Prostatic disease, as referred to here, includes benign prostatic hypertrophy (BPH), prostatitis, and prostatic cancer. These etiologies affect a majority of men over the age of 60. Although the size of the prostate does not reflect the severity of BPH symptoms, it is clear that hypertrophy of the prostate gland and/or hyperplasia of stromal tissue cells is involved. Web site: http://www.delphion.com/details?pn=US05496271__
Patents 99
•
Composition and method of treating diseases and disorders of the prostate Inventor(s): Choi; In Ja (Taejeon, KR), Kim; Jee Hyang (Taejeon, KR), Lee; Jae Yong (Taejeon, KR), Seo; Min Hyo (Taejeon, KR) Assignee(s): Samyang Corporation (Seoul, KR) Patent Number: 6,277,391 Date filed: June 4, 1999 Abstract: This invention relates to a composition and method for treating diseases and disorders of the prostate such as prostatitis, benign prostatic hypertrophy, and prostate carcinoma. The prostate is treated by intraprostatic injection of a biodegradable sustained release formulation. By injecting the treatment substance directly into the prostate, improved treatment results are obtained with a much lower treatment substance dosage. Additionally, by incorporating the treatment substance into a biodegradable sustained release formulation, the need for frequent repetition of injections is eliminated. Excerpt(s): This application claims priority under 37 C.F.R. 119 from earlier filed application No. KR98-20895, filed Jun. 5, 1998, in the Korean Patent Office. The present invention relates generally to a method of treating diseases and disorders of the prostate such as prostatitis, benign prostatic hypertrophy, and prostate carcinoma. More particularly, it concerns making treatment by injecting a biodegradable sustained release formulation directly into the prostate. Prostate diseases such as prostatitis, benign prostatic hypertrophy, prostatodynia, and prostate carcinoma afflict many adult males. The largest population of men stricken with prostate problems are those over age fifty. However, inherited prostate problems can appear in much younger men. Web site: http://www.delphion.com/details?pn=US06277391__
•
Detection of prostatitis Inventor(s): Wheeler; Ronald E. (412 C.R. 243, P.O. Box 217, Durango, CO 81302) Assignee(s): none reported Patent Number: 6,365,340 Date filed: November 11, 1999 Abstract: The present invention is directed to a method of detecting prostatitis comprising obtaining an expressed prostatic secretion from a patient; contacting a device having diagnostic test reagents to the expressed prostatic secretion, the diagnostic test reagents reacting with the expressed prostatic secretion to produce a change in the device; reading the change in the device to produce a positive or negative experimental test result, wherein the experimental test result is positive when the experimental test result is pre-determined to correspond with a number above 10 for the number of white blood cell per high powered field and the experimental test result is negative when the experimental test result corresponds with a number of 10 or less for the number of white blood cell per high powered field; and determining presence of prostatitis with the positive experimental test result and the absence of prostatitis with the negative experimental test result. The present invention is also directed to a device for use in the inventive method. The device has two indicators, one for the presence of prostatitis and one for the absence of prostatitis.
100 Prostatitis
Excerpt(s): The present invention relates to a device and process for detecting prostatitis. The prostate gland (or prostate) is a walnut-sized, mucous-producing organ in males that lies just below the urinary bladder. The prostate typically grows and enlarges throughout life. The only known function of the prostate is to produce a secretion that nourishes and protects the sperm during reproduction. The urethra, the canal that in most mammals discharges urine from the bladder, passes through the prostate gland. Unfortunately, this anatomical feature creates problems, often associated with difficulty in urination, as males age. A national survey of U.S. physician visits estimated that the diagnosis of prostatitis results in 2 million office visits per year in the United States and is the most frequent diagnosis resulting in an office visit to urologists in men less than 50-years-old. Collins, M. M., et al. (1998) J. Urol. 159:1224-1228. Prostatitis is defined as an inflammation or infection of the prostate gland. While prostatitis may be acute, associated with systemic findings of fever, chills and rigors, most cases of prostatitis are chronic and tend to be incurable with relatively frequent recurrences despite optimal standard therapy. Chronic prostatitis (inflammation or infection of the prostate) is common to all adult men. It is associated with virtually all cases of prostate cancer and is present in every prostate biopsy regardless of other findings. Chronic prostatitis may not cause significant symptoms in many men, but in others it can be a devastating disease that severely affects the quality of life of those afflicted. It is difficult to diagnose and even more difficult to treat. Web site: http://www.delphion.com/details?pn=US06365340__ •
Intraprostatic injection of zinc ions for treatment of inflammatory conditions and benign and malignant tumors of the prostate Inventor(s): Fahim; Mostafa S. (500 Hulen Dr., Columbia, MO 65203) Assignee(s): none reported Patent Number: 4,946,688 Date filed: July 5, 1988 Abstract: A method of treating the prostate by intraprostatic injection of zinc ions in a concentration effective to increase the amount of prostatic antibacterial factor and to inhibit the rate of prostatic growth. The treatment is applied to patients with prostatitis, to patients with benign adenomatous hyperplasia of the prostate after prostatic resection and to patients which early prostatic carcinoma as an alternative to surgery as needed to provide long-term remission. The treatment is also applied prophylactically to prevent the development of prostatitis, particularly in males of advanced age. Excerpt(s): Inflammation and benign and malignant tumors of the prostate afflict a large number of adult males. The etiology of these conditions is generally unknown, but may involve the normal aging process and associated alterations in hormonal balance. Mankind is not unique in this regard and other animals with a compact or solid prostate, such as dogs, suffer comparable disease states. Chronic prostatitis is the most common chronic infection in adult males. It has been claimed to afflict about 35% of all male subjects at sometime during their lives. The typical patient is a middle-aged or elderly male referred for evaluation of repeated episodes of cystitis and pyelonephritis or epididymitis. Benign adenomatous hyperplasia of the prostate is also common malady seen in men over age 50 while adenocarcinoma of the prostate accounts for the majority of malignancies in men over age 65. Chronic prostatitis can be classified into: (1) non-specific prostatitis, (2) specific prostatitis due in to infection with bacteria or fungi and (3) granulomatous, which may be non-specific (with unknown cause) or
Patents 101
allergic, which is usually accompanied by some general allergic disease as bronchial asthma. Although granulomatous prostatitis is very rare, it should be differentiated from prostatic carcinoma. Web site: http://www.delphion.com/details?pn=US04946688__ •
Laser fiber apparatus having a contact tip and adjacent diffuser element and surgical methods for using same Inventor(s): Bruce; Johnny M. (Magnolia, TX) Assignee(s): Endeavor Surgical Products, Inc. (The Woodlands, TX) Patent Number: 5,534,000 Date filed: March 17, 1994 Abstract: An improved laser fiber assembly is provided which is capable of both effecting direct ablation of tissue or of effecting deep tissue coagulation. The fiber assembly is preferably provided with an orbicular tip for effecting direct ablation in a contact mode. Adjacent the orbicular tip is a cylindrical diffuser element which effects a cylindrical shaped emission pattern when the.orbicular tip is not in contact with tissue. The diffuser element is preferably protected with a covering, such as a teflon tubing element. Alternative embodiments use one or more cylindrical-segment diffuser elements in place of the cylindrical element. The fiber assembly is useful in a wide variety of surgical situations, and is particularly useful for treatment of benign prostatitis hyperplasia. The method of the invention includes the steps of bringing the tip of the dual action fiber assembly into contact with tissue to be ablated or adjacent tissue to be treated for deep tissue coagulation. Excerpt(s): The present invention relates to optical laser fibers and methods of using them in surgical procedures. More particularly, the present invention relates to laser fiber assemblies and methods of using them in the treatment of various surgical procedures involving emission of laser energy in order to effect deep tissue coagulation or direct ablation. Optical lasers, such as Nd:YAG lasers, are commonly used in the conduct of surgical procedures. One advantage of laser surgery is that it can often be performed through a relatively small incision or by insertion into an existing body passageway. Laser surgical procedures can frequently be performed on an out-patient basis, resulting in significantly lower cost and less inconvenience to the patient. Dramatic shortening in recovery time is often seen in comparison to traditional surgery which it replaces. For these reasons, substantial effort and expense are being directed toward the development of new laser apparatus and improved methods of surgical treatment using medical lasers. Various configurations of optical fibers have been developed for different types of surgical procedures. One particularly useful configuration involves contact laser surgery, wherein the tip of an optical fiber assembly is brought into direct contact with tissue desired to be removed, thereby causing it to be cut or vaporized, hereinafter referred to as "ablation". Sometimes, however, ablation is not the most effective means for dealing with a medical problem. Accordingly, an alternative optical fiber assembly often referred to as a "side-firing" fiber has found applications in a variety of situations not readily susceptible to treatment by direct ablation. Web site: http://www.delphion.com/details?pn=US05534000__
102 Prostatitis
•
Method for the treatment of urologic disorders Inventor(s): Bush; Irving M. (Box 365, Burlington, IL 60109) Assignee(s): none reported Patent Number: 4,822,610 Date filed: August 26, 1987 Abstract: A novel method for the treatment of prostatitis, seminal vesiculitis, benign prostatic hypertrophy, prostatic abscess, bladder neck hypertrophy, urinary tract infection including urethritis and decreased liquification of semen by administering a pharmaceutically acceptable dosage of guaifenesin, or guaifenesin including zinc sulfate. Excerpt(s): The present invention relates to a novel method for the treatment of the urologic conditions known as prostatitis (P), seminal vesiculitis (SV), benign prostatic hypertrophy (BPH), prostatic abscess (PA), bladder neck hypertrophy (BNH), urinary tract infection (UTI) including urethritis and decreased liquification of semen (DLS). These diseases of the urinary and genital tract of males and females are among the most common diseases (8%) seen in medical practice. They are often recurring, debilitating or persistent and take a great toll in patient morbidity. Many of the symptoms associated with P, SV, BPH, PA, BNH, UTI and DLS are related to the inability of associated organs to drain their mucoid or mucopurulent secretions which may or may not contain bacteria that are often resistent to many antibiotics. This inability to drain has been solved at the present time only through painful massage by the treating physician. Guaifenesin C.sub.10 H.sub.14 O.sub.4 1,2 - Propanediol, 3 (2 methoxyphenoxyl)-3-(o Methoxyphenoxyl)-1,2-propanediol has in the past and at present been used as an expectorant. By increasing respiratory tract fluid (mucus) guaifenesin reportedly reduces the viscosity of tenacious secretions leading to removal of the offending material. Guaifenesin may also reduce respiratory tract adhesiveness and surface tension promoting ciliary action. It therefore has been used in the management of coughs associated with the common cold, bronchitis, laryngitis, pharyngitis, pertussis, influenza, measles and chronic paranasal sinusitis, all of which are diseases of the upper respiratory tract. Web site: http://www.delphion.com/details?pn=US04822610__
•
Method for treating chronic prostatitis or chronic pelvic pain syndrome Inventor(s): Nickel; Curtis J. (Elginburg, CA), Pontari; Michel A. (Lafayette Hill, PA), Stoner; Elizabeth (Westfield, NJ), Waldstreicher; Joanne (Scotch Plains, NJ) Assignee(s): Merck & Co., Inc. (Rahway, NJ), Temple University of the Commonwealth of Higher Ed. (Philadelphia, PA) Patent Number: 6,403,640 Date filed: August 24, 2000 Abstract: The use of a COX-2 selective inhibitor for the treatment of chronic prostatitis or chronic pelvic pain syndrome is disclosed. Excerpt(s): Chronic prostatitis or chronic pelvic pain syndrome is an extremely prevalent disease in men (Collins M M, et al., "How common is prostatitis? A national survey of physician visits," Journal of Urology, 159:1224-1228 (1998)). Although the epidemiologic evidence is limited, it appears that the prevalence of prostatitis is
Patents 103
approximately 2-9% in adult men. It has been suggested that 35-50% of men are affected by prostatitis at some time in life. Approximately 2 million ambulatory patient visits are made annually for prostatitis, accounting for 8% of all visits to urologists and 1% of all visits to primary care physicians. Many men remain symptomatic for much of their lives. Chronic prostatitis is characterized by evidence of prostatic inflammation and by the presence or absence of white blood cells in prostatic fluid and/or pain associated with the prostate. This syndrome does not exist prior to puberty but has a peak incidence between the ages of 18 and 50. Suggestions as to the origins of these conditions have included a chemical imbalance in the prostate, infection undetected by current microbiological methods and autoimmunity to the prostate gland itself. Chronic non-bacterial prostatitis and prostatodynia (Chronic Pelvic Pain Syndrome) is characterized by pain and/or discomfort in the genitourinary, pelvic or perineal area and is associated with variable voiding and sexual dysfunction. Chronic nonbacterial prostatitis [Chronic Pelvic Pain Syndrome NIH Category IIIA] is an inflammatory and painful condition of unknown etiology characterized by excessive inflammatory cells in prostatic secretions despite a lack of documented urinary tract infections, and negative bacterial cultures of urine and prostatic secretions. Prostatodynia [Chronic Pelvic Pain Syndrome NIH Category IIIB] is a painful condition of unknown etiology characterized by a decided lack of inflammatory cells in prostatic secretions, no documented urinary tract infections and negative bacterial cultures in urine and prostatic secretions. Chronic nonbacterial prostatitis is more common than bacterial prostatitis. Symptoms mimic those of chronic bacterial prostatitis. Patients usually show an increase in the number of white blood cells and oval fat bodies in their expressed prostatic secretions. However, they rarely have a history of urinary tract infection, and lower-tract localization cultures fail to reveal a pathogenic organism. Web site: http://www.delphion.com/details?pn=US06403640__ •
Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia Inventor(s): Guess; Harry A. (Chapel Hill, NC), Pearson; Jay Dee (Hatfield, PA), Waldstreicher; Joanne (Scotch Plains, NJ) Assignee(s): Merck & Co., Inc. (Rahway, NJ) Patent Number: 6,054,455 Date filed: May 17, 1999 Abstract: A tachykinin receptor antagonist, in particular a neurokinin-1 receptor antagonist, is useful for the treatment or prevention of chronic nonbacterial prostatitis and/or prostatodynia. Excerpt(s): Prostatitis and prostatodynia are extremely prevalent diseases in men (Collins M M, et al., "How common is prostatitis? A national survey of physician visits," Journal of Urology, 159:1224-1228 (1998)). There are more outpatient visits for prostatitis than for benign prostatic hypertrophy (BPH) or prostate cancer. Although the epidemiologic evidence is limited, it appears that the prevalence of prostatitis is approximately 2-9% in adult men. It has been suggested that 35-50% of men are affected by prostatitis at some time in life. Based on the National Ambulatory Medical Care Surveys from 1990-1994, approximately 2 million ambulatory visits are made annually for prostatitis. This accounts for 8% of all visits to urologists and 1% of all visits to primary care physicians. Many men remain symptomatic for much of their lives. This category of poorly understood syndromes is characterized by evidence of prostatic inflammation and by the presence or absence of white blood cells in prostatic fluid
104 Prostatitis
and/or pain associated with the prostate. Within this group of syndromes, the origins of chronic idiopathic prostatitis, asymptomatic prostatitis, and prostatodynia are problematic and are probably the least understood. The origin of these diseases have been attributed to some undefinable bacterial or viral infection, but this has never been proven. These syndromes do not exist prior to puberty but have a peak incidence between the ages of 18 and 50. It is possible that these three specific entities actually represent the same disease process in different phases or forms. Suggestions as to the origins of these conditions have included a chemical imbalance in the prostate, infection undetected by current microbiological methods, and autoimmunity to the prostate gland itself. Chronic nonbacterial prostatitis is an inflammatory and pain condition of unknown etiology characterized by excessive inflammatory cells in prostatic secretions despite no history of documented urinary tract infection and negative bacterial cultures of urine and prostatic secretions. Chronic nonbacterial prostatitis is even more common than bacterial prostatitis. Symptoms simulate those of chronic bacterial prostatitis and these patients usually show an increase in the number of white blood cellss and oval fat bodies in their expressed prostatic secretions. However, they rarely have a history of urinary tract infection, and lower-tract localization cultures fail to reveal a pathogenic organism. Patients with prostatodynia have negative bacterial cultures, normal prostatic secretions, and no history of urinary tract infection. Symptoms of chronic nonbacterial prostatitis and prostatodynia vary but include urinary urgency and frequency, nocturia, dysuria, and pain and discomfort perceived in the pelvic, suprapubic, or genital area. Sometimes postejaculatory pain and discomfort are prominent features. Physical findings for both conditions are nonspecific. Web site: http://www.delphion.com/details?pn=US06054455__ •
Method for treating or preventing prostatic conditions Inventor(s): Adler; Stuart R. (Creve Coeur, MO), Banz; William J. (Carterville, IL), Dandliker; Walter B. (La Jolla, CA), Hou; Yuqing (Carbondale, IL), Meyers; Cal Y. (Carbondale, IL), Winters; Todd A. (Murphysboro, IL) Assignee(s): Southern Illinois University Office of Research, Development and (Carbondale, IL) Patent Number: 6,608,111 Date filed: June 23, 1999 Abstract: Provided is a method comprising administering (+) -Z- bisdehydrodoisynolic acid to a patient for treating, inhibiting or delaying the onset of prostatic conditions including prostatitis, benign prostatic hypertrophy and prostate cancer without accompanying feminizing effects. Excerpt(s): The present invention relates to the field of pharmaceutical therapeutics. More specifically, the present invention relates to the use of estrogenic carboxylic acids in improved therapies for the treatment of a variety of symptoms and disease conditions in mammals. The present invention also relates to the field of chemical synthesis, more specifically, the synthesis of estrogenic carboxylic acids. Estrogens, such as (+)-17.beta.estradiol (E2), have physiological effects on males as well as females. In addition to their activity in reproductive tissue, they promote rapid weight gain in specific species, and have been marketed to fatten livestock quickly. Trenkle, A H: "The Mechanisms of Action of Estrogens in Feeds on Mammalian and Avian Growth." Proceedings of a Symposium: The Use of Drugs in Animal Feed. National Academy of Science, Washington D.C. 150-164 (1968); Meyers, U.S. Pat. No. 5,420,161. Estrogens have long
Patents 105
been prescribed for their beneficial effects by reducing susceptibility to osteoporosis and ameliorating menopausal and postmenopausal symptoms. Evans S F, Davie M W: "Low and Conventional Dose Transdermal Oestradiol Are Equally Effective at Preventing Bone Loss In Spine and Femur at All Post-Menopausal Ages." Clin Endocrinol. 44:79-84 (1996); Agarwal S K, Judd H L: "Menopause." Curr Ther Endocrinol Metab. 6:624-631 (1997). Long-term clinical studies suggest that estrogens may be beneficial in promoting cardiovascular health. Wilson P W: "The Impact of Estrogen on Cardiovascular Disease." Perspective Studies: The Framingham Study. Postgrad Med 51-53:89-90 (1989). More recently, estrogens have shown promise as an adjunct in treatment of Alzheimer's disease. Filley C M: "Alzheimer's Disease in Women." Am J Obstet Gynecol 176:1-7 (1997). Unfortunately, some estrogenic compounds administered in therapeutic doses are suspected carcinogens in target tissues including breast and uterus. Persson I: "Cancer Risk in Women Receiving Estrogen-Progestin Replacement Therapy." Maturitas 23:S37-45 (1996). Non-steroidal estrogens and antiestrogens, including pharmaceuticals, environmental compounds, and phytochemicals, are currently receiving significant attention. This is understandable from the myriad potential applications increasingly being reported for estrogenic compounds, e.g., treating menopause- and postmenopause-related problems, as anti-carcinogens, alleviating osteoporosis, for contraceptive use, in estrogen-replacement therapy, treating prostatic disease, improving serum lipid profiles, etc. The multiplicity of estrogenic effects now being discovered has led many investigators to target specific populations for treatment with estrogen agonists and antagonists. Synthetic nonsteroidal compounds such as triphenylethylene derivatives (e.g., tamoxifen), dihydronapthalene derivatives (e.g., nafoxidine), and benzothiophene derivatives (e.g., raloxifene) exhibit estrogenic and anti-estrogenic activity in various tissues, these respective compounds showing specific advantages in the management of bone, uterine, serum cholesterol, and adipose tissue. See, generally, Trenkle, A H: "The Mechanisms of Action of Estrogens in Feeds on Mammalian and Avian Growth." Proceedings of a Symposium: The Use of Drugs in Animal Feed. National Academy of Science, Washington D.C. 150-164 (1968); Evans S F, Davie M W: "Low and Conventional Dose Transdermal Oestradiol Are Equally Effective at Preventing Bone Loss In Spine and Femur at All Post-Menopausal Ages." Clin Endocrinol. 44:79-84 (1996); Agarwal S K, Judd H L: "Menopause." Curr Ther Endocrinol Metab. 6:624-631 (1997); Wilson P W: "The Impact of Estrogen on Cardiovascular Disease." Perspective Studies: The Framingham Study. Postgrad Med 51-53:89-90 (1989); Filley C M: "Alzheimer's Disease in Women." Am J Obstet Gynecol 176:1-7 (1997); Persson I: "Cancer Risk in Women Receiving Estrogen-Progestin Replacement Therapy." Maturitas 23:S37-45 (1996); Heer J, Billeter J R, Miescher K: "Totalsynthese der racemischen bisdehydro-doisynolsaure. Uber oestrogene carbosauren IV." Helv. Chim. Acta 28:1342-1354 (1945); Ke H Z, Chen H A, Simmons H A, Qi H, Crawford D T, Pirie C M, Chidsey-Frink K L, Ma Y F, Jee W S S, Thompson D D: "Comparative Effects of Droloxifene, Tamoxifen, and Estrogen on Bone, Serum Cholesterol, and Uterine Histology in the Ovariectomized Rat Model." Bone 20:31-39 (1997); Sato M, Rippy M K, Bryant H U: "Raloxifene, Tamoxifen, Nafoxidine, or Estrogen Effects on Reproductive and Nonreproductive Tissues in Ovariectomized Rats." FASEB J 10:905-912 (1996); Dodge J A, Glasebrook A L, Magee D A, Phillips D L, Sato M, Short L L, Bryant H U: "Environmental Estrogens: Effects on Cholesterol Lowering and Bone in the Ovariectomized Rat." J Steroid Biochem Molec Biol 59:155-161(1996); Hart J E: "Endocrine Pathology of Estrogens: Species Differences." Pharmac Ther 47:203-218 (1990); Heywood R, Wadsworth P F: "The Experimental Toxicology of Estrogens." Pharmac Ther 8:125-142 (1980); Baker V L, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J, Jaffe R B: "Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, A Selective Estrogen Receptor Modulator, in Women with Regular
106 Prostatitis
Menstrual Cycles." J Clin Endocrin Metab 83:6-13 (1998); Danzo B J: "Environmental Xenobiotics May Disrupt Normal Endocrine Function by Interfering with the Binding of Physiological Ligands to Steroid Receptors and Binding Proteins." Environ Health Perspect 105:294-301 (1997); Baker V L, Jaffe R B: "Clinical Uses of Antiestrogens." Obstet Gynecol Surv 51:45-59 (1996); Knight D C, Eden J A: "A Review of the Clinical Effects of Phytoestrogens." Obstet Gynecol 87:897-904 (1996); Cooper R L, Kaviock R J: "Endocrine Disruptors and Reproductive Development: A Weight-of-Evidence Overview." J Endocrinol 152:159-166 (1997); Reubinoff B E, Wurtman J, Rojansky N, Adler D, Stein P, Schenker J G, Brzezinski A: "Effects of Hormone Replacement Therapy on Weight, Body Composition, Fat Distribution, and Food Intake in Early Postmenopausal Women: A Prospective Study." Fertil Steril 64:963-968 (1995). Web site: http://www.delphion.com/details?pn=US06608111__ •
Method of producing a medicinal tea for treating infertility in males and for treating prostatitis Inventor(s): Gideon; Salva (201 Lloyd Manor Road, Suite 200, Etobicoke, Ontario, CA) Assignee(s): none reported Patent Number: 5,736,144 Date filed: December 4, 1995 Abstract: A medicinal substance for increasing fertility in mammalian males and for use as an anti-microbial or anti-inflammatory agent by mammals produced by boiling radish leaves, radish stems or portions thereof in water for a period of time sufficient to produce a tea containing an extract from the radish leaves and stems or portions thereof. Alternatively, the radish leaves and stems may be placed in hot water for a period of time sufficient to produce a tea containing the extract. The resulting tea can be drunk hot or cold and may be stored in a refrigerator for extended periods of time for later use. Patients taking a daily dosage of this tea have shown greatly improved sperm density and improved motility and morphology after use for several weeks. Dosages of this tea are also effective in treating prostatitis. The preferred radish plant is the spring radish of the species Raphanus sativus. The leaves of other radish plants including wild and winter or oriental radishes may also be used. Excerpt(s): The present invention relates to treatments for treating infertility in males and for treating prostatitis. More particularly, the invention relates to a natural medicine treatment for treating infertility in males who suffer from germinal epithelium failure and for treating prostatitis in males. For many male and female couples, infertility is an aggravating problem forcing a couple to seek medical attention. The couple's infertility may be caused by the male who may be diagnosed as being infertile or sub-fertile due to poor or insufficient semen quantity and/or quality. Generally, a total sperm count of less than approximately 20 million, with adequate motility and morphology, is considered to be a low sperm count, and males exhibiting such characteristics are considered to be subfertile or oligospermatic. Additionally or alternatively, sperm morphology and motility is another indication of oligospermia, such as when the percentage of abnormal spermatozoa exceeds approximately 40%. U.S. Pat. No. 5,166,190 issued Nov. 24, 1992 to Mather et al. and assigned to Genentech, Inc. discloses a method for increasing fertility in a male mammal exhibiting germinal epithelium failure, comprising administering to the mammal, preferably to the testis thereof, an effective amount of activin. Unfortunately, activin is not readily available and must be prepared, such as by being synthesized in a recombinant cell culture as
Patents 107
described for example in U.S. Pat. No. 4,798,885 issued Jan. 17, 1989. Hence, activin may be quite an expensive medication to consume. In addition, the necessary dosage of activin is subject to a great deal of therapeutic discretion, with a key factor for selecting an appropriate dosage being the result obtained, as measured by increases in sperm density by semen analysis or the number of spermatocytes, or by. other criteria as deemed appropriate by the practitioner. Such active involvement by the practitioner implies added cost to the treatment of infertility. Web site: http://www.delphion.com/details?pn=US05736144__ •
Method of treatment of chronic prostatitis with 17.beta.-N-monosubstitutedcarbamoyl-4-aza-5.alpha.-androst-1-en-3-ones Inventor(s): Gormley; Glenn J. (Westfield, NJ), Stoner; Elizabeth (Westfield, NJ) Assignee(s): Merck & Co., Inc. (Rahway, NJ) Patent Number: 5,629,318 Date filed: June 2, 1995 Abstract: The present invention is concerned with the use of 17.beta.-Nmonosubstituted-carbamaoyl-4-aza-5.alpha.-androst-1-en-3-one compounds as testosterone-5.alpha.-reductase inhibitors for the treatment of chronic prostatitis. Excerpt(s): This application is a 371 of PCT/US93/11155 filed Nov. 18, 1993. The present invention is concerned with the use of 17.beta.-N-monosubstituted-carbamoyl-4-aza5.alpha.-androst-1-en-3-one compounds as testosterone-5.alpha.-reductase inhibitors for the treatment of chronic prostatitis. Prostatitis in general constitutes about 10 to 15% of all urological practice. This category of poorly understood syndromes can be characterized by evidence of prostatic inflammation and by the presence or absence of white blood cells in prostatic fluid and/or pain associated with the prostate. Within this group of syndromes, the origins of chronic idiopathic prostatitis, asymptomatic prostatitis, and prostatodynia are problematic and are probably the least understood. The origin of these diseases have been attributed to some undefinable bacterial or viral infection, but this has never been proven. These syndromes do not exist prior to puberty but have a peak incidence between the ages of 18 and 50. It is possible that these three specific entities actually represent the same disease process in different phases or forms. Suggestions as to the origins of these conditions have included a chemical imbalance in the prostate, infection undetected by current microbiological methods, and autoimmunity to the prostate gland itself. Web site: http://www.delphion.com/details?pn=US05629318__
•
Methods and compositions for preventing and treating prostate disorders Inventor(s): Neal; Gary W. (4701 Guinn Rd., Knoxville, TN 37931) Assignee(s): none reported Patent Number: 6,642,274 Date filed: September 8, 2000 Abstract: The present invention relates to methods, compositions, devices and kits for the prevention and treatment of prostate disorders in mammals, including, but not limited to, benign prostatic hypertrophy, carcinoma of the prostate, prostadynia,
108 Prostatitis
prostatitis, and chronic prostatitis. The present invention provides methods for preventing and treating prostate disorders in mammals by administration of a therapeutic compound to mucosal membranes in the lower urinary tract of the mammal. The present invention also provides devices for administering a therapeutic compound to mucosal membranes in the lower urinary tract of the mammal. Excerpt(s): The present invention generally relates to novel compositions, methods, devices and kits for the prevention and/or treatment of prostate disorders in mammals. The present invention also generally relates to devices for the administration of therapeutic compounds to mucosal membranes in the lower urinary tract of mammals. Diseases of the prostate are common maladies of male mammals, especially men. They include benign prostatic hypertrophy (BPH), carcinoma of the prostate (CaP), prostadynia, prostatitis, and chronic prostatitis. The steadily increasing age of the world's population is a testament to the success of modem medicine and preventive care. However, this success has brought with it the problem of a greater number of men suffering from BPH, CaP and other prostate disorders. Web site: http://www.delphion.com/details?pn=US06642274__ •
Methods for diagnosing benign prostatic diseases Inventor(s): Carlson; Grant D. (460 Clark La., Orange, CT 06477), Kramp; William J. (1061 Johnson Rd., Woodbridge, CT 06525), Luderer; Albert A. (28 Catbrier Rd., Weston, CT 06883), Soriano; Thomas F. (2 Benz St., Ansonia, CT 06524), Thiel; Robert P. (789 Litchfield Turnpike, Bethany, CT 06524) Assignee(s): none reported Patent Number: 5,912,135 Date filed: February 21, 1996 Excerpt(s): The present invention relates to novel methods for diagnosing benign prostatic diseases (BPD), such as benign prostatic hyperplasia, prostatitis, or glandular atrophy, in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPD. Optionally, if the patient has a total PSA level of between 10.1 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient can also be measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPD. One proposed method for detecting CAP is disclosed in Serial Number WO 92/01936 to Hans Lilja et al., (Lilja application), filed Jul. 22, 1991, under the Patent Cooperation Treaty (PCT). In general, the Lilja application discloses using immunoassays to measure free PSA and a complexed form of PSA. Free PSA is a 33 kDa single chain glycoenzyme that is produced by the epithelial cells lining the acini and prostatic ducts of the prostate gland. Complexed PSA refers primarily to a 90 kDa complex of PSA bound to alpha 1- antichymotrypsin (ACT) protein. Free PSA and complexed PSA, and their proportions are applied in the diagnosis of patients with CAP. Throughout, the specification discloses using a combination of a free PSA to total PSA (F/T) proportion and a complexed PSA to total PSA (C/T) proportion for use in diagnosing CAP. No prostate needle biopsy were performed on the patients, and the patients covered a full range of total PSA values. The text provides no guidance as to
Patents 109
specifically how one uses these proportions. In an embodiment for those patients in the gray diagnostic zone, the method comprises four steps. First, one measures the total PSA level in the blood or serum of the patient. Second, one measures the free PSA level in the blood or serum of a patient, but only if he has a total PSA level of between about 2.5 ng/ml and about 10.0 ng/ml. If the patient has a total PSA level below 2.5 ng/ml then he is diagnosed to have BPD. If the patient has a total PSA level above 10.0 ng/ml then he is presumed to have CAP and must be biopsied. Third, one calculates the proportion of free PSA to total PSA. Fourth and finally, one diagnoses the patient as having BPD if the calculated proportion of free PSA to total PSA is equal to or greater than about 25%. Optionally, if the patient is between 50 years old and under 60 years old, one can use a lower cutoff level of 3.5 ng/ml, and if the patient is at least 60 years old, then one can perform the same steps using a lower cutoff level of 4.0 ng/ml. Web site: http://www.delphion.com/details?pn=US05912135__ •
Prostate formula Inventor(s): Wheeler; Ronald E. (412 C.R. 243, Durango, CO 81301) Assignee(s): none reported Patent Number: 6,197,309 Date filed: August 3, 1999 Abstract: A composition providing an all-natural, non-surgical preventative of or improvement to disorders of the prostate gland is described. The invention relates to a composition for the prevention of or improvement of prostatitis, and for relieving symptoms and improving objective signs of prostatitis. The formula of the composition preferably includes the following ingredients each in a therapeutically effective amount: Vitamin C, Vitamin B6, Vitamin E, zinc, glycine, L-alanine, Glutamic acid, Saw palmetto, Pygeum extract, Pumpkin seed, Stinging nettle, Echinacea, garlic, Ginkgo leaves, and selenium. Excerpt(s): The present invention relates generally to a composition that provides an allnatural, non-surgical preventative of or improvement to disorders of the prostate gland. More specifically, the invention relates to a composition for the prevention of or improvement of prostatitis, and for relieving symptoms and improving objective signs of prostatitis. The prostate gland (or prostate) is a walnut-sized, mucous-producing organ in males that lies just below the urinary bladder. The prostate typically grows and enlarges throughout life. The only known function of the prostate is to produce a secretion that nourishes and protects the sperm during reproduction. The urethra, the canal that in most mammals discharges urine from the bladder, passes through the prostate gland. Unfortunately, this anatomical feature creates problems, often associated with difficulty in urination, as males age. In men, the prostate gland is the source of several common disorders including prostatitis and benign prostatic hypertrophy (BPH), wherein the prostrate gland becomes inflamed or enlarged. Prostatitis is defined as an inflammation or infection of the prostate gland. While prostatitis may be acute, associated with systemic findings of fever, chills and rigors, most cases of prostatitis are chronic and tend to be incurable with relatively frequent recurrences despite optimal standard therapy. Chronic prostatitis (inflammation or infection of the prostate) is common to all adult men. It is associated with virtually all cases of prostate cancer and is present in every prostate biopsy regardless of other findings. Chronic prostatitis may not cause significant symptoms in many men, but in others it can be a devastating
110 Prostatitis
disease that severely affects the quality of life of those afflicted. It is difficult to diagnose and even more difficult to treat. Web site: http://www.delphion.com/details?pn=US06197309__ •
Reaction product of arginine and p-aminobenzoic acid, cosmetic, and human and animal health compositions thereof Inventor(s): Schutt; Steven R. (Prescott, AZ) Assignee(s): Epicare Ltd. (Prescott, AZ) Patent Number: 6,585,988 Date filed: April 1, 2002 Excerpt(s): This invention relates to cosmetic and human and animal health compositions, and, more particularly, to the reaction product of arginine and paminobenzoic acid (PABA), and compositions thereof, useful for treating wounds, lesions, burns, sunburn, the hair and scalp, hemorrhoids and teeth, in animals and humans, including bovine mastitis. The prior art does not disclose the reaction product of arginine and p-aminobenzoic acid (PABA), and cosmetic and health compositions and formulations thereof. For example, U.S. Pat. No. 4,499,067 discloses only acyl arginine derivatives without PABA; U.S. Pat. No. 4,921,939 discloses only forming guanidine sweetening agents by reaction of substituted arcyl amines with guanidino moieties; U.S. Pat. No. 5,110,797 discloses peptide substituted/reacted arginine, however, without PABA; and U.S. Pat. No. 5,298,647 discloses PABA/amino acid reaction products which may be used as ultraviolet protecting agents, but arginine is not disclosed. A method of controlling the regulatory mechanism in humans that governs cell division in a damaged cell structure which comprises reactivating the proliferative phase regulated by DNA, to enable the damaged cell to redifferentiate itself according to its basic genetic code, by administering to the human the reaction product of arginine and p-aminobenzoic acid. Web site: http://www.delphion.com/details?pn=US06585988__
•
Seat for treating prostatitis Inventor(s): Rabon; Larry D (Timmonsville, SC) Assignee(s): Rabon; Larry D. (Florence, SC) Patent Number: 6,125,486 Date filed: July 7, 1999 Abstract: A seat for treating and reducing the occurrence of prostatitis. The seat may be adapted to or formed into any chair, vehicle seat, or any other like device. In particular, the adaptation of the seat in a rough-riding vehicle would reduce perineal trauma. The seat comprises an inflatable tube having a hole therethrough that is surrounded by a shoulder and with a cushion in the hole. Although the shoulder is very firm, the cushion is soft and provides relatively no resistance. The user sits in the tube and as a result pressure to the perineum is avoided and pressure is supported by the legs, hip or rear area. Excerpt(s): The present invention relates to a device for treating prostatitis. In particular, the present invention relates to a seat for reducing the occurrence of and providing relief
Patents 111
from prostatitis. The current definition of prostatitis has been put forward by Dr. John Krieger as Chairman of Research and Clinical Definitions Group at the National Institute of Diabetes and Digestive and Kidney Diseases, (NIDDK). Under the NIH/NIDDK system, the nomenclature consists of four main categories: acute bacterial prostatitis, chronic bacterial prostatitis, chronic prostatitis/chronic pelvic pain syndrome (CPPS), asymptomatic inflammatory prostatitis, chronic prostatitis/chronic pelvic pain syndrome. According to the June 1996 issue of Urology Times, various theories have been developed to resolve the cause of chronic prostatitis, especially if no infection can be detected. One theory speculates that the cause is urodynamic dysfunction. Others believe that the disease may be caused by psychological factors. While others theorize that the infection is just not detected using traditional techniques. Web site: http://www.delphion.com/details?pn=US06125486__ •
Substituted 3-phenanthridinone derivatives as 5-alpha-reductase inhibitors Inventor(s): Graham; Donald W. (Mountainside, NJ), Hagmann; William K. (Westfield, NJ) Assignee(s): Merck & Co., Inc. (Rahway, NJ) Patent Number: 5,621,104 Date filed: September 15, 1995 Abstract: The present invention provides for the preparation of compounds,namely, 3phenanthridinones and their derivatives and their unique ability to inhibit 5-alphareductase or their isozymes thereof in mammals enabling said compounds for treating hyperandrogenic conditions of acne, androgenic alopecia, male pattern baldness,female hirsutism,benign prostatic hyperplasia, prostatitis and prostatic cancer. Excerpt(s): The present invention provides novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the selective inhibition of the isozyme 5.alpha.-reductase 1. Certain undesirable physiological manifestations, such as acne vulgaris, seborrhea, female hirsutism, male pattern baldness (alopecia) and benign prostatic hyperplasia, are the result of hyperandrogenic stimulation caused by an excessive accumulation of testosterone or similar androgenic hormones in the metabolic system. Early attempts to provide a chemotherapeutic agent to counter the undesirable results of hyperandrogenicity resulted in the discovery of several steroidal antiandrogens having undesirable hormonal activities of their own. The estrogens, for example, not only counteract the effect of the androgens but have a feminizing effect as well. Non-steroidal antiandrogens have also been developed, for example, 4'-nitro-3'-trifluoromethylisobutyranilide. See Neri, et al., Endocrinol. 1972, 91 (2). However, these products, though devoid of hormonal effects, compete with all natural androgens for receptor sites, and hence have a tendency to feminize a male host or the male ferns of a female host and/or initiate feed-back effects which would cause hyperstimulation of the testes. The principal mediator of androgenic activity in some target organs, e.g. the prostate, is 5.alpha.-dihydrotestosterone, formed locally in the target organ by the action of testosterone-5.alpha.-reductase. Inhibitors of testosterone-5.alpha.-reductase will serve to prevent or lessen symptoms of hyperandrogenic stimulation in these organs. It is now known that a second 5.alpha.-reductase isozyme exists, which interacts with epidermal tissues, especially in scalp tissues. This form is conventionally designated as 5.alpha.reductase 1, while the isozyme that principally interacts with the prostatic tissues is
112 Prostatitis
designated as 5.alpha.-reductase 2. Both isozymes are active in the prostatic tissues. Thus, in the treatment of hyperandrogenic disease conditions e.g. benign prostatic hyperplasia (BPH), it would be desirable to have one drug entity which is active against both isozymes in the prostate to significantly inhibit dihydrotesterone production, while also having another drug entity which is highly selective for inhibiting the isozyme 5.alpha.-reductase 1 associated with the scalp, for use in treating conditions of the skin and scalp, e.g. acne and alopecia in males and hirsutism in females. Additionally, such a selective 5.alpha.-reductase 1 inhibitor could also be used in combination with finasteride (PROSCAR.RTM.), which is highly selective for 5.alpha.-reductase 2, for combination therapy in the treatment of BPH. Therefore it is an object of this invention to provide compounds that have sufficient activity in the inhibition of one or both 5.alpha.-reductase isozymes. It is an additional object of this invention to provide compounds that are useful in the treatment and/or prevention of benign prostatic hyperplasia. It is an additional object of this invention to provide compounds that are useful in the treatment of female hirsutism, male pattern baldness, acne, androgenetic alopecia, prostatic cancer, and insufficient plasma levels of high density lipoproteins. The compounds of the invention have utility in one or more of the aforementioned areas. Web site: http://www.delphion.com/details?pn=US05621104__ •
Therapeutic drug for the treatment of micturition disorders Inventor(s): Ueda; Tomohiro (Kyoto, JP), Yamauchi; Tamio (Suita, JP) Assignee(s): Taiho Pharmaceutical Co., Ltd. (Tokyo, JP) Patent Number: 6,329,428 Date filed: July 5, 2000 Abstract: The present invention is drawn to a therapeutic drug for micturition disorders and diseases of the lower urinary tract system, containing an organic acid salt of [2-[4-(3ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyl]-dimethylsulfonium. The invention enables treatment of diseases of the lower urinary tract system which cause urinary disorders, such as interstitial cystitis and prostatitis, which arise from unelucidated causes and thus are regarded intractable diseases. Excerpt(s): The present invention relates to a therapeutic drug for treating diseases of the lower urinary tract system, including those of the bladder and prostate, which can cause micturition disorders. The invention also relates to a therapeutic drug for micturition disorders accompanying these diseases. Micturition disorder is a term which collectively refers to micturition-related pathological conditions, encompassing dysuria, pollakiuria, miction pain, and urinary incontinence. Dysuria generally refers to a state where smooth urination is disturbed. Typical symptoms include: delay between the desire to void and the initiation of micturition; thin stream of urine, time for voiding prolonged; post-micturition dribble; conscious exertion of abdominal pressure needed to initiate voiding; and sense of residual urine remaining in the bladder immediately after urination. A special form of dysuria is urinary retention, which refers to a state in which voluntary micturition is disturbed and is characterized by retention of urine. Causes of urinary retention are broadly divided into (1) those attributed to neurological factors, including incoordination of the bladder smooth muscle and detrusor-sphincter dyssynergia, and (2) those attributed to organic factors, such as prostate-associated diseases, bladder neck sclerosis, and urethral stricture. Until today, however, the causes have not yet clearly elucidated and current theory holds that neurological changes and
Patents 113
organic changes are closely related to each other. Thus, in order to formulate a remedy, studies should be directed not only at localized anatomy, but at the entire urinary system, including the bladder, the prostate, and the external sphincter (see Medicine Journal, vol. 33, S-1, 193-197 (1997). Web site: http://www.delphion.com/details?pn=US06329428__ •
Treatment for prostatitis and apparatus therefor Inventor(s): Faour; Ali M. (23412 Al Wahda Street Dafco Build., Sharjah, AE) Assignee(s): none reported Patent Number: 6,136,020 Date filed: June 26, 1998 Abstract: A method and apparatus for treating prostatitis is provided. The apparatus includes two probes, a control unit, and a monitor. A urethral probe selectively applies low frequency pulses to the prostate region as well as infrared heating. A rectal probe applies microwave heating to the prostate region and also includes an ultrasound element for generating an image of the prostate to facilitate diagnosis and treatment of the patient. Excerpt(s): The present invention relates to methods for treating prostatitis. More specifically, it relates to an improved method and apparatus for applying thermal and microwave energy, as well as electro-stimulation to the prostate region to effect treatment of prostatitis. Ultrasound is used for diagnostic purposes. Various treatments for prostatitis and other prostate problems have been developed over the years, and have ranged from various surgical procedures to medication. One of the newest procedures involves the use of heat or thermal therapy, and several devices for applying heat to the prostate tissues have been developed, with varying levels of success. U.S. Pat. No. 5,733,315 discloses the use of ultrasound to apply thermal energy to the prostate tissues. The ultrasound element has a plurality of regions which are deactivated to reduce the amount of heat applied to the rectal wall of the patient. In contrast, the present invention has several elements for applying heat to the prostate tissues, and the elements are controlled to selectively apply heat to various portions of the prostate tissues without applying excessive heat to the rectal wall or other non-affected areas. Web site: http://www.delphion.com/details?pn=US06136020__
•
Use of gibberellins for the treatment of prostatitis Inventor(s): Oden; Per (Motorb.ang.tsv agen 38, S-902 91 T afte.ang., SE) Assignee(s): none reported Patent Number: 5,580,857 Date filed: January 24, 1994 Abstract: The use of active gibberellins for the preparation of a pharmaceutical composition for the treatment of prostatitis. The method results in a decrease in prostate mass. Excerpt(s): The present invention relates to the use of the group of compounds known as gibberellins for the preparation of a pharmaceutical composition for the treatment of
114 Prostatitis
prostatitis, including hypertrophy and hyperplastic adenoma of the prostate, and psoriasis, as well as a method for treating these and other conditions by administering a gibberellin or a pharmaceutically acceptable salt or lactones thereof. The gibberellins are a group of compounds which are found in plants and certain fungi. Gibberellins are plant growth regulators (phytohormones), stimulating growth and differentiation of plants in very small amounts. About 75 different gibberellins have been isolated and described. About half of the gibberellins have 20 carbon atoms, and these are referred to as C.sub.20 -gibberellins. The remaining gibberellins lack carbon atom number 20 and are referred to as C.sub.19 -gibberellins. The numbering of the carbon atoms follows the accepted rules for tetracyclic diterpenes (McCrindle and Overton, Advan. Org. Chem. 1965, 5, 47-113) and is used herein (see